Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | OCT 23 | The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded |
| NEWS 4 | OCT 30 | CHEMLIST enhanced with new search and display field |
| NEWS 5 | NOV 03 | JAPIO enhanced with IPC 8 features and functionality |
| NEWS 6 | NOV 10 | CA/CAplus F-Term thesaurus enhanced |
| NEWS 7 | NOV 10 | STN Express with Discover! free maintenance release Version 8.01c now available |
| NEWS 8 | NOV 20 | CA/CAplus to MARPAT accession number crossover limit increased to 50,000 |
| NEWS 9 | DEC 01 | CAS REGISTRY updated with new ambiguity codes |
| NEWS 10 | DEC 11 | CAS REGISTRY chemical nomenclature enhanced |
| NEWS 11 | DEC 14 | WPIDS/WPINDEX/WPIX manual codes updated |
| NEWS 12 | DEC 14 | GBFULL and FRFULL enhanced with IPC 8 features and functionality |
| NEWS 13 | DEC 18 | CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS 14 | DEC 18 | CA/CAplus patent kind codes updated |
| NEWS 15 | DEC 18 | MARPAT to CA/CAplus accession number crossover limit increased to 50,000 |
| NEWS 16 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS 17 | DEC 27 | CA/CAplus enhanced with more pre-1907 records |
| NEWS 18 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS 19 | JAN 16 | CA/CAplus Company Name Thesaurus enhanced and reloaded |
| NEWS 20 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS 21 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS 22 | JAN 22 | CA/CAplus updated with revised CAS roles |
| NEWS 23 | JAN 22 | CA/CAplus enhanced with patent applications from India |
| NEWS 24 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS 25 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS 26 | FEB 13 | CASREACT coverage to be extended |
| NEWS 27 | Feb 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS 28 | Feb 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS 29 | Feb 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS 30 | Feb 26 | MEDLINE reloaded with enhancements |
| NEWS 31 | Feb 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS 32 | Feb 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS 33 | Feb 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS 34 | Feb 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:15:39 ON 02 MAR 2007

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:15:53 ON 02 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 FEB 2007  HIGHEST RN 923894-67-1
DICTIONARY FILE UPDATES:  28 FEB 2007  HIGHEST RN 923894-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s telmisartan
L1            8 TELMISARTAN

=> d 8

L1   ANSWER 8 OF 8  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   144701-48-4  REGISTRY
ED   Entered STN:  02 Dec 1992
CN   [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-
     benzimidazol]-3'-yl)methyl]-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-
     benzimidazol]-1'-yl)methyl]- (9CI)
OTHER NAMES:
CN   4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-
     benzimidazolyl]methyl]-2-biphenylcarboxylic acid
CN   BIBR 277
```

CN BIBR 277SE
CN Micardis
CN Pritor
CN Telmisartan
MF C33 H30 N4 O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

598 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
600 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus uspatful medline

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 7.35 | 7.56 |

FILE 'CAPLUS' ENTERED AT 12:16:26 ON 02 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE 'USPATFULL' ENTERED AT 12:16:26 ON 02 MAR 2007


FILE 'MEDLINE' ENTERED AT 12:16:26 ON 02 MAR 2007

=> s l1 or telmisartan or pritor or micardis or bibr 277 or bibr 277se
L2 1943 L1 OR TELMISARTAN OR PRITOR OR MICARDIS OR BIBR 277 OR BIBR 277SE

```
=> s l2 and (diabetes or diabete or insuline resistance or hyperinsulinemia or
glucose intolerance or insuline sensitivity )
L3          761 L2 AND (DIABETES OR DIABETE OR INSULINE RESISTANCE OR HYPERINSUL
                INEMIA OR GLUCOSE INTOLERANCE OR INSULINE SENSITIVITY )

=> s l3 and pd<+2003
<------User Break------>

=> s l3 and pd<=2003
L4          124 L3 AND PD<=2003

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5           113 DUP REM L4 (11 DUPLICATES REMOVED)

=> focus
PROCESSING COMPLETED FOR L5
L6           113 FOCUS L5 1-

=> d ibib abs hitstr 1-113

L6   ANSWER 1 OF 113  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2003:96709  CAPLUS
DOCUMENT NUMBER:         138:163224
TITLE:                   Effects of telmisartan on arterial stiffness
                         in type 2 diabetes patients with essential
                         hypertension
AUTHOR(S):               Asmar, Roland; Gosse, Phillipe; Topouchian, Jirar;
                         N'tela, Gilbert; Dudley, Amanda; Shepherd, Gillian L.
CORPORATE SOURCE:        The Cardiovascular Institute, Paris, Fr.
SOURCE:                  JRAAS (2002), 3(3), 176-180
                         CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER:               JRAAS Ltd.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   Arterial wall stiffness, an important independent risk factor for
     cardiovascular disease in patients with hypertension, is worsened by the
     coexistence of diabetes mellitus.  This randomized, prospective,
     double-blind, crossover trial assessed the effects of telmisartan
     on arterial stiffness in patients with Type 2 diabetes with
     essential hypertension.  After a two-week placebo wash out period, 28
     ambulatory patients received telmisartan (40 mg) or placebo for
     three weeks.  Following a second two-week placebo wash out period,
     patients received the alternate treatment for a further three weeks.
     Augmentation index and central blood pressure (BP) were determined using the
     SphygmoCor device and pulse wave velocity (PWV) was measured using an
     automatic device, the Complior, at the beginning and the end of each
     period.  Telmisartan significantly reduced the carotid-femoral
     PWV compared with placebo (mean adjusted treatment difference -0.95 m/s;
     95% CI: -1.67, -0.23 m/s; p = 0.013).  Peripheral and central diastolic,
     systolic and pulse pressures were also significantly reduced with
     telmisartan compared with placebo.  In conclusion,
     telmisartan reduces arterial stiffness and peripheral and central
     BPs as assessed by PWV and pulse contour anal. in hypertensive patients
     with Type 2 diabetes.  These properties of telmisartan
     suggest that it may improve cardiovascular outcome in this patient
     population.
IT   144701-48-4, Telmisartan
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (telmisartan effect on arterial stiffness in type 2
        diabetes patients with essential hypertension)
RN   144701-48-4  CAPLUS
CN   [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-
```

benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:824351 CAPLUS
DOCUMENT NUMBER: 136:112467
TITLE: Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus
AUTHOR(S): Asmar, Roland
CORPORATE SOURCE: The Cardiovascular Institute, Paris, 75016, Fr.
SOURCE: JRAAS (2001), 2(Suppl. 2), S8-S11
CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER: JRAAS Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Arterial wall stiffness is an important independent risk factor for cardiovascular disease in hypertensive patients, which is further exacerbated by co-existent diabetes mellitus. Increased arterial stiffness is directly associated with an increase in pulse wave velocity (PWV) and indirectly with increased central and peripheral blood pressure. Following a two-week placebo run-in period, 27 patients with mild to moderate essential hypertension and Type 2 diabetes mellitus, were randomized to once daily treatment with either telmisartan 40 mg or placebo for three weeks, and after a two-week washout period, crossed-over to the alternative treatment for a further three weeks. Carotid/femoral and carotid/radial PWV were measured non-invasively using the automatic Complior device, and central parameters (central blood pressure, pulse contour anal., and augmentation index) were measured using the SphygmoCor system, at the start and end of each treatment period. Compared with placebo, treatment with telmisartan significantly reduced carotid/femoral PWV (mean adjusted treatment difference -0.95 m/s, 95% confidence intervals: -1.67, -0.23 m/s, p=0.013), as well as peripheral and central diastolic, systolic and pulse pressure. In conclusion, the results of this study show that telmisartan is effective in reducing arterial stiffness in hypertensive patients with Type 2 diabetes mellitus, and may potentially have beneficial effects on cardiovascular outcomes, beyond blood-pressure lowering effects, in this patient group.

IT 144701-48-4, Telmisartan
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(telmisartan effect on arterial distensibility and central blood pressure in patients with hypertension and type 2 diabetes mellitus)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:795609 CAPLUS

DOCUMENT NUMBER: 139:270158

TITLE: The telmisartan programme of research to show telmisartan end-organ proteCTION (PROTECTION) programme

AUTHOR(S): Weber, Michael

CORPORATE SOURCE: State University of New York Downstate College of Medicine, New York, USA

SOURCE: Journal of Hypertension (2003), 21(Suppl. 6), S37-S46
CODEN: JOHYD3; ISSN: 0263-6352

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Angiotensin-II receptor blockers (ARBs) have been shown to provide stroke, cardiac and renal protection in high-risk hypertensive patients. Telmisartan is a powerful and selective ARB that provides sustained blood pressure reduction for a full 24 h after a single dose and continues to protect against circadian blood pressure surges in the critical early morning hours. The objective of the Program of Research tO show Telmisartan End-organ proteCTION (PROTECTION) is to measure the end-organ protective effects of telmisartan in patients at high risk of renal, cardiac and vascular damage. An extensive series of clin. trials is being conducted to compare telmisartan with valsartan, losartan, amlodipine and ramipril in patients at increased risk of end-organ damage. Nine clin. studies will examine the effects of telmisartan in about 5000 hypertensive patients with isolated systolic hypertension, type 2 diabetes, obesity, left ventricular hypertrophy or renal disease. All of the studies will be conducted using state-of-the-art technol., including such techniques as ambulatory blood pressure monitoring and magnetic resonance imaging. This program will also investigate the effects of an ARB on key surrogate

markers of organ tissue damage. This series of trials will characterize the end-organ protective effects of telmisartan in hypertensive patient populations at high risk of clin. events.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(telmisartan treatment for end-organ protection in hypertensive patients and the telmisartan program PROTECTION)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:306863 CAPLUS

DOCUMENT NUMBER: 135:251642

TITLE: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats

AUTHOR(S): Wienen, Wolfgang; Richard, Serge; Champeroux, Pascal; Audeval-Gerard, Chantal

CORPORATE SOURCE: Department of Pharma Research, Boehringer Ingelheim Pharma KG, Biberach, Germany

SOURCE: JRAAS (2001), 2(1), 31-36
CODEN: JRAAAG; ISSN: 1470-3203

PUBLISHER: JRAAS Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study compared the cardiovascular and renal effects of long-term telmisartan (3 and 10 mg/kg/day) and lisinopril (10 mg/kg/day) in an animal model combining hypertension and diabetes mellitus. It was a parallel-group study of diabetic, spontaneously hypertensive rats (SHR), treated with control or active treatment for eight months. A non-diabetic SHR control group was run in parallel. Diabetes was induced by streptozotocin (45 mg/kg i.v.) in SHRs aged 9-10 wk. Animals were treated with telmisartan (3 or 10 mg/kg/day), lisinopril (10 mg/kg/day) or vehicle. Plasma glucose levels, blood pressure (BP), and urinary protein and albumin excretion were measured monthly. Telmisartan treatment significantly reduced BP of diabetic SHRs in a dose-dependent manner ($p<0.05$, low-dose, n=18; $p<0.01$, high-dose, n=15). The BP reduction in the lisinopril group was similar to that in the telmisartan 10 mg/kg/day group. Compared with

non-diabetic SHRs, untreated diabetic SHRs developed severe proteinuria and albuminuria over the exptl. period ($p<0.01$). In diabetic SHRs, proteinuria and albuminuria were dose-dependently and significantly attenuated by treatment with telmisartan ($p<0.01$ with the higher dose) and lisinopril ($p<0.01$). Compared with the untreated diabetic SHRs, cardiac hypertrophy was significantly reduced after treatment with both doses of telmisartan and with lisinopril. Telmisartan , 10 mg/kg/day, but not lisinopril, significantly attenuated the diabetes-induced increase in glomerular volume In conclusion, telmisartan, 10 mg/kg/day, is at least as beneficial as lisinopril, 10 mg/kg/day, in lowering BP, reducing cardiac hypertrophy and attenuating renal excretion of protein and albumin in this model.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparative antihypertensive, renoprotective, and cardioprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2003:656399 CAPLUS |
| DOCUMENT NUMBER: | 139:191449 |
| TITLE: | Renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy |
| INVENTOR(S): | Pedersen-Bjergaard, Ulrik; Agerholm-Larsen, Birgit; Thorsteinsson, Birger; Pramming, Stig |
| PATENT ASSIGNEE(S): | Den. |
| SOURCE: | U.S. Pat. Appl. Publ., 17 pp.<br>CODEN: USXXCO |
| DOCUMENT TYPE: | Patent |
| LANGUAGE: | English |
| FAMILY ACC. NUM. COUNT: | 1 |

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003158090 | A1 | 20030821 | US 2002-195330 | 20021004 <-- |

PRIORITY APPLN. INFO.: US 2001-306859P P 20010723

AB The present invention provides novel methods of treatment of diabetes mellitus as well as methods of diagnosing the susceptibility of hypoglycemia in an individual. The method of treatment includes administering to an individual a sufficient amount of at least one inhibitor of the renin-angiotensin II system and at least one antidiabetic, for example insulin. Another objective of the present invention is to provide methods of preventing hypoglycemia in an individual in need thereof comprising administering to said individual a pharmaceutical effective amount of an inhibitor of the renin-angiotensin II system. In particular, such an individual may be an individual suffering from diabetes mellitus. A further objective of the present invention is to provide methods to diagnose the susceptibility to hypoglycemia of an individual comprising detecting within a predetd. tissue sample the genotype of the angiotensin-converting enzyme (ACE) gene; or detecting within a predetd. tissue sample the activity of ACE; and correlating said genotype or activity to the susceptibility of hypoglycemia.

IT 144701-48-4, Telmisartan
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 6 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:376495 CAPLUS
DOCUMENT NUMBER: 135:236137
TITLE: The role of angiotensin II receptor antagonists in the management of diabetes
AUTHOR(S): Barnett, Anthony H.
CORPORATE SOURCE: Birmingham Heartlands Hospital, Birmingham, UK
SOURCE: Blood Pressure, Supplement (2001), (1), 21-26
CODEN: BPSUEY; ISSN: 0803-8023
PUBLISHER: Taylor & Francis
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Diabetic nephropathy, which develops in about 30% of patients with diabetes, is a progressive condition. It is characterized by increased blood pressure, declining glomerular filtration rate and

albuminuria. Lowering of blood pressure in diabetic patients is associated with reduced cardiovascular risk and renal protection. Inhibitors of angiotensin-converting enzyme (ACE) are the current gold standard treatment for hypertension in patients with type I diabetes because, in addition to their blood pressure lowering ability, they are thought to oppose the increased intraglomerular pressure that is mediated in part by angiotensin II. The angiotensin II receptor antagonists, a more recently developed class of antihypertensive agents, appear to be as effective as ACE inhibitors in delaying the progression of renal injury in animal models of diabetes. They act by selectively blocking the binding of angiotensin II to the AT1 receptor and may, therefore, offer a more complete blockade of the renin-angiotensin system than ACE inhibitors. The renal and antihypertensive effects of this class of drug in patients with diabetes are now being investigated in long-term clin. trials. The multicenter Diabetics Exposed to Telmisartan And EnalaprIL (DETAIL) study is a randomized, double-blind, parallel-group comparison of the renal and antihypertensive effects of the angiotensin II receptor antagonist telmisartan and the ACE inhibitor enalapril in 272 patients with type II diabetes. The primary outcome is change in glomerular filtration rate over the 5 yr of the study.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of angiotensin II receptor antagonists in management of diabetes)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:167787 CAPLUS

DOCUMENT NUMBER: 134:202715

TITLE: Pharmaceutical formulations of ACE and ATII inhibitors for prevention of stroke, diabetes and/or congestive heart failure

INVENTOR(S): Schoelkens, Bernward; Bender, Norbert; Rangoonwala, Badrudin; Dagenais, Gilles; Gerstein, Hertzel; Ljunggren, Anders; Yusuf, Salim

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001015673 | A2 | 20010308 | WO 2000-EP8341 | 20000825 <-- |
| WO 2001015673 | A3 | 20020307 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2382387 | C | 20010308 | CA 2000-2382387 | 20000825 <-- |
| CA 2382387 | A1 | 20010308 | | |
| CA 2500709 | A1 | 20010308 | CA 2000-2500709 | 20000825 <-- |
| BR 2000013540 | A | 20020430 | BR 2000-13540 | 20000825 <-- |
| EP 1212081 | A2 | 20020612 | EP 2000-965898 | 20000825 <-- |
| EP 1212081 | B1 | 20051026 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| TR 200200518 | T2 | 20020621 | TR 2002-518 | 20000825 <-- |
| TR 200202466 | T2 | 20021223 | TR 2002-2466 | 20000825 <-- |
| TR 200202467 | T2 | 20021223 | TR 2002-2467 | 20000825 <-- |
| HU 200202461 | A2 | 20021228 | HU 2002-2461 | 20000825 <-- |
| JP 2003508426 | T | 20030304 | JP 2001-519887 | 20000825 <-- |
| EE 200200085 | A | 20030415 | EE 2002-85 | 20000825 <-- |
| EP 1437131 | A1 | 20040714 | EP 2004-6330 | 20000825 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| AT 307604 | T | 20051115 | AT 2000-965898 | 20000825 |
| RU 2272651 | C2 | 20060327 | RU 2002-107673 | 20000825 |
| ES 2250192 | T3 | 20060416 | ES 2000-965898 | 20000825 |
| BG 106319 | A | 20021229 | BG 2002-106319 | 20020118 <-- |
| NO 2002000850 | A | 20020221 | NO 2002-850 | 20020221 <-- |
| ZA 2002001471 | A | 20030303 | ZA 2002-1471 | 20020221 <-- |
| AU 2005203694 | A1 | 20050908 | AU 2005-203694 | 20050817 |
| US 2006194868 | A1 | 20060831 | US 2006-415137 | 20060502 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| SE 1999-3028 | A | 19990827 |
| AU 2000-76484 | A3 | 20000825 |
| CA 2000-2382387 | A3 | 20000825 |
| EP 2000-965898 | A3 | 20000825 |
| US 2000-645556 | B1 | 20000825 |
| WO 2000-EP8341 | W | 20000825 |

AB The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS), i.e., inhibitors of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor (ATII) antagonists or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, in the manufacture of a medicament for the prevention and/or treatment of stroke, diabetes and/or congestive heart failure (CHF). A large-scale clin. trial was designed to examine the effect of the ACE inhibitor ramipril vs. placebo in reducing cardiovascular events. There was a clear 32% reduction in the ramipril group in the number of patients who developed a stroke, and this is surprising since patients were normotensive when recruited to the study. The number of patients who developed CHF was significantly reduced by 21% in the ramipril group, which is unexpected since patients had no signs or symptoms of CHF at

study start. Equally surprising is the marked 36% reduction in the number of patients who developed diabetes in the ramipril group.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of inhibitors of renin-angiotensin system for prevention and/or treatment of stroke, diabetes and/or congestive heart failure)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 8 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2003:78061 USPATFULL |
| TITLE: | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| INVENTOR(S): | Davis, Harry R., Berkeley Heights, NJ, UNITED STATES<br>Kosoglou, Teddy, Jamison, PA, UNITED STATES |
| PATENT ASSIGNEE(S): | Schering Corporation (U.S. corporation) |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003053981 | A1 | 20030320 | <-- |
| APPLICATION INFO.: | US 2002-57534 | A1 | 20020125 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-264600P | 20010126 (60) |
| | US 2001-323842P | 20010921 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | APPLICATION |
| LEGAL REPRESENTATIVE: | SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530 |
| NUMBER OF CLAIMS: | 81 |
| EXEMPLARY CLAIM: | 1 |
| LINE COUNT: | 4194 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted β-lactam sterol

absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2002:323139 USPATFULL | | | |
| TITLE: | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | | | |
| INVENTOR(S): | Davis, Harry R., Berkeley Heights, NJ, UNITED STATES<br>Kosoglou, Teddy, Jamison, PA, UNITED STATES | | | |
| PATENT ASSIGNEE(S): | Schering Corporation (U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2002183305 | A1 | 20021205 | <-- |
| APPLICATION INFO.: | US 2002-57646 | A1 | 20020125 (10) | |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2001-264275P | | 20010126 (60) | |
| | US 2001-323842P | | 20010921 (60) | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530 | | | |
| NUMBER OF CLAIMS: | 81 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 4256 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2002:336849 USPATFULL | | | |
| TITLE: | Sterol absorption inhibitor compositions | | | |
| INVENTOR(S): | Cho, Wing-Kee Philip, Princeton, NJ, UNITED STATES<br>Davis, Harry R., Berkeley Heights, NJ, UNITED STATES<br>Kosoglou, Teddy, Jamison, PA, UNITED STATES<br>Picard, Gilles J., Braine L'Alleud, BELGIUM | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2002192203 | A1 | 20021219 | <-- |
| | US 7030106 | B2 | 20060418 | |
| APPLICATION INFO.: | US 2002-136968 | A1 | 20020501 (10) | |
| RELATED APPLN. INFO.: | Division of Ser. No. US 2002-57323, filed on 25 Jan 2002, PENDING | | | |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2001-264396P | | 20010126 (60) | |
| | US 2001-323839P | | 20010921 (60) | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 4987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes , obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:273408 USPATFULL
TITLE: Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
Kosoglou, Teddy, Jamison, PA, UNITED STATES
Picard, Gilles J., Brussels, BELGIUM
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002151536 | A1 | 20021017 | <-- |
| APPLICATION INFO.: | US 2002-57323 | A1 | 20020125 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-264396P | 20010126 (60) |
| | US 2001-323839P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 5004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes , obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:283080 USPATFULL
TITLE: Method of treatment and/or prophylaxis
INVENTOR(S): Smith, Maree Therese, Bardon, AUSTRALIA
Brown, Lindsay Charles, Sinnamon Park, AUSTRALIA

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003199424 | A1 | 20031023 | <-- |
| APPLICATION INFO.: | US 2003-393056 | A1 | 20030320 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2002-365858P | 20020320 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 2302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the use of angiotensin II receptor I (AT.sub.1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The present invention also discloses the use of AT.sub.1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially in individuals having, or at risk of developing, a neuropathic condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(method of treatment and prophylaxis of neuropathic condition)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 13 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:245001 USPATFULL
TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
INVENTOR(S): Boehm, Peter, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
Meinicke, Wolf Thomas, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Riedel, Axel, Maselheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003171415 | A1 | 20030911 | <-- |
| APPLICATION INFO.: | US 2003-354713 | A1 | 20030130 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2001-EP9428, filed on 16 Aug 2001, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 2000-20691 | 20000822 |
| | DE 2001-DE108215 | 20010220 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment of indications which can be positively influenced by inhibition of AT.sub.1 mediated effects with maintenance of AT.sub.2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT.sub.1 receptors in the subepithelial area or increase of AT.sub.2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 14 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:93574 USPATFULL

TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
INVENTOR(S): Gougoutas, Jack Z., Princeton, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003064935 | A1 | 20030403 | <-- |
| | US 6774112 | B2 | 20040810 | |
| APPLICATION INFO.: | US 2002-117914 | A1 | 20020408 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-283097P | 20010411 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1995
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula ##STR1##

wherein

R.sup.1, R.sup.2 and R.sup.2a are independently hydrogen, OH, OR.sup.5, alkyl, --OCHF.sub.2, --OCF.sub.3, --SR.sup.5a or halogen;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5b, alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CONR.sup.6R.sup.6a, --CO.sub.2R.sup.5c, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5d)R.sup.6d, --CN, --NHCOR.sup.5e, --NHSO.sub.2R.sup.5f, --NHSO.sub.2Aryl, --SR.sup.5g, --SOR.sup.5h, --SO.sub.2R.sup.5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:759925 CAPLUS
DOCUMENT NUMBER: 139:316443
TITLE: Renal involvement in hypertensive cardiovascular disease
AUTHOR(S): Sharma, A. M.

CORPORATE SOURCE: McMaster University, Hamilton, ON, Can.
SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F12-F18
CODEN: EHJSFT; ISSN: 1520-765X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Cardiovascular morbidity and mortality are elevated in renally impaired patients, especially if they are hypertensive. Diabetes is also associated with a high prevalence of cardiovascular morbidity and end-stage renal disease. Albuminuria, elevated serum creatinine, decreased creatinine clearance and proteinuria independently predict cardiovascular risk. Even patients with mild renal impairment should be treated to slow kidney disease progression and reduce vascular damage. Blood pressure control is effective in reducing vascular complications of diabetes, but not all classes of antihypertensive agents provide renoprotection. Angiotensin-converting enzyme inhibitors are superior to beta-blockers in preventing or delaying the loss of kidney function associated with hypertension. The renoprotection appears to be in part independent of the antihypertensive effect. Angiotensin II receptor blockers (ARBs) also reduce the risk of renal complications in diabetics. Telmisartan seems well suited to provide renoprotection because, unlike other ARBs, it is almost exclusively excreted by the liver and no initial dose adjustment is required for patients with mild-to-moderate renal impairment. Other advantages of telmisartan include its very high volume of distribution and long terminal elimination half-life. Clin. trials to evaluate telmisartan will address the problems of diabetes, renal impairment and end-organ disease.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(relationship between hypertensive cardiovascular disease and renal disease)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:166532 USPATFULL
TITLE: C-aryl glucoside SGLT2 inhibitors and method
INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES

Ellsworth, Bruce, Princeton, NJ, UNITED STATES
Meng, Wei, Pennington, NJ, UNITED STATES
Wu, Gang, Princeton, NJ, UNITED STATES
Sher, Philip M., Plainsboro, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003114390 | A1 | 20030619 | <-- |
| | US 6936590 | B2 | 20050830 | |
| APPLICATION INFO.: | US 2002-264410 | A1 | 20021004 | (10) |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 2410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1##

alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:96100 USPATFULL
TITLE: Retinoid-related receptor function regulating agent
INVENTOR(S): Sugiyama, Yasuo, Kawanishi, JAPAN
Momose, Yu, Takarazuka, JAPAN
Kimura, Hiroyuki, Sakai, JAPAN
Sakamoto, Junichi, Toyonaka, JAPAN
Odaka, Hiroyuki, Kobe, JAPAN
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6545009 | B1 | 20030408 | <-- |
| | WO 2000001679 | | 20000113 | <-- |
| APPLICATION INFO.: | US 2000-720644 | | 20001228 | (9) |
| | WO 1999-JP3520 | | 19990630 | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-186698 | 19980701 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Tsang, Cecilia
ASSISTANT EXAMINER: Sackey, Ebenezer
LEGAL REPRESENTATIVE: Cha, Mark, Ramesh, Elaine
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia,

preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2002:251945 USPATFULL | | | |
| TITLE: | C-aryl glucoside SGLT2 inhibitors and method | | | |
| INVENTOR(S): | Ellsworth, Bruce, Princeton, NJ, UNITED STATES<br>Washburn, William N., Titusville, NJ, UNITED STATES<br>Sher, Philip M., Plainsboro, NJ, UNITED STATES<br>Wu, Gang, Princeton, NJ, UNITED STATES<br>Meng, Wei, Pennington, NJ, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2002137903 | A1 | 20020926 | <-- |
| | US 6515117 | B2 | 20030204 | |
| APPLICATION INFO.: | US 2002-151436 | A1 | 20020520 | (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-679027, filed on 4 Oct 2000, GRANTED, Pat. No. US 6414126 | | | |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2000-194615P | | 20000405 | (60) |
| | US 1999-158773P | | 19991012 | (60) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000 | | | |
| NUMBER OF CLAIMS: | 17 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 1148 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An SGLT2 inhibiting compound is provided having the formula ##STR1##

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2002:160855 USPATFULL | | | |
| TITLE: | C-aryl glucoside SGLT2 inhibitors and method | | | |
| INVENTOR(S): | Ellsworth, Bruce, Princeton, NJ, United States<br>Washburn, William N., Titusville, NJ, United States<br>Sher, Philip M., Plainsboro, NJ, United States<br>Wu, Gang, Princeton, NJ, United States<br>Meng, Wei, Pennington, NJ, United States | | | |
| PATENT ASSIGNEE(S): | Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 6414126 | B1 | 20020702 | <-- |
| APPLICATION INFO.: | US 2000-679027 | | 20001004 | (9) |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2000-194615P | | 20000405 | (60) |
| | US 1999-158773P | | 19991012 | (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gitomer, Ralph
ASSISTANT EXAMINER: Khare, Devesh
LEGAL REPRESENTATIVE: Provoost, Jonathan N.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

where

R.sup.1, R.sup.2, and R.sup.2a are independently hydrogen, OH, OR.sup.5, lower alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i or halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5a, OAryl, OCH.sub.2Aryl, lower alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2R.sup.5b, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2R.sup.5d, --NHSO.sub.2Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2R.sup.5g, --SO.sub.2Aryl, or a five, six or seven membered heterocycle, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently lower alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle;

A is O, S, NH, or (CH.sub.2).sub.n where n is 0-3.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:265968 USPATFULL
TITLE: Oxyiminoalkanoic acid derivatives
INVENTOR(S): Momose, Yu, Hyogo, JAPAN
Odaka, Hiroyuki, Hyogo, JAPAN
Imoto, Hiroshi, Shiga, JAPAN
Kimura, Hiroyuki, Osaka, JAPAN
Sakamoto, Junichi, Osaka, JAPAN

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003186985 | A1 | 20031002 | <-- |
| | US 6924300 | B2 | 20050802 | |
| APPLICATION INFO.: | US 2002-331056 | A1 | 20021227 (10) | |

RELATED APPLN. INFO.: Division of Ser. No. US 2000-714699, filed on 16 Nov 2000, GRANTED, Pat. No. US 6495581 Division of Ser. No. US 1999-423854, filed on 15 Nov 1999, GRANTED, Pat. No.

US 6251926 A 371 of International Ser. No. WO 1999-JP2407, filed on 10 May 1999, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-127921 | 19980511 |
| | JP 1998-127922 | 19980511 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 6054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methylpyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:106793 USPATFULL
TITLE: Method of treatment
INVENTOR(S): Shahinfar, Shahnaz, Newton Square, PA, UNITED STATES
Zhang, Zhongxin, Blue Bell, PA, UNITED STATES
Brenner, Barry M., Weston, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003073705 | A1 | 20030417 | <-- |
| APPLICATION INFO.: | US 2002-143415 | A1 | 20020510 | (10) |

| | NUMBER | DATE |
|---|---|---|

| | |
|---|---|
| PRIORITY INFORMATION: | US 2001-290839P 20010514 (60) |
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | APPLICATION |
| LEGAL REPRESENTATIVE: | MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907 |
| NUMBER OF CLAIMS: | 32 |
| EXEMPLARY CLAIM: | 1 |
| NUMBER OF DRAWINGS: | 6 Drawing Page(s) |
| LINE COUNT: | 1200 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine, or pharmaceutically acceptable salts thereof are useful.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 22 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2001:97948 USPATFULL |
| TITLE: | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| INVENTOR(S): | Momose, Yu, Takarazuka, Japan<br>Odaka, Hiroyuki, Kobe, Japan<br>Imoto, Hiroshi, Kusatsu, Japan<br>Kimura, Hiroyuki, Sakai, Japan<br>Sakamoto, Junichi, Toyonaka, Japan |
| PATENT ASSIGNEE(S): | Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation) |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6251926 | B1 | 20010626 | <-- |

| | | | |
|---|---|---|---|
| | WO 9958510 | 19991118 | <-- |
| APPLICATION INFO.: | US 1999-423854 | 19991115 | (9) |
| | WO 1999-JP2407 | 19990510 | |
| | | 19991115 | PCT 371 date |
| | | 19991115 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-127921 | 19980511 |
| | JP 1998-127922 | 19980511 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
ASSISTANT EXAMINER: Wright, Sonya
LEGAL REPRESENTATIVE: Riesen, Philippe Y.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 5841
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:332756 USPATFULL
TITLE: Oxyiminoalkanoic acid derivatives
INVENTOR(S): Momose, Yu, Takarazuka, JAPAN
Odaka, Hiroyuki, Kobe, JAPAN
Imoto, Hiroshi, Kusatsu, JAPAN
Kimura, Hiroyuki, Sakai, JAPAN
Sakamoto, Junichi, Toyonaka, JAPAN
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN
(non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6495581 | B1 | 20021217 | <-- |
| APPLICATION INFO.: | US 2000-714699 | | 20001116 | (9) |

RELATED APPLN. INFO.: Division of Ser. No. US 423854, now patented, Pat. No. US 6251926

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-127921 | 19980511 |
| | JP 1998-127922 | 19980511 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Wright, Sonya
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer

of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methyl pyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof which has excellent hypoglycemic and hypolipidemic actions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:283219 USPATFULL | | | |
| TITLE: | Heterocyclic containing biphenyl aP2 inhibitors and method | | | |
| INVENTOR(S): | Robl, Jeffrey A., Newtown, PA, UNITED STATES<br>Magnin, David R., Hamilton, NJ, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003199563 | A1 | 20031023 | <-- |
| | US 6927227 | B2 | 20050809 | |
| APPLICATION INFO.: | US 2002-321137 | A1 | 20021217 (10) | |
| RELATED APPLN. INFO.: | Division of Ser. No. US 2000-519079, filed on 6 Mar 2000, GRANTED, Pat. No. US 6548529 | | | |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 1999-127745P | | 19990405 (60) | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000 | | | |
| NUMBER OF CLAIMS: | 34 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 3547 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:226410 USPATFULL
TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
INVENTOR(S): Anderson, Craig, Devonport/Auckland, NEW ZEALAND
Yusuf, Salim, Carlisle, CANADA
Sleight, Peter, Wheatley, Oxfordshire, UNITED KINGDOM
Hilbrich, Lutz, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003158223 | A1 | 20030821 | <-- |
| APPLICATION INFO.: | US 2002-79703 | A1 | 20020220 | (10) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 26 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:172321 USPATFULL
TITLE: Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES

Robl, Jeffrey A., Newtown, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002091078 | A1 | 20020711 | <-- |
| | US 6649622 | B2 | 20031118 | |
| APPLICATION INFO.: | US 2001-771310 | A1 | 20010126 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-178598P | 20000128 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 3597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein A, B, X, and Y are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:149184 USPATFULL
TITLE: Pyridone inhibitors of fatty acid binding protein and method
INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES
Robl, Jeffrey A., Newtown, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002077340 | A1 | 20020620 | <-- |
| | US 6670380 | B2 | 20031230 | |
| APPLICATION INFO.: | US 2001-989212 | A1 | 20011120 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-252014P | 20001120 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided having the formula ##STR1##

wherein A, Q, and X are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such compounds alone or in combination with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:888552 CAPLUS
DOCUMENT NUMBER: 137:380012
TITLE: Method of treatment for prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function
INVENTOR(S): Shahinfar, Shahnaz; Brenner, Barry M.; Zhang, Zhongxin
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002092081 | A1 | 20021121 | WO 2002-US14919 | 20020510 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003073705 | A1 | 20030417 | US 2002-143415 | 20020510 <-- |
| CA 2445913 | A1 | 20031029 | CA 2002-2445913 | 20020510 <-- |
| EP 1389105 | A1 | 20040218 | EP 2002-731759 | 20020510 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2005501815 | T | 20050120 | JP 2002-588998 | 20020510 |

PRIORITY APPLN. INFO.:
US 2001-290839P P 20010514
WO 2002-US14919 W 20020510

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[((2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4, -b]pyridine, or pharmaceutically acceptable salts thereof are useful.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:226419 USPATFULL | | | |
| TITLE: | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method | | | |
| INVENTOR(S): | Cheng, Peter T., Princeton, NJ, UNITED STATES<br>Zhang, Hao, Belle Mead, NJ, UNITED STATES<br>Hariharan, Narayanan, Richboro, PA, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003158232 | A1 | 20030821 | <-- |
| | US 6967212 | B2 | 20051122 | |
| APPLICATION INFO.: | US 2002-294525 | A1 | 20021114 (10) | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2002-153454, filed on 22 May 2002, PENDING | | | |
| | NUMBER | DATE | | |
| PRIORITY INFORMATION: | US 2001-294380P | 20010530 (60) | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000 | | | |
| NUMBER OF CLAIMS: | 20 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 3 Drawing Page(s) | | | |
| LINE COUNT: | 3975 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R.sup.2a, R.sup.2b, R.sup.2c, X.sub.1 to X.sub.7, R.sup.1, R.sup.2, R.sup.3, R.sup.3a, R.sup.4, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:134647 USPATFULL
TITLE: Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES
Hariharan, Narayanan, Richboro, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003092736 | A1 | 20030515 | <-- |
| APPLICATION INFO.: | US 2002-153454 | A1 | 20020522 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-294380P | 20010530 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R.sup.2a, R.sup.2b, R.sup.2c, X.sub.1 to X.sub.7, R.sup.1, R.sup.2, R.sup.3, R.sup.3a, R.sup.4, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:102390 USPATFULL
TITLE: Heterocyclic containing biphenyl aP2 inhibitors and method
INVENTOR(S): Robl, Jeffrey A., Newtown, PA, United States
Sulsky, Richard B., West Trenton, NJ, United States
Magnin, David R., Hamilton, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6548529 | B1 | 20030415 | <-- |
| APPLICATION INFO.: | US 2000-519079 | | 20000306 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-127745P | 19990405 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Shameem, Golam M M
LEGAL REPRESENTATIVE: Hermenau, Ronald S., Kilcoyne, John, Rodney, Burton
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:428761 CAPLUS
DOCUMENT NUMBER: 137:11000
TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction
INVENTOR(S): Sahota, Pritam Singh
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2002043807 | A2 | 20020606 | WO 2001-EP13976 | | 20011129 <-- |
| WO 2002043807 | A3 | 20030814 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW | | | | | |
| RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | | |
| CA 2430924 | A1 | 20020606 | CA 2001-2430924 | | 20011129 <-- |
| AU 2002026365 | A5 | 20020611 | AU 2002-26365 | | 20011129 <-- |
| EP 1353727 | A2 | 20031022 | EP 2001-995680 | | 20011129 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004514703 | T | 20040520 | JP 2002-545776 | | 20011129 |
| US 2002107236 | A1 | 20020808 | US 2001-8445 | | 20011203 <-- |
| US 2004087484 | A1 | 20040506 | US 2003-433189 | | 20030624 |
| PRIORITY APPLN. INFO.: | | | US 2000-250540P | P | 20001201 |
| | | | WO 2001-EP13976 | W | 20011129 |

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 33 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:790344 CAPLUS
DOCUMENT NUMBER: 133:340269
TITLE: Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy
INVENTOR(S): Nakagawa, Shizue; Nagisa, Yasutaka; Ikeda, Hitoshi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000066161 | A1 | 20001109 | WO 2000-JP2766 | 20000427 <-- |
| W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2371554 | A1 | 20001109 | CA 2000-2371554 | 20000427 <-- |
| BR 2000010084 | A | 20020115 | BR 2000-10084 | 20000427 <-- |
| EP 1197223 | A1 | 20020417 | EP 2000-921056 | 20000427 <-- |
| EP 1197223 | B1 | 20050216 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| NZ 514855 | A | 20040130 | NZ 2000-514855 | 20000427 |
| AU 774799 | B2 | 20040708 | AU 2000-41434 | 20000427 |
| RU 2239454 | C2 | 20041110 | RU 2001-132073 | 20000427 |
| AT 289204 | T | 20050315 | AT 2000-921056 | 20000427 |
| PT 1197223 | T | 20050429 | PT 2000-921056 | 20000427 |
| ES 2233362 | T3 | 20050616 | ES 2000-921056 | 20000427 |
| JP 2001010975 | A | 20010116 | JP 2000-134243 | 20000428 <-- |
| US 7064141 | B1 | 20060620 | US 2001-958740 | 20011016 |
| ZA 2001008527 | A | 20021017 | ZA 2001-8527 | 20011017 <-- |
| NO 2001005257 | A | 20011026 | NO 2001-5257 | 20011026 <-- |

US 2006189669 A1 20060824 US 2006-406345 20060419
PRIORITY APPLN. INFO.: JP 1999-121498 A 19990428
WO 2000-JP2766 W 20000427
US 2001-958740 A3 20011016

OTHER SOURCE(S): MARPAT 133:340269

AB Disclosed are drugs which contain a compound having an angiotensin II antagonism or its salt and are useful in, for example, preventing or treating simplex retinopathy or preproliferating retinopathy by inhibiting the progression thereof. Administration of candesartan cilexetil to diabetes model rats inhibited the production of VEGF and improved retinal elec. potentials. Formulations for capsules, tablets, and ophthalmic suspensions containing the invention compds. are also provided.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin II antagonists for treatment of retinopathy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 34 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:113449 USPATFULL

TITLE: Methods for tissue protection using highly effective inhibition of the renin-angiotensin system

INVENTOR(S): Weinberg, Marc S., Seekonk, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003078190 | A1 | 20030424 | <-- |
| APPLICATION INFO.: | US 2002-155824 | A1 | 20020524 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-293835P | 20010525 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211

NUMBER OF CLAIMS: 133

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 3074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and pharmaceutical compositions are provided for protecting tissue of a subject from the effects of angiotensin II. The methods involve administering to subjects angiotensin receptor blockers (ARB), either by themselves at doses beyond those recommended or effective for the management of hypertension, or in combination with angiotensin-converting enzyme inhibitors (ACEI). The pharmaceutical compositions include both an ARB and an ACEI and are formulated in certain preferred embodiments for once-daily oral administration. The methods and pharmaceutical compositions are useful for the treatment of proteinuria, chronic or congestive heart failure, aneurysms, and vascular tissue hypertrophy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan 144701-48-4D, Telmisartan, prodrug derivs.
(renin-angiotensin system inhibition for protecting tissue from effects of angiotensin II)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 35 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:36849 USPATFULL
TITLE: Method for reducing mortality with an angiotensin II antagonist
INVENTOR(S): Beere, Polly A., Lahaska, PA, United States
Chang, Paul I., Doylestown, PA, United States
Pitt, Bertram, Ann Arbor, MI, United States
Rucinska, Eva J., Blue Bell, PA, United States
Segal, Robert, Gwynedd Valley, PA, United States
Sharma, Divakar, Hatfield, PA, United States
Snavely, Duane B., Chalfont, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6201002 | B1 | 20010313 | <-- |
| APPLICATION INFO.: | US 1998-3159 | | 19980106 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1997-34927P | 19970110 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: Camara, Valerie J., Daniel, Mark R.
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II antagonists to treat symptomatic heart failure)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 36 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2002652897 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12411451
TITLE: Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
AUTHOR: Sharma Arya M; Janke Jurgen; Gorzelniak Kerstin; Engeli Stefan; Luft Friedrich C
CORPORATE SOURCE: HELIOS Klinikum Berlin, Franz Volhard Clinic-Charite, Humboldt University of Berlin, and Max Delbruck Center for Molecular Medicine, Berlin, Germany.. sharma@ccc.mcmaster.ca
SOURCE: Hypertension, (2002 Nov) Vol. 40, No. 5, pp. 609-11.
Journal code: 7906255. E-ISSN: 1524-4563.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200211
ENTRY DATE: Entered STN: 5 Nov 2002
Last Updated on STN: 11 Dec 2002
Entered Medline: 8 Nov 2002

AB Obesity is the prime risk factor for the development of type 2 diabetes. Recent clinical trials have shown that blockade of the renin-angiotensin system, either by inhibiting the angiotensin-converting enzyme or blocking the angiotensin type 1 receptor, may substantially lower the risk for type 2 diabetes. The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II markedly inhibits adipogenic differentiation of human adipocytes via the angiotensin type I receptor and that expression of angiotensin II-forming enzymes in adipose tissue is inversely correlated with insulin sensitivity, we propose the hypothesis that blockade of the renin-angiotensin system prevents diabetes by promoting the recruitment and differentiation of adipocytes. Increased formation of adipocytes would counteract the ectopic deposition of lipids in other tissues (muscle, liver, pancreas), thereby improving insulin sensitivity and preventing the development of type 2 diabetes.

L6 ANSWER 37 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:122803 CAPLUS
DOCUMENT NUMBER: 142:219083
TITLE: Preparation of phosphorus-containing rapamycin derivatives for use in pharmaceutical compositions as immunosuppressive and anticancer agents
INVENTOR(S): Metcalf, Chester A., III; Rozamus, Leonard W.; Wang, Yihan; Berstein, David L.
PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 635,054.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2005032825 | A1 | 20050210 | US 2004-862149 | 20040604 |
| US 7091213 | B2 | 20060815 | | |
| US 2003220297 | A1 | 20031127 | US 2003-357152 | 20030203 <-- |
| US 2004073024 | A1 | 20040415 | US 2003-635054 | 20030806 |
| US 2006264405 | A1 | 20061123 | US 2006-429582 | 20060505 |

| | | | | |
|---|---|---|---|---|
| US 2006264456 | A1 | 20061123 | US 2006-494418 | 20060727 |
| PRIORITY APPLN. INFO.: | | | US 2002-353252P | P 20020201 |
| | | | US 2002-426928P | P 20021115 |
| | | | US 2002-428383P | P 20021122 |
| | | | US 2002-433930P | P 20021217 |
| | | | US 2003-357152 | A2 20030203 |
| | | | US 2003-635054 | A2 20030806 |
| | | | US 2003-486367P | P 20030711 |
| | | | US 2004-862149 | A2 20040604 |
| | | | US 2004-889163 | B2 20040712 |
| | | | US 2005-711859P | P 20050826 |

OTHER SOURCE(S): CASREACT 142:219083; MARPAT 142:219083

GI




AB Rapamycin derivs. containing phosphorus moiety, such as I [A = O, S, NR2, absent; Q = V, OV, SV, NR2, absent; V = aliphatic, heteroaliph., aryl, heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR2VA; J = P(:K)(YR5)2, P(YR5)2, P(:K)(YR5)GR6; K = O, S; Y = O, S, NR2, bond; R2, R5 = aliphatic, heteroaliph., aryl, heteroaryl, H; R6 = PK(YR5)YR5, SO2YR5, C(O)YR5; G = O, S, NR2, (M)X; M = (un)substituted methylene, alkyl, alkylene; X = 1-6], and pharmaceutically acceptable derivs. thereof, were prepared for therapeutic use as immunosuppressive and anticancer agents. These rapamycin derivs. are useful for treatment of graft vs. host disease, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation, ocular uveitis; adult T-cell leukemia, lymphoma, fungal infections, hyperproliferative restenosis, graft vascular atherosclerosis, coronary artery disease, cerebrovascular disease, arteriosclerosis, atherosclerosis, nonatheromatous arteriosclerosis, or vascular wall damage from cellular events leading toward immune mediated vascular damage, stroke or multi-infarct dementia. Thus, I [A-QJ = OP(O)(OBu)Me] was prepared by reacting rapamycin with methylphosphonic dichloride and n-butanol using 3,5-lutidine in CH2Cl2 under a nitrogen atmospheric Binding affinity of the rapamycin phosphorus derivs. for human FKBP-12 protein was assayed, dosages for restenosis prevention were discussed.

IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of phosphorus-containing rapamycin derivs. for use in pharmaceutical compns. as immunosuppressive and anticancer agents)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:157602 CAPLUS
DOCUMENT NUMBER: 136:205430
TITLE: Pharmaceutical compositions containing AT-receptor antagonist or insulin secretion enhancers
INVENTOR(S): Allison, Malcolm; Gatlin, Marjorie Regan
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002015933 | A2 | 20020228 | WO 2001-EP9587 | 20010820 <-- |
| WO 2002015933 | A3 | 20030814 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001087698 | A5 | 20020304 | AU 2001-87698 | 20010820 <-- |
| EP 1351683 | A2 | 20031015 | EP 2001-967289 | 20010820 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004514654 | T | 20040520 | JP 2002-520854 | 20010820 |
| US 2004034065 | A1 | 20040219 | US 2003-362340 | 20030616 |
| US 2006089389 | A1 | 20060427 | US 2005-295928 | 20051207 |
| US 2006281790 | A1 | 20061214 | US 2006-508353 | 20060823 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-643641 | A | 20000822 |
| US 2000-327553P | P | 20000822 |
| WO 2001-EP9587 | W | 20010820 |
| US 2003-362340 | B1 | 20030616 |
| US 2005-295928 | B1 | 20051207 |

AB A pharmaceutical composition comprises as active ingredients an AT1-receptor antagonist or a salt, an insulin secretion enhancer or a its salt or an insulin sensitizer or its salt. Thus, tablets contained Starlix DS 60, lactose monohydrate 141.5, microcryst. cellulose 71, Povidone-K30 12, and Croscarmellose sodium 18.4, colloidal SiO2 6.4, Mg stearate 5.7, and Opadry 9 mg.

IT 144701-48-4, Telmisartan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing AT-receptor antagonist or insulin secretion enhancers)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 39 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:762798 CAPLUS

DOCUMENT NUMBER: 135:308910

TITLE: Pharmaceutical compositions containing an aldosterone synthase inhibitor and an AT1-receptor antagonist

INVENTOR(S): Steele, Ronald Edward

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001076574 | A2 | 20011018 | WO 2001-EP4116 | 20010410 <-- |
| WO 2001076574 | A3 | 20020425 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2405895 | A1 | 20011018 | CA 2001-2405895 | 20010410 | <-- |
| BR 2001010079 | A | 20021231 | BR 2001-10079 | 20010410 | <-- |
| EP 1282410 | A2 | 20030212 | EP 2001-940317 | 20010410 | <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2003530343 | T | 20031014 | JP 2001-574092 | 20010410 | <-- |
| NZ 521855 | A | 20041029 | NZ 2001-521855 | 20010410 | |
| NZ 534086 | A | 20060831 | NZ 2001-534086 | 20010410 | |
| US 2003083342 | A1 | 20030501 | US 2002-149107 | 20020827 | <-- |
| IN 2002CN01650 | A | 20050128 | IN 2002-CN1650 | 20021008 | |
| NO 2002004920 | A | 20021127 | NO 2002-4920 | 20021011 | <-- |
| ZA 2002008204 | A | 20031014 | ZA 2002-8204 | 20021011 | <-- |
| US 2004204444 | A1 | 20041014 | US 2004-826106 | 20040415 | |
| US 2005059697 | A1 | 20050317 | US 2004-940544 | 20040914 | |
| US 2006122217 | A1 | 20060608 | US 2005-291008 | 20051130 | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-196742P | P | 20000412 |
| NZ 2001-521855 | A1 | 20010410 |
| WO 2001-EP4116 | W | 20010410 |
| US 2002-149107 | A3 | 20020827 |
| US 2004-940544 | B1 | 20040914 |

AB The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. A pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof is used for the prevention of, delay of progression of, and treatment of a disease or condition selected from the group consisting of hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, hypothyroidism, myocardial infarction, etc. For example, a hard gelatin capsules were prepared containing valsartan 80.0 mg, microcryst. cellulose 110.0 mg, Polyvidone K30 45.2 mg, sodium lauryl sulfate 1.2 mg, crospovidone 26.0 mg, and magnesium stearate 2.6 mg by a granulation method.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 40 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:188513 USPATFULL | | | |
| TITLE: | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | | | |
| INVENTOR(S): | Devasthale, Pratik, Plainsboro, NJ, UNITED STATES<br>Jeon, Yoon T., Belle Mead, NJ, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003130306 | A1 | 20030710 | <-- |
| | US 6673815 | B2 | 20040106 | |
| APPLICATION INFO.: | US 2002-289053 | A1 | 20021106 | (10) |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2001-333022P | | 20011106 (60) | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000 | | | |
| NUMBER OF CLAIMS: | 39 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 1699 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, X.sub.1 is CH or N and, A, E, M, G, X.sub.2, X.sub.3, X.sub.4, R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:134608 USPATFULL | | | |
| TITLE: | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | | | |
| INVENTOR(S): | Cheng, Peter T., Princeton, NJ, UNITED STATES<br>Jeon, Yoon, Belle Mead, NJ, UNITED STATES<br>Wang, Wei, Princeton, NJ, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003092697 | A1 | 20030515 | <-- |

| | | | |
|---|---|---|---|
| | US 7105556 | B2 | 20060912 |
| APPLICATION INFO.: | US 2002-153342 | A1 | 20020522 (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-294505P | 20010530 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 2127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, X.sub.1 is C or N, and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, A, m, n, X.sub.2, X.sub.3 and X.sub.4 are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:757520 CAPLUS
DOCUMENT NUMBER: 139:255390
TITLE: Method of treatment and prophylaxis of neuropathic condition
INVENTOR(S): Smith, Maree Therese; Brown, Lindsay
PATENT ASSIGNEE(S): The University of Queensland, Australia
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2003077912 | A1 | 20030925 | WO 2003-AU336 | | 20030320 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2003209851 | A1 | 20030929 | AU 2003-209851 | | 20030320 <-- |
| US 2003199424 | A1 | 20031023 | US 2003-393056 | | 20030320 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-365858P | P | 20020320 |
| | | | WO 2003-AU336 | W | 20030320 |

AB The invention is involves the use of angiotensin II receptor 1 (AT1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The invention also discloses the use of AT1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially
in individuals having, or at risk of developing, a neuropathic condition.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treatment and prophylaxis of neuropathic condition)
RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:390959 CAPLUS
DOCUMENT NUMBER: 133:12837
TITLE: Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
AUTHOR(S): Israili, Z. H.
CORPORATE SOURCE: Emory University School of Medicine, Atlanta, GA, 30303, USA
SOURCE: Journal of Human Hypertension (2000), 14(Suppl. 1), S73-S86
CODEN: JHHYEN; ISSN: 0950-9240
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 174 refs. Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive agents. Recent clin. trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement in renal function), and cardioprotective effect in patients with heart failure. Several large long-term studies are in progress to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart disease and diabetic nephropathy. The ARBs specifically block the interaction of angiotensin II at the AT, receptor, thereby relaxing smooth muscle, increasing salt and water excretion, reducing plasma volume, and decreasing cellular hypertrophy. These agents exert their blood pressure-lowering effect mainly by reducing peripheral vascular resistance usually without a rise in heart rate. Most of the com. available ARBs control blood pressure for 24 h after once daily dosing. Sustained efficacy of blood pressure control, without any evidence of tachyphylaxis,

has been demonstrated after long-term administration (3 yr) of some of the ARBs. The efficacy of ARBs is similar to that of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or calcium channel blockers in patients with similar degree of hypertension. Higher daily doses, dietary salt restriction, and concomitant diuretic or ACE inhibitor administration amplify the antihypertensive effect of ARBs. The ARBs have a low incidence of adverse effects (headache, upper respiratory infection, back pain, muscle cramps, fatigue and dizziness), even in the elderly patients. After the approval of losartan, five other ARBs (candesartan cilexetil, eprosartan, irbesartan, telmisartan, and valsartan) and three combinations with hydrochlorothiazide (irbesartan, losartan and valsartan) have been approved as antihypertensive agents, and some 28 compds. are in various stages of development. The ARBs are non-peptide compds. with varied structures; some (candesartan, losartan, irbesartan, and valsartan) have a common tetrazolo-biphenyl structure. Except for irbesartan, all active ARBs have a carboxylic acid group. Candesartan cilexetil is a prodrug, while losartan has a metabolite (EXP3174) which is more active than the parent drug. No other metabolites of ARBs contribute significantly to the antihypertensive effect. The variation in the mol. structure of the ARBs results in differences in the binding affinity to the receptor and pharmacokinetic profiles. The differences observed in lipid solubility, absorption/distribution, plasma protein binding, bioavailability, biotransformation, plasma half-life, and systemic elimination influence the time of onset, duration of action, and efficacy of the ARBs. On the basis of the daily mg dose, the anti-hypertensive potency of the ARBs follows the sequence: candesartan cilexetil > telmisartan losartan > irbesartan valsartan > eprosartan. After oral administration, the ARBs are rapidly absorbed (time for peak plasma levels = 0.5-4 h) but they have a wide range of bioavailability (from a low of 13% for eprosartan to a high of 60-80% for irbesartan); food does not influence the bioavailability, except for valsartan (a reduction of 40-50%) and eprosartan (increase). A limited dose-peak plasma levels/areas under the plasma level-time curve proportionality is observed for some of the ARBs. Most of these drugs have high plasma protein binding (95-100%); irbesartan has the lowest binding among the group (90%). The steady-state vols. of distribution vary from a low of 9 L (candesartan) to a high of 500 L ( telmisartan). Plasma elimination half-life is short for candesartan cilexetil and losartan (1-4 h), intermediate for eprosartan and valsartan (5-10 h), and longer for candesartan, irbesartan and telmisartan (11-38 h); the active metabolite of losartan has a longer half-life than for the parent drug. The drugs and their active metabolites do not accumulate to a significant extent after repeated dosing, except for telmisartan (100%). Most of the orally administered dose of ARBs is excreted via bile into the feces; from 2% ( telmisartan) to 33% (candesartan) of the oral dose is excreted in the urine. In most cases, changes in pharmacokinetic parameters due to aging, mild to moderate renal disease and heart failure do not require dosage modification; dosage has to be individualized for eprosartan, losartan, telmisartan and valsartan in patients with hepatic disease. In general, pharmacokinetic drug-drug interactions are rare, with the exception of combination of digoxin and telmisartan. The ARBs are an important treatment option for hypertension, being relatively safe and efficacious. The beneficial effects of the ARB therapy go beyond blood pressure control. They may prove to have beneficial hemodynamic and neurohormonal effects in heart failure and provide renoprotection in diabetic nephropathy.

REFERENCE COUNT: 189 THERE ARE 189 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 44 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:141004 USPATFULL
TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003096846 | A1 | 20030522 | <-- |
| | US 6653314 | B2 | 20031125 | |
| APPLICATION INFO.: | US 2002-80981 | A1 | 20020222 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002
Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 5718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:100110 USPATFULL
TITLE: Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES
Ress, Rudyard J., Flemington, NJ, UNITED STATES
Strony, John T., Lebanon, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
Hauer, William, Warren, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003069221 | A1 | 20030410 | <-- |
| APPLICATION INFO.: | US 2002-57339 | A1 | 20020125 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-323842P | 20010921 (60) |
| | US 2001-264396P | 20010126 (60) |
| | US 2001-264600P | 20010126 (60) |
| | US 2001-264275P | 20010126 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 3423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2003255815 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12781906
TITLE: The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
AUTHOR: Unger Thomas
CORPORATE SOURCE: Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany.. Thomas.unger@charite.de
SOURCE: The American journal of cardiology, (2003 May 22) Vol. 91, No. 10A, pp. 28G-34G. Ref: 52
Journal code: 0207277. ISSN: 0002-9149.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200307
ENTRY DATE: Entered STN: 4 Jun 2003
Last Updated on STN: 10 Jul 2003
Entered Medline: 9 Jul 2003

AB The renin-angiotensin system evolved to maintain volume homeostasis and blood pressure and to prevent ischemia during acute volume loss. But in the present age, these mechanisms are redundant, and the clinical significance of angiotensin II results from its pathologic effects, which are mediated by the angiotensin II type 1 (AT(1)) receptor. Activation of AT(1) receptors has been linked to pathologic processes that contribute to atherosclerosis and ischemic events, including oxidative stress, inflammatory processes, low-density lipoprotein cholesterol trafficking, and prothrombotic states. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) program will compare the efficacy of the angiotensin II receptor blocker (ARB) telmisartan, the angiotensin-converting enzyme (ACE) inhibitor ramipril, and combination therapy with telmisartan plus ramipril for reducing cardiovascular risk. The ARB telmisartan is distinguished by its long duration of action, which compares favorably with some other ARBs and conventional antihypertensives. Ramipril was shown in the Heart Outcomes Prevention Evaluation (HOPE) study to reduce the risk for myocardial infarction (MI) and other cardiovascular events in patients at high risk for cardiovascular events but without heart failure or a low ejection fraction. The ONTARGET program consists of 2 randomized, double-blind, multicenter international trials: a principal trial, ONTARGET, and a parallel trial, Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease (TRANSCEND). The treatment arms for the principal ONTARGET study are telmisartan 80 mg, ramipril 10 mg, and combination therapy with telmisartan 80 mg plus ramipril 10 mg; for the parallel study TRANSCEND, the treatment arms are telmisartan 80 mg and placebo. Both trials will assess cardiovascular outcomes in patients at high risk using the same criteria as that of the HOPE study, with a single exception: the TRANSCEND trial will enroll patients who do not tolerate

ACE inhibitor treatment. The primary end points in both ONTARGET and TRANSCEND are death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. The secondary end points include newly diagnosed heart failure, revascularization, new-onset type 2 diabetes mellitus, nephropathy, cognitive decrease and dementia, and newly diagnosed atrial fibrillation; these will be used for hypothesis generation.

L6 ANSWER 47 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2002274881 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12015188
TITLE: Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
AUTHOR: Rippin J; Bain S C; Barnett A H
CORPORATE SOURCE: Department of Medicine, University of Birmingham, Birmingham B9 5SS, UK. (DETAIL study).
SOURCE: Journal of diabetes and its complications, (2002 May-Jun) Vol. 16, No. 3, pp. 195-200. Journal code: 9204583. ISSN: 1056-8727.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL) Journal; Article; (JOURNAL ARTICLE) (MULTICENTER STUDY) (RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200210
ENTRY DATE: Entered STN: 17 May 2002 Last Updated on STN: 8 Oct 2002 Entered Medline: 4 Oct 2002

AB The DETAIL (diabetics exposed to telmisartan and enalapril) study will compare the long-term renal outcome of treatment with the angiotensin II receptor antagonist (ARA) telmisartan versus the angiotensin-converting enzyme (ACE) inhibitor enalapril in patients with mild-to-moderate hypertension and diabetic nephropathy. In short-term clinical studies, ACE inhibitors reduce microalbuminuria and, in the longer term, they are superior to conventional therapies in maintaining normal renal function. ARAs also appear to be renoprotective in diabetic animals. In this double-blind, parallel-group study, 252 patients with Type 2 diabetes and concurrent hypertension (mean seated systolic blood pressure < or = 180 mm Hg, on treatment seated diastolic blood pressure < or = 95 mm Hg) have been randomised to once-daily telmisartan 40 mg or enalapril 10 mg; doses are mandatorily titrated to 80 and 20 mg once daily, respectively, after 4 weeks. The primary endpoint will be the change from baseline in glomerular filtration rate (GFR) after 5 years of therapy, using the iohexol method and central laboratory analysis. The secondary endpoints to be evaluated will be: changes in GFR in relation to baseline after 1-4 years of therapy; percentage changes in albumin excretion rate after 1-5 years; and incidences of end-stage renal disease, cardiovascular events, all-cause mortality, and adverse events. The planned date for the completion of the study is 2005.

L6 ANSWER 48 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:203196 CAPLUS
DOCUMENT NUMBER: 138:215317
TITLE: Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
INVENTOR(S): Liang, Matthew H.; Manson, Joann E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp. CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003049314 | A1 | 20030313 | US 2001-942084 | 20010828 <-- |
| US 6576256 | B2 | 20030610 | | |

PRIORITY APPLN. INFO.: US 2001-942084 20010828

AB Methods and compns. are provided for reducing the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The methods comprise administering a combination of: a cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B6, vitamin B12, and folic acid. Pharmaceutical formulations combining all the active agents in unit-dose form for once-daily dosing are provided. Tablets containing pravastatin 40 mg, ramipril 10 mg, aspirin (in enteric coated granules) 81 mg, Vitamin B6 50 mg, Vitamin B12 1 mg, folic acid 3 mg, calcium carbonate 50 mg, magnesium oxide 25 mg, magnesium carbonate 25 mg, microcryst. cellulose 25 mg, lactose 25 mg, and magnesium stearate 1 mg are used to treat subjects at elevated cardiac risk.

IT 144701-48-4, Telmisartan
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as renin-angiotensin system inhibitor; treatment of patients at elevated cardiovascular risk with combination of cholesterol-lowering agent, inhibitor of renin-angiotensin system, and aspirin)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 49 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:574955 CAPLUS
DOCUMENT NUMBER: 137:129903
TITLE: Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| WO 2002058731 | A2 | 20020801 | WO 2002-US1196 | 20020125 | <-- |
| WO 2002058731 | A3 | 20031120 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2434436 | A1 | 20020801 | CA 2002-2434436 | 20020125 | <-- |
| CA 2562982 | A1 | 20020801 | CA 2002-2562982 | 20020125 | <-- |
| CA 2563051 | A1 | 20020801 | CA 2002-2563051 | 20020125 | <-- |
| US 2003069221 | A1 | 20030410 | US 2002-57339 | 20020125 | <-- |
| EP 1385548 | A2 | 20040204 | EP 2002-707500 | 20020125 | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| BR 2002006644 | A | 20040225 | BR 2002-6644 | 20020125 | |
| HU 200303923 | A2 | 20040301 | HU 2003-3923 | 20020125 | |
| EP 1413331 | A2 | 20040428 | EP 2004-161 | 20020125 | |
| EP 1413331 | A3 | 20040630 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004517919 | T | 20040617 | JP 2002-559065 | 20020125 | |
| CN 1582168 | A | 20050216 | CN 2002-804219 | 20020125 | |
| EP 1541175 | A2 | 20050615 | EP 2005-3029 | 20020125 | |
| EP 1541175 | A3 | 20060412 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| EP 1671650 | A1 | 20060621 | EP 2006-5831 | 20020125 | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| CN 1915429 | A | 20070221 | CN 2006-10126233 | 20020125 | |
| ZA 2003005692 | A | 20041025 | ZA 2003-5692 | 20030723 | |
| ZA 2003005694 | A | 20041025 | ZA 2003-5694 | 20030723 | |
| ZA 2003005693 | A | 20050209 | ZA 2003-5693 | 20030723 | |
| IN 2003CN01150 | A | 20050422 | IN 2003-CN1150 | 20030724 | |
| NO 2003003358 | A | 20030912 | NO 2003-3358 | 20030725 | <-- |
| US 2004097482 | A1 | 20040520 | US 2003-639900 | 20030813 | |
| US 2005153952 | A1 | 20050714 | US 2004-998400 | 20041129 | |
| US 2006199793 | A1 | 20060907 | US 2005-158429 | 20050622 | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2001-264275P | P | 20010126 |
| US 2001-264396P | P | 20010126 |
| US 2001-264600P | P | 20010126 |
| US 2001-323842P | P | 20010921 |
| US 2001-323839P | P | 20010921 |
| CA 2002-2434682 | A3 | 20020125 |
| CN 2002-807208 | A3 | 20020125 |
| EP 2002-705933 | A3 | 20020125 |
| EP 2002-707500 | A3 | 20020125 |
| EP 2002-714773 | A3 | 20020125 |
| US 2002-57323 | A3 | 20020125 |
| US 2002-57646 | A1 | 20020125 |
| WO 2002-US1196 | W | 20020125 |
| US 2002-136968 | A3 | 20020501 |

OTHER SOURCE(S): MARPAT 137:129903

GI



I

AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.

IT 144701-48-4, Telmisartan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 50 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:127720 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003087935 | A1 | 20030508 | <-- |
| | US 6727271 | B2 | 20040427 | |
| APPLICATION INFO.: | US 2002-81075 | A1 | 20020222 (10) | |

RELATED APPLN. INFO.: Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 5712
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:100164 USPATFULL
TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003069275 | A1 | 20030410 | <-- |
| | US 6919358 | B2 | 20050719 | |
| APPLICATION INFO.: | US 2002-80965 | A1 | 20020222 (10) | |

RELATED APPLN. INFO.: Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 5710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic,

hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:708455 CAPLUS
DOCUMENT NUMBER: 138:378867
TITLE: Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms
AUTHOR(S): Miyata, Toshio; van Ypersele de Strihou, Charles; Ueda, Yasuhiko; Ichimori, Kohji; Inagi, Reiko; Onogi, Hiroshi; Ishikawa, Naoyoshi; Nangaku, Masaomi; Kurokawa, Kiyoshi
CORPORATE SOURCE: Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan
SOURCE: Journal of the American Society of Nephrology ( 2002), 13(10), 2478-2487
CODEN: JASNEU; ISSN: 1046-6673
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The implication of advanced glycation end products (AGE) in the pathogenesis of atherosclerosis and of diabetic and uremic complications has stimulated a search for AGE inhibitors. This study evaluates the AGE inhibitory potential of several well-tolerated hypotensive drugs. Olmesartan, an angiotensin II type 1 receptor (AIIR) antagonist, as well as temocaprilat, an angiotensin-converting enzyme (ACE) inhibitor, unlike nifedipine, a calcium blocker, inhibit in vitro the formation of two AGE, pentosidine and Nε-carboxymethyllysine (CML), during incubation of nonuremic diabetic, nondiabetic uremic, or diabetic uremic plasma or of BSA fortified with arabinose. This effect is shared by all tested AIIR antagonists and ACE inhibitors. On an equimolar basis, they are more efficient than aminoguanidine or pyridoxamine. Unlike the latter two compds., they do not trap reactive carbonyl precursors for AGE, but impact on the production of reactive carbonyl precursors for AGE by chelating transition metals and inhibiting various oxidative steps, including carbon-centered and hydroxyl radicals, at both the pre- and post-Amadori steps. Their effect is paralleled by a lowered production of reactive carbonyl precursors. Finally, they do not bind pyridoxal, unlike aminoguanidine. Altogether, this study demonstrates for the first time that widely used hypotensive agents, AIIR antagonists and ACE inhibitors, significantly attenuate AGE production This study provides a new framework for the assessment of families of AGE-lowering compds. according to their mechanisms of action.

IT 144701-48-4, Telmisartan
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower formation of advanced glycation end products and mechanisms therein)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 53 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2002:160755 USPATFULL |
| TITLE: | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| INVENTOR(S): | Cheng, Peter T., Princeton, NJ, United States<br>Devasthale, Pratik, Plainsboro, NJ, United States<br>Jeon, Yoon, Belle Mead, NJ, United States<br>Chen, Sean, Princeton, NJ, United States<br>Zhang, Hao, Belle Mead, NJ, United States |
| PATENT ASSIGNEE(S): | Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation) |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6414002 | B1 | 20020702 | <-- |
| APPLICATION INFO.: | US 2001-812960 | | 20010320 (9) | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000 | | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | GRANTED |
| PRIMARY EXAMINER: | Higel, Floyd D. |
| ASSISTANT EXAMINER: | Sackey, Ebenezer |
| LEGAL REPRESENTATIVE: | Burton Rodney |
| NUMBER OF CLAIMS: | 30 |
| EXEMPLARY CLAIM: | 1 |
| NUMBER OF DRAWINGS: | 0 Drawing Figure(s); 0 Drawing Page(s) |
| LINE COUNT: | 5133 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:759924 CAPLUS
DOCUMENT NUMBER: 139:316442
TITLE: New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?
AUTHOR(S): Jennings, G.
CORPORATE SOURCE: Baker Heart Research Institute, Melbourne, Australia
SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F3-F11
CODEN: EHJSFT; ISSN: 1520-765X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The risk for coronary heart disease (CHD) increases with the number of risk factors. Thus, the clin. focus in prevention of CHD should be on patients with multiple risk factors. Both hypertension and a history of myocardial infarction are acknowledged risk factors for heart failure - the most severe form of CHD - but hypertension is more common. Anal. of data from the Framingham Heart Study shows that hypertension is associated with a greater population-attributable risk for heart failure. Angiotensin II, acting via the angiotensin II type 1 receptor, has been implicated in pathol. associated with ischemic heart disease and heart failure. Data on the efficacy of angiotensin-converting enzyme inhibitors in reducing cardiovascular events are comprehensive, with benefits demonstrated for patients with multiple risk factors, target organ damage, acute myocardial infarction and heart failure. Several recent trials have shown that angiotensin II receptor blockers reduce the progression of nephropathy in patients with type 2 diabetes mellitus. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program will provide a large body of data on the efficacy of the angiotensin II receptor Mocker telmisartan in lowering cardiovascular morbidity and mortality in patients with multiple risk factors.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of angiotensin II receptor blockers in cardiovascular risk management)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 55 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:166611 USPATFULL
TITLE: Combinations
INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003114469 | A1 | 20030619 | <-- |
| APPLICATION INFO.: | US 2002-231427 | A1 | 20020828 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-325485P | 20010927 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 2636
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition, comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and

(b) at least one of the active ingredients selected from the group consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:266021 USPATFULL
TITLE: Fibrinogen-lowering agents
INVENTOR(S): Imura, Yoshimi, Toyono-gun, JAPAN
Hirakata, Masao, Kobe-shi, JAPAN

| | NUMBER | KIND | DATE |
|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003187038 | A1 | 20031002 | <-- |
| APPLICATION INFO.: | US 2003-344719 | A1 | 20030214 | (10) |
| | WO 2001-JP7239 | | 20010824 | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 2000-260881 | 20000825 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 1512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We offer a fibrinogen-lowering agent comprising a compound having an angiotensin II antagonistic activity, a prodrug thereof, or a salt thereof. Because of having an excellent effect of lowering fibrinogen, the above fibrinogen-lowering agent is useful as a prophylactic or therapeutic agent for various diseases caused by hyperfibrionogenemia, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(fibrinogen lowering agents containing angiotensin II antagonists)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 57 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:201442 USPATFULL
TITLE: Combinations
INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003139429 | A1 | 20030724 | <-- |
| | US 7019010 | B2 | 20060328 | |
| APPLICATION INFO.: | US 2002-236651 | A1 | 20020906 | (10) |

| | NUMBER | DATE | |
|---|---|---|---|
| PRIORITY INFORMATION: | US 2001-325485P | 20010927 | (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition, comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and

(b) at least one of the active ingredients selected from the group consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:120858 USPATFULL
TITLE: Combination of organic compounds
INVENTOR(S): Steele, Ronald Edward, Long Valley, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003083342 | A1 | 20030501 | <-- |
| APPLICATION INFO.: | US 2002-149107 | A1 | 20020827 | (10) |
| | WO 2001-EP4116 | | 20010410 | |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereofeither alone or in combination with (ii) an AT.sub.1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically

acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 59 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:173610 USPATFULL
TITLE: Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
INVENTOR(S): Segal, Robert, Gwynedd Valley, PA, United States
Robinson, Paul J., Hertfordshire, United Kingdom
Deckelbaum, Lawrence I., Gladwyne, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE | | |
|---|---|---|---|---|---|
| PATENT INFORMATION: | US 6300356 | B1 | 20011009 | | <-- |
| | WO 9943210 | | 19990902 | | <-- |
| APPLICATION INFO.: | US 2000-601938 | | 20000810 | (9) | |
| | WO 1999-US3828 | | 19990222 | | |
| | | | 20000810 | PCT 371 date | |
| | | | 20000810 | PCT 102(e) date | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 1998-8937 | 19980427 |
| | US 1998-75915P | 19980225 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: Camara, Valerie J., Daniel, Mark R.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1520
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in die risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II receptor antagonists for decreasing QT dispersion or inhibiting progression of QT prolongation in humans)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 60 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2002104848 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11835907
TITLE: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
AUTHOR: Yusuf Salim
CORPORATE SOURCE: Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.. yusufs@mcmaster.ca
SOURCE: The American journal of cardiology, (2002 Jan 24) Vol. 89, No. 2A, pp. 18A-25A; discussion 25A-26A. Journal code: 0207277. ISSN: 0002-9149.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (META-ANALYSIS)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200202
ENTRY DATE: Entered STN: 12 Feb 2002
Last Updated on STN: 23 Feb 2002
Entered Medline: 22 Feb 2002

AB The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of cardiovascular death, myocardial infarction (MI), and death in patients at risk for cardiovascular events but without heart failure. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that ramipril also reduced atherosclerosis. These results

suggest that the renin-angiotensin system (RAS) has a more important role in the development and progression of atherosclerosis than previously believed, and they indicate the need for further clinical studies to define the range of benefits available from modifying the RAS. Achieving maximum benefit may require treatment with both an ACE inhibitor and an angiotensin II type-1 receptor blocker (ARB). The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) study indicated that combining an ACE inhibitor with an ARB decreased blood pressure and improved the ejection fraction more than treatment with either drug alone in patients with congestive heart failure. The Valsartan in Heart Failure Trial (Val-HeFT) showed that the combination of an ACE inhibitor and an ARB reduced hospitalization for heart failure in patients with congestive heart failure by 27.5%, although no decrease in all-cause mortality was observed. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is a large, long-term study (23,400 patients, 5.5 years). It will compare the benefits of ACE inhibitor treatment, ARB treatment, and treatment with an ACE inhibitor and ARB together, in a study population with established coronary artery disease, stroke, peripheral vascular disease, or diabetes with end-organ damage. Patients with congestive heart failure will be excluded. In a parallel study, patients unable to tolerate an ACE inhibitor will be randomized to receive telmisartan or placebo (the Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease [TRANSCEND]). The primary endpoint for both trials is a composite of cardiovascular death, MI, stroke, and hospitalization for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. These 2 trials are expected to provide new insights into the optimal treatment of patients at high risk of complications from atherosclerosis.

L6 ANSWER 61 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:709669 CAPLUS
DOCUMENT NUMBER: 140:1129
TITLE: Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation
AUTHOR(S): Yamagishi, S.; Amano, S.; Inagaki, Y.; Okamoto, T.; Inoue, H.; Takeuchi, M.; Choei, H.; Sasaki, N.; Kikuchi, S.
CORPORATE SOURCE: Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan
SOURCE: Drugs under Experimental and Clinical Research ( 2003), 29(2), 75-80
CODEN: DECRDP; ISSN: 0378-6501
PUBLISHER: Bioscience Ediprint Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The renin-angiotensin system has been implicated in the development and progression of atherosclerosis, thereby contributing to adverse cardiovascular events. However, its role in diabetic retinopathy remains to be elucidated. Since pericyte loss and dysfunction have been considered as one of the characteristic changes of the early phase of diabetic retinopathy, we investigated the effects of angiotensin II (Ang II) on the growth and function of bovine cultured retinal pericytes. Ang II stimulated intracellular reactive oxygen species (ROS) generation in pericytes in a dose-dependent manner. Telmisartan, a newly developed Ang II type 1 receptor antagonist, completely inhibited ROS generation in pericytes induced by Ang II. Ang II decreased DNA synthesis in pericytes, which was significantly prevented by an antioxidant N-acetylcysteine. Furthermore, telmisartan or N-acetylcysteine were found to completely inhibit the Ang II-induced upregulation of

vascular endothelial growth factor mRNA levels in pericytes. The present results suggest that Ang II-type 1 receptor interaction could induce pericyte loss and dysfunction through intracellular ROS generation, thus being involved in the development and progression of diabetic retinopathy.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 62 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2005:33212 USPATFULL

TITLE: Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof

INVENTOR(S): Ojima, Mami, Amagasaki, JAPAN
Kitayoshi, Takahito, Suita, JAPAN
Miyamoto, Masaomi, Takarazuka, JAPAN

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6852743 | B1 | 20050208 | |
| | WO 2001005428 | | 20010125 | <-- |
| APPLICATION INFO.: | US 2002-31398 | | 20020118 | (10) |
| | WO 2000-JP4830 | | 20000719 | |
| | | | 20020118 | PCT 371 date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1999-205877 | 19990721 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(preventives for recurrence of cerebrovascular failure containing benzimidazoles as angiotensin II antagonists)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 63 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:289188 USPATFULL
TITLE: Activator of PPAR delta
INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, UNITED STATES
Haffner, Curt Dale, Durham, NC, UNITED STATES
Lambert, Millard Hurst, III, Durham, NC, UNITED STATES
Maloney, Patrick Reed, Durham, NC, UNITED STATES
Sierra, Michael Lawrence, Les Ulis, FRANCE
Sternbach, Daniel David, Durham, NC, UNITED STATES
Sznaidman, Marcos Luis, Durham, NC, UNITED STATES
Willson, Timothy Mark, Durham, NC, UNITED STATES
Xu, Huaqiang Eric, Durham, NC, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003203947 | A1 | 20031030 | <-- |
| | US 6723740 | B2 | 20040420 | |
| APPLICATION INFO.: | US 2003-383011 | A1 | 20030306 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-18935, filed on 19 Dec 2001, PENDING A 371 of International Ser. No. WO 2000-EP5720, filed on 22 Jun 2000, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 1999-14977 | 19990625 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:127094 USPATFULL
TITLE: Methods for identifying novel multimeric agents that modulate receptors
INVENTOR(S): Christensen, Burton G., Alamo, CA, UNITED STATES

Griffin, John H., Atherton, CA, UNITED STATES
Jenkins, Thomas E., La Honda, CA, UNITED STATES
Judice, J. Kevin, El Granada, CA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003087306 | A1 | 20030508 | <-- |
| APPLICATION INFO.: | US 2001-15534 | A1 | 20011213 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-493462, filed on 28 Jan 2000, ABANDONED Continuation of Ser. No. US 1999-327904, filed on 8 Jun 1999, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1998-92938P | 19980715 (60) |
| | US 1998-88466P | 19980608 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Page(s)
LINE COUNT: 8387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same of different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2004:72635 USPATFULL
TITLE: Activators of PPAR delta
INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, United States
Haffner, Curt Dale, Durham, NC, United States
Lambert, III, Millard Hurst, Durham, NC, United States
Maloney, Patrick Reed, Durham, NC, United States
Sierra, Michael Lawrence, Les Ulis, FRANCE
Sternbach, Daniel David, Durham, NC, United States
Sznaidman, Marcos Luis, Durham, NC, United States
Willson, Timothy Mark, Durham, NC, United States
Xu, Huaqiang Eric, Durham, NC, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6710063 | B1 | 20040323 | |
| | WO 2001000603 | | 20010104 | <-- |
| APPLICATION INFO.: | US 2001-18935 | | 20011219 (10) | |
| | WO 2000-EP5720 | | 20000622 | |

| | NUMBER | DATE |
|---|---|---|

PRIORITY INFORMATION: GB 1999-14977 19990625
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Shameem, Golam M. M.
LEGAL REPRESENTATIVE: Brink, Robert H.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:306948 USPATFULL
TITLE: Composition and method for treating hypertension
INVENTOR(S): Stokes, Gordon, St Leonards, AUSTRALIA
PATENT ASSIGNEE(S): Northern Sydney Area Health Service (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003216384 | A1 | 20031120 | <-- |
| APPLICATION INFO.: | US 2002-255447 | A1 | 20020925 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | AU 2002-2369 | 20020516 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for the treatment and/or prevention of hypertension, said composition comprising an synergistic anti-hypertensive combination of a therapeutically effective amount of at least one angiotensin II inhibitor, and a therapeutically effective amount of at least one nitric oxide donor; said composition optionally further comprising a pharmaceutically acceptable carrier, diluent and/or adjuvant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II inhibitor-nitric oxide donor synergistic combination for treating hypertension)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 67 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:312692 USPATFULL | | | |
| TITLE: | Phosphorus-containing compounds and uses thereof | | | |
| INVENTOR(S): | Berstein, David L., Waban, MA, UNITED STATES<br>Metcalf, Chester A., III, Needham, MA, UNITED STATES<br>Rozamus, Leonard W., Bedford, MA, UNITED STATES<br>Wang, Yihan, Newton, MA, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003220297 | A1 | 20031127 | <-- |
| APPLICATION INFO.: | US 2003-357152 | A1 | 20030203 | (10) |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2002-353252P | | 20020201 | (60) |
| | US 2002-426928P | | 20021115 | (60) |
| | US 2002-428383P | | 20021122 | (60) |
| | US 2002-433930P | | 20021217 | (60) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | David L. Berstein, ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234 | | | |
| NUMBER OF CLAIMS: | 39 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 3696 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns a new family of phosphorus-containing compounds containing a moiety JQA--in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a chemical bond linking a R.sup.5 moiety to P;

and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:199127 USPATFULL
TITLE: Methods of treating sexual dysfunction associated with hypertension
INVENTOR(S): Sahota, Pritam Singh, New Providence, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002107236 | A1 | 20020808 | <-- |
| APPLICATION INFO.: | US 2001-8445 | A1 | 20011203 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-250540P | 20001201 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of treating SD associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 69 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:759933 CAPLUS
DOCUMENT NUMBER: 139:301175
TITLE: PROGRESS beyond HOPE and LIFE: the ONTARGET trial

programme
AUTHOR(S): Sleight, P.
CORPORATE SOURCE: John Radcliffe Hospital, Oxford, UK
SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F40-F47
CODEN: EHJSFT; ISSN: 1520-765X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Large-scale cardiovascular trials traditionally have targeted clin. hypertension, diabetes or survivors of myocardial infarction, but the recent trend in such trials has been to consider the treatment of high-risk individuals rather than specific diseases. This allows the use of a much broader screening process to enroll patients. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) act directly on the renin-angiotensin system to effect blood pressure control. The Heart Outcomes Prevention Evaluation (HOPE) and the Perindopril pROtection against REcurrent Stroke Study (PROGRESS) showed that angiotensin-converting enzyme inhibitors (ramipril and perindopril plus the diuretic indapamide), significantly decreased the risk for stroke and other adverse cardiovascular outcomes. Both studies showed benefits in patients with conventionally normal blood pressure. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial showed that losartan, an ARB, could also significantly decrease the risk of stroke to an extent greater than that predicted by the decrease in blood pressure. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program is currently underway to study the effect of ramipril and the ARB telmisartan, and a combination of the two agents in patients at high risk of cardiovascular disease.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 70 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:99270 USPATFULL
TITLE: Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
INVENTOR(S): Kamei, Shigeru, Takarazuka-shi, JAPAN
Ojima, Mami, Amagasaki-shi, JAPAN
Kitayoshi, Takahito, Suita-shi, JAPAN
Igari, Yasutaka, Kobe-shi, JAPAN

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003068374 | A1 | 20030410 | <-- |
| APPLICATION INFO.: | US 2002-204185 | A1 | 20020819 | (10) |
| | WO 2001-JP1191 | | 20010220 | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 2000-48980 | 20000221 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 2121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release preparation containing a physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer which are improved in the release-control and

stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(sustained-release compns. containing physiol. active compds. hardly-soluble in water, polyvalent metal compds., and biodegradable polymers)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 71 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:266305 USPATFULL
TITLE: Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES
Ress, Rudyard J., Flemington, NJ, UNITED STATES
Strony, John T., Lebanon, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002147184 | A1 | 20021010 | <-- |
| APPLICATION INFO.: | US 2002-56680 | A1 | 20020125 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-324123P | 20010921 (60) |
| | US 2001-264396P | 20010126 (60) |
| | US 2001-264600P | 20010126 (60) |
| | US 2001-264275P | 20010126 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 3296
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and

(b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2006:154381 USPATFULL | | | |
| TITLE: | Method for preventing, treating or inhibiting development of simple retinopathy and preproliferative retinopathy | | | |
| INVENTOR(S): | Nakagawa, Shizue, Osaka, JAPAN<br>Nagisa, Yasutaka, Higashiosaka, JAPAN<br>Ikeda, Hitoshi, Higashiosaka, JAPAN | | | |
| PATENT ASSIGNEE(S): | Takeda Pharmaceutical Company Limited, Osaka, JAPAN (non-U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 7064141 | B1 | 20060620 | |
| | WO 2000066161 | | 20001109 | <-- |
| APPLICATION INFO.: | US 2000-958740 | | 20000427 | (9) |
| | WO 2000-JP2766 | | 20000427 | |
| | | | 20011016 | PCT 371 date |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | JP 1999-121498 | | 19990428 | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | GRANTED | | | |
| PRIMARY EXAMINER: | Fay, Zohreh | | | |
| LEGAL REPRESENTATIVE: | Wenderoth, Lind & Ponack, L.L.P. | | | |
| NUMBER OF CLAIMS: | 2 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 1057 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(angiotensin II antagonists for treatment of retinopathy)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 73 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173948 USPATFULL
TITLE: Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
INVENTOR(S): Strony, John T., Lebanon, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119796 | A1 | 20030626 | <-- |
| | US 7056906 | B2 | 20060606 | |
| APPLICATION INFO.: | US 2002-247085 | A1 | 20020919 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-324118P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 2932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one hormone replacement therapy composition; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5α-stanols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:99262 USPATFULL
TITLE: Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
INVENTOR(S): Chungi, Shubha, Sharon, MA, UNITED STATES
Iorio, Theodore L., Millis, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003068366 | A1 | 20030410 | <-- |
| | US 6669955 | B2 | 20031230 | |
| APPLICATION INFO.: | US 2001-941948 | A1 | 20010828 (9) | |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 1701
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B.sub.6, B.sub.12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulation is provided as a simple and convenient therapy to reduce the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The formulation is also therapeutic for individuals during or immediately following an occurrence of acute myocardial infarction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:330256 USPATFULL
TITLE: Use of inhibitors of the renin-angiotensin system
INVENTOR(S): Montgomery, Hugh Edward, London, UNITED KINGDOM
Martin, John Francis, London, UNITED KINGDOM
Erusalimsky, Jorge Daniel, London, UNITED KINGDOM

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002187939 | A1 | 20021212 | <-- |
| | US 7071183 | B2 | 20060704 | |
| APPLICATION INFO.: | US 2002-206659 | A1 | 20020726 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-529628, filed on 15 Jun 2000, PENDING A 371 of International Ser. No. WO 1998-GB3122, filed on 19 Oct 1998, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 1997-22026 | 19971017 |
| | GB 1998-10855 | 19980520 |
| | US 1997-67819P | 19971205 (60) |
| | US 1998-94902P | 19980731 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with

hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(renin-angiotensin system inhibitors for treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency or for enhancing metabolic function)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 76 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:120855 USPATFULL | | | |
| TITLE: | Compositions and methods for treating colorectal polyps and cancer | | | |
| INVENTOR(S): | Tamura, Masaaki, Nashville, TN, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003083339 | A1 | 20030501 | <-- |
| APPLICATION INFO.: | US 2002-133056 | A1 | 20020426 | (10) |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2001-286621P | | 20010426 | (60) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707 | | | |
| NUMBER OF CLAIMS: | 36 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 6 Drawing Page(s) | | | |
| LINE COUNT: | 4380 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of decreasing a biological function of an AT.sub.2 receptor in a subject in need thereof is disclosed. The method includes administering an effective amount of a therapeutic agent to the subject to decrease a biological function of an AT.sub.2 receptor. Cancer

therapy, particularly colorectal cancer therapy, by the method is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(compns. and methods for treating colorectal polyps and cancer)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 77 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:113776 USPATFULL
TITLE: In vivo delivery methods and compositions
INVENTOR(S): Kensey, Kenneth, Malvern, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003078517 | A1 | 20030424 | <-- |
| APPLICATION INFO.: | US 2001-839785 | A1 | 20010420 (9) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood

viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(in vivo delivery methods and compns.)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 78 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:79112 USPATFULL
TITLE: Tnf-alpha inhibitors
INVENTOR(S): Ikeya, Kazuaki, Ikoma-gun, JAPAN
Kitayoshi, Takahito, Suita-shi, JAPAN

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003055039 | A1 | 20030320 | <-- |
| | US 6833381 | B2 | 20041221 | |
| APPLICATION INFO.: | US 2002-203805 | A1 | 20020814 | (10) |
| | WO 2001-JP1069 | | 20010215 | |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB TNF-α inhibitors containing a heterocyclic compound having angiotensin II antagonistic activity which are useful as preventives/remedies for inflammatory diseases, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(TNF-α inhibitors containing heterocyclic compds. having angiotensin II antagonisms)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 79 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119847 USPATFULL
TITLE: In vivo delivery methods and compositions
INVENTOR(S): Kensey, Kenneth R., Malvern, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061835 | A1 | 20020523 | <-- |
| APPLICATION INFO.: | US 2001-828761 | A1 | 20010409 (9) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PATENTED Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PATENTED Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, PATENTED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in

combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(methods for in vivo drug delivery based on monitoring blood flow parameters)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 80 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2002:54986 USPATFULL | | | |
| TITLE: | In vivo delivery methods and compositions | | | |
| INVENTOR(S): | Kensey, Kenneth, Malvern, PA, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2002032149 | A1 | 20020314 | <-- |
| APPLICATION INFO.: | US 2001-841389 | A1 | 20010424 (9) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 81 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2001:212586 USPATFULL | | | |
| TITLE: | In vivo delivery methods and compositions | | | |
| INVENTOR(S): | Kensey, Kenneth R., Malvern, PA, United States | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2001044584 | A1 | 20011122 | <-- |
| APPLICATION INFO.: | US 2001-819924 | A1 | 20010328 (9) | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735 | | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, | | | |

PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 82 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:328709 CAPLUS
DOCUMENT NUMBER: 137:345373
TITLE: Angiotensin II receptor antagonists role in arterial hypertension
AUTHOR(S): Hernandez-Hernandez, R.; Sosa-Canache, B.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.; Cammarata, R.
CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.
SOURCE: Journal of Human Hypertension (2002), 16(Suppl. 1), S93-S99
CODEN: JHHYEN; ISSN: 0950-9240

PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT1 receptor blockers antagonize all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the AT1 receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT1 receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being with low incidence of side effects even at long term use. Monotherapy in mild-to-moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of thiazide diuretic is added, 60-70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium antagonists and beta-blocking agents. AT1 receptor blockers are specially indicated in patients with hypertension who are being treated with ACE inhibitors and developed side effects such as, cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted and seem promising.
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 83 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:390956 CAPLUS
DOCUMENT NUMBER: 133:187
TITLE: Angiotensin II receptor antagonists in arterial hypertension
AUTHOR(S): Hernandez-Hernandez, R.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.
CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.
SOURCE: Journal of Human Hypertension (2000), 14(Suppl. 1), S69-S72
CODEN: JHHYEN; ISSN: 0950-9240
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 34 refs. Angiotensin II receptor antagonists (AT-1) represent a new group of orally active antihypertensive agents. Activation on AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone with production of thirst, and promote growth of vascular and cardiac muscle; these effects are blocked by AT-1 antagonist agents. The first chemical useful, orally active AT-1 receptor antagonist was losartan, followed by other agents currently in clin. use, such as: valsartan, eprosartan, irbesartan, telmisartan, candesartan, and many others under investigation. AT-1 receptor antagonists are effective in reducing high blood pressure in hypertensive patients. Monotherapy in mild to moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of a thiazide diuretic is added, 60 to 70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme inhibitors,

diuretics, calcium antagonists and beta-blocking agents. Tolerability has been reported to be very good. AT-1 receptor antagonists would be a drug of choice in otherwise well-controlled hypertensive patients treated with angiotensin-converting enzyme inhibitors who developed cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 84 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:232558 USPATFULL
TITLE: Aldosterone blocker therapy to prevent or treat inflammation-related disorders
INVENTOR(S): Rocha, Ricardo, Gurnee, IL, UNITED STATES
Zack, Marc, Evanston, IL, UNITED STATES
McMahon, Ellen, Sunset Hills, MO, UNITED STATES
Blasi, Eileen R., St. Louis, MO, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003162759 | A1 | 20030828 | <-- |
| APPLICATION INFO.: | US 2001-916136 | A1 | 20010726 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-221358P | 20000727 (60) |
| | US 2001-261352P | 20010112 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 55 Drawing Page(s)
LINE COUNT: 5061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aldosterone blockers used for the treatment and prevention of inflammation are disclosed

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 85 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173961 USPATFULL
TITLE: Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119809 | A1 | 20030626 | <-- |
| | US 7132415 | B2 | 20061107 | |
| APPLICATION INFO.: | US 2002-247095 | A1 | 20020919 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-323942P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,

07033-0530
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides therapeutic combinations and methods including at least one sterol or 5α-stanol absorption inhibitor that can be useful for treating xanthomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:322441 USPATFULL
TITLE: Haplotypes of the AGTR1 gene
INVENTOR(S): Anastasio, Alison E., New Haven, CT, UNITED STATES
Finkel, Kevin, Cheshire, CT, UNITED STATES
Koshy, Beena, North Haven, CT, UNITED STATES
Lee, Helen, Shelton, CT, UNITED STATES
PATENT ASSIGNEE(S): Genaissance Pharmaceuticals, Inc. (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002182605 | A1 | 20021205 | <-- |
| | US 6521747 | B2 | 20030218 | |
| APPLICATION INFO.: | US 2001-867915 | A1 | 20010530 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-228542P | 20000828 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENAISSANCE PHARMACEUTICALS, 5 SCIENCE PARK, NEW HAVEN, CT, 06511
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel genetic variants of the Angiotensin Receptor 1 (AGTR1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the AGTR1 gene. Compositions and methods for haplotyping and/or genotyping the AGTR1 gene in an individual are also disclosed. Polynucleotides defined by the sequence of the haplotypes disclosed herein are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 87 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119917 USPATFULL
TITLE: Ethers of 7-desmethylrapamycin
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES
Enever, Robin, New City, NY, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061905 | A1 | 20020523 | <-- |
| | US 6440991 | B2 | 20020827 | |
| APPLICATION INFO.: | US 2001-956322 | A1 | 20010919 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-237469P | 20001002 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides ethers of 7-desmethylrapamycin which are useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 88 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119916 USPATFULL
TITLE: Hydroxyesters of 7-desmethylrapamycin
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES
Enever, Robin, New City, NY, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061904 | A1 | 20020523 | <-- |
| | US 6399626 | B2 | 20020604 | |
| APPLICATION INFO.: | US 2001-955685 | A1 | 20010919 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-237470P | 20001002 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 640
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides hydroxyesters of 7-desmethylrapamycin which are useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 89 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119915 USPATFULL
TITLE: 1-oxorapamycins
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061903 | A1 | 20020523 | <-- |
| | US 6399625 | B2 | 20020604 | |
| APPLICATION INFO.: | US 2001-954880 | A1 | 20010918 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-235750P | 20000927 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 854
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides 1-oxorapamycins, which are useful in inducing immunosuppression, as a neurotrophic agent, and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 90 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:78778 USPATFULL
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND
Oddou, Pascale, Basel, SWITZERLAND
Neuhart, Eric Michel, Mulhouse, FRANCE

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002042436 | A1 | 20020411 | <-- |
| | US 6544968 | B2 | 20030408 | |
| APPLICATION INFO.: | US 2001-915048 | A1 | 20010725 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | EP 1999-810061 | 19990126 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II receptor antagonists for treating acute myocardial infarction)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 91 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:17328 USPATFULL
TITLE: Dha-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES
Swindell, Charles, Merion, PA, UNITED STATES
Webb, Nigel, Bryn Mawr, PA, UNITED STATES
Bradley, Matthews, Layton, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002010208 | A1 | 20020124 | <-- |
| | US 6602902 | B2 | 20030805 | |
| APPLICATION INFO.: | US 2001-846838 | A1 | 20010501 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 92 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:123317 USPATFULL
TITLE: Rapidly disintegrable solid preparation
INVENTOR(S): Shimizu, Toshihiro, Hyogo, Japan
Sugaya, Masae, Osaka, Japan
Nakano, Yoshinori, Hyogo, Japan

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2001010825 | A1 | 20010802 | <-- |
| | US 7070805 | B2 | 20060704 | |

APPLICATION INFO.: US 2001-800839 A1 20010307 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-403429, filed on 20 Oct 1999, PENDING A 371 of International Ser. No. WO 1999-JP4015, filed on 27 Jul 1999, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-213049 | 19980728 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 93 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2001002404 | A1 | 20010531 | <-- |
| | US 6576636 | B2 | 20030610 | |
| APPLICATION INFO.: | US 2000-730450 | A1 | 20001205 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 94 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2004085581 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14974331
TITLE: [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?]. Gefasspatient mit hohem Infarktrisiko. Schutzt der AT1-Blocker so gut wie ein ACE-Hemmer?.

AUTHOR: Anonymous
SOURCE: MMW Fortschritte der Medizin, (2003 Dec 18) Vol. 145, No. 51-52, pp. 39.
Journal code: 100893959. ISSN: 1438-3276.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200404
ENTRY DATE: Entered STN: 21 Feb 2004
Last Updated on STN: 28 Apr 2004
Entered Medline: 27 Apr 2004

L6 ANSWER 95 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:334719 USPATFULL
TITLE: Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003235595 | A1 | 20031225 | <-- |
| APPLICATION INFO.: | US 2003-397969 | A1 | 20030325 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, GRANTED, Pat. No. US 6458383 Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 110
EXEMPLARY CLAIM: 1
LINE COUNT: 3903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to oral pharmaceutical compositions and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. Compositions of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the composition forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the compositions provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 96 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:307001 USPATFULL
TITLE: Thrombin receptor antagonists
INVENTOR(S): Chackalamannil, Samuel, Califon, NJ, UNITED STATES
Clasby, Martin C., Plainsboro, NJ, UNITED STATES
Greenlee, William J., Teaneck, NJ, UNITED STATES
Wang, Yuguang, North Brunswick, NJ, UNITED STATES
Xia, Yan, Edison, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
Chelliah, Mariappan V., Edison, NJ, UNITED STATES

PATENT ASSIGNEE(S): SCHERING CORPORATION (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003216437 | A1 | 20031120 | <-- |
| APPLICATION INFO.: | US 2003-412982 | A1 | 20030414 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2002-373072P | 20020416 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heterocyclic-substituted tricyclics of the formula ##STR1##

or a pharmaceutically acceptable salt thereof, wherein:

the dotted line represents an optional single bond;

represents an optional double bond;

n is 0-2;

Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14;

R.sup.13 and R.sup.14 are independently selected from (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, --OH, (C.sub.1-C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or

R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms;

Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and

B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 97 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:277178 USPATFULL
TITLE: PDE9 inhibitors for treating cardiovascular disorders
INVENTOR(S): DeNinno, Michael Paul, Gales Ferry, CT, UNITED STATES
Hughes, Bernadette, Sandwich, UNITED KINGDOM
Kemp, Mark Ian, Sandwich, UNITED KINGDOM
Palmer, Michael John, Sandwich, UNITED KINGDOM
Wood, Anthony, Sandwich, UNITED KINGDOM
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|

PATENT INFORMATION: US 2003195205 A1 20031016 <--
APPLICATION INFO.: US 2002-283514 A1 20021030 (10)

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 2001-26395 | 20011102 |
| | GB 2001-30695 | 20011221 |
| | GB 2002-16761 | 20020718 |
| | US 2002-350777P | 20020122 (60) |
| | US 2002-399905P | 20020730 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 1888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R.sup.1 is H or C.sub.1-6 alkyl, wherein R.sup.1 is attached to either N.sup.1 or N.sup.2; R.sup.2 is C.sub.1-6 alkyl optionally substituted by hydroxy or alkoxy; C.sub.3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar.sup.1; R.sup.3 is C.sub.1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar.sup.2; C.sub.3-7cycloalkyl optionally substituted by C.sub.1-6alkyl; OAr.sup.2; SAr.sup.2; NHC(O)C.sub.1-6 alkyl; het.sup.2; xanthene; and naphthalene. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 98 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:238541 USPATFULL
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND
Oddou, Pascale, Basel, SWITZERLAND
Neuhart, Eric Michel, Mulhouse, FRANCE

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 2003166699 | A1 | 20030904 <-- |
| | US 6767905 | B2 | 20040727 |
| APPLICATION INFO.: | US 2003-376049 | A1 | 20030227 (10) |

RELATED APPLN. INFO.: Division of Ser. No. US 2001-915048, filed on 25 Jul 2001, GRANTED, Pat. No. US 6544968 Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | EP 1999-810061 | 19990126 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the

secondary prevention of acute MI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II receptor antagonists for treating acute myocardial infarction)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 99 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:214427 USPATFULL | | | |
| TITLE: | Method of treating cardiovascular disease | | | |
| INVENTOR(S): | Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES<br>Sehgal, Surendra N., Snohomish, WA, UNITED STATES<br>Adelman, Steven J., Doylestown, PA, UNITED STATES | | | |
| PATENT ASSIGNEE(S): | Wyeth, Madison, NJ (U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003149070 | A1 | 20030807 | <-- |
| | US 6670355 | B2 | 20031230 | |
| APPLICATION INFO.: | US 2002-313217 | A1 | 20021206 (10) | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2001-880295, filed on 13 Jun 2001, ABANDONED | | | |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2000-212117P | | 20000616 (60) | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940 | | | |
| NUMBER OF CLAIMS: | 39 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 574 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 100 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173960 USPATFULL
TITLE: Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
INVENTOR(S): LeBeaut, Alexandre P., Morristown, NJ, UNITED STATES
Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119808 | A1 | 20030626 | <-- |
| APPLICATION INFO.: | US 2002-246996 | A1 | 20020919 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-324121P | 20010921 (60) |
| | US 2002-351957P | 20020125 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 3092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects associated with certain HMG-CoA reductase inhibitors by coadministration of at least one sterol or 5α-stanol absorption inhibitor, pharmaceutically acceptable salts or solvates thereof, and at least one HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 101 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173582 USPATFULL
TITLE: Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
Ress, Rudyard J., Flemington, NJ, UNITED STATES
Strony, John T., Lebanon, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119428 | A1 | 20030626 | <-- |
| | US 7053080 | B2 | 20060530 | |
| APPLICATION INFO.: | US 2002-247397 | A1 | 20020919 | (10) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-323840P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 3027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for the treatment of obesity using sterol or 5α-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5α-stanol absorption inhibitors and at least one obesity control medication.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 102 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:110457 USPATFULL
TITLE: Method and apparatus for dispensing inhalator medicament
INVENTOR(S): Johnson, Keith A., Durham, NC, UNITED STATES
Casper, Robert A., Sanford, NC, UNITED STATES
Gardner, David L., Chapel Hill, NC, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003075172 | A1 | 20030424 | <-- |
| APPLICATION INFO.: | US 2002-267013 | A1 | 20021008 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-344544P | 20011019 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISS, BATEMAN, O'BRYANT & COMPAGNI, 136 SOUTH MAIN STREET, SUITE 700, SALT LAKE CITY, UT, 84101
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 846
AB An apparatus and method for delivering a plurality of medication includes providing first and second medicament on a medicament pack in separate containers for preventing either medicament from interfering with the stability of the other. In accordance with the method, the medicaments are preferably delivered in a single inhalation.

L6 ANSWER 103 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:37867 USPATFULL
TITLE: Methods for effecting neuroprotection
INVENTOR(S): Ferguson, Alastair V., Kingston, CANADA
Bains, Jaideep S., Calgary, CANADA

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002022587 | A1 | 20020221 | <-- |
| APPLICATION INFO.: | US 2001-817229 | A1 | 20010327 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-192585P | 20000328 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for preventing damage to excitable cells following ischemic by administering to a patient who is undergoing or who has undergone an ischemic event an effective amount of a compound which increases a transient potassium (K.sup.+) conductance in the excitable cells of the patient. The present invention also provides a method for screening for compounds which increase a transient K.sup.+ current in the excitable cells of a patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 104 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:173168 USPATFULL
TITLE: Solid pharmaceutical preparation
INVENTOR(S): Shimizu, Toshihiro, Itami, Japan
Sugaya, Masae, Ikeda, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6299904 | B1 | 20011009 | <-- |
| | WO 9853798 | | 19981203 | <-- |
| APPLICATION INFO.: | US 1999-424434 | | 19991123 | (9) |
| | WO 1998-JP2298 | | 19980526 | |
| | | | 19991123 | PCT 371 date |
| | | | 19991123 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-136724 | 19970527 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Fubara, Blessing
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohols selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 105 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:119057 USPATFULL
TITLE: Solid preparation
INVENTOR(S): Toshihiro, Shimizu, Osaka, Japan
Masae, Sugaya, Osaka, Japan

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2001009678 | A1 | 20010726 | <-- |
| | US 6586004 | B2 | 20030701 | |
| APPLICATION INFO.: | US 2001-800748 | A1 | 20010307 | (9) |

RELATED APPLN. INFO.: Division of Ser. No. US 1999-424434, filed on 23 Nov 1999, PENDING A 371 of International Ser. No. WO 1998-JP2298, filed on 26 May 1998, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-136724 | 19970527 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohol selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 106 OF 113 USPATFULL on STN
ACCESSION NUMBER: 1998:98932 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 5795909 | | 19980818 | <-- |
| APPLICATION INFO.: | US 1996-651312 | | 19960522 | (8) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 107 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:214415 USPATFULL
TITLE: Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
INVENTOR(S): Eisert, Wolfgang, Hannover, GERMANY, FEDERAL REPUBLIC OF

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003149058 | A1 | 20030807 | <-- |
| APPLICATION INFO.: | US 2003-376072 | A1 | 20030227 | (10) |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-694610, filed on 23 Oct 2000, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | DE 1999-991211210 | 19991022 |
| | US 1999-167797P | 19991129 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treatment of the human or non-human animal body for treating fibrin-dependent microcirculation disorders is disclosed, for example, microcirculation disorders caused by metabolic diseases, inflammatory reactions or autoimmune diseases; peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation comprising administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a pyrimido-pyrimidine selected from dipyridamole, mopidamol and the pharmaceutically acceptable salts thereof, and the use of said pyrimido-pyrimidine for the manufacture of a corresponding pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 108 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:85867 USPATFULL
TITLE: Oral delivery formulation
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES
Solari, Nancy E., West Newton, MA, UNITED STATES
Flangan, Margaret A., Stow, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003059471 | A1 | 20030327 | <-- |
| APPLICATION INFO.: | US 2001-997277 | A1 | 20011129 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1997-69501P | 19971215 (60) |
| | US 1998-73867P | 19980204 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 2950
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Flakes containing drugs and methods for forming and using such flakes are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 109 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:323094 USPATFULL
TITLE: Dipeptide derivatives
INVENTOR(S): Fink, Cynthia Anne, Lebanon, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002183260 | A1 | 20021205 | <-- |
| | US 6777443 | B2 | 20040817 | |
| APPLICATION INFO.: | US 2002-142693 | A1 | 20020509 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-291088P | 20010515 (60) |
| | US 2001-339575P | 20011211 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula ##STR1##

wherein R, R.sub.1, COOR.sub.2, R.sub.3-R.sub.7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 110 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:32538 USPATFULL
TITLE: Treatment for cardiovascular disease
INVENTOR(S): Kivlighn, Saluh, Doylestown, PA, UNITED STATES
Johnson, Richard, Bellaire, TX, UNITED STATES
Mazzali, Marilda, Houston, TX, UNITED STATES
PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002019360 | A1 | 20020214 | <-- |
| APPLICATION INFO.: | US 2001-892505 | A1 | 20010628 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-214825P | 20000628 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: McDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005-3096
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 111 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:22499 USPATFULL
TITLE: Method of treating cardiovascular disease
INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES
Sehgal, Surendra N., Snohomish, WA, UNITED STATES
Adelman, Steven J., Doylestown, PA, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ, 07054-0874 (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002013335 | A1 | 20020131 | <-- |
| APPLICATION INFO.: | US 2001-880295 | A1 | 20010613 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-212117P | 20000616 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 112 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:48090 USPATFULL
TITLE: Method for reducing pericardial fibrosis and adhesion formation
INVENTOR(S): Spinale, Francis G., Charleston, SC, United States
de Gasparo, Marc, Rossemaison, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6211217 | B1 | 20010403 | <-- |
| APPLICATION INFO.: | US 1999-270412 | | 19990316 (9) | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Ferraro, Gregory D.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT.sub.1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine (valsartan) of formula ##STR1##

or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 113 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:21788 USPATFULL
TITLE: Stabilized pharmaceutical preparation
INVENTOR(S): Fukuta, Makoto, Nara, Japan
Itoh, Hiroki, Suita, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6187340 | B1 | 20010213 | <-- |
| APPLICATION INFO.: | US 1998-149122 | | 19980909 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-245778 | 19970910 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Williamson, Michael A.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stabilized pharmaceutical preparation which is coated with a coating agent comprising an agent for the protection from light, said agent being capable of producing free radicals when exposed to ultraviolet rays, and a free radical scavenger; which is stable to light, especially ultraviolet rays, or heat, and which has excellent storage-stability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Hypothesis Paper

# Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells

Arya M. Sharma, Jürgen Janke, Kerstin Gorzelniak, Stefan Engeli, Friedrich C. Luft

*Abstract*—Obesity is the prime risk factor for the development of type 2 diabetes. Recent clinical trials have shown that blockade of the renin-angiotensin system, either by inhibiting the angiotensin-converting enzyme or blocking the angiotensin type 1 receptor, may substantially lower the risk for type 2 diabetes. The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II markedly inhibits adipogenic differentiation of human adipocytes via the angiotensin type I receptor and that expression of angiotensin II–forming enzymes in adipose tissue is inversely correlated with insulin sensitivity, we propose the hypothesis that blockade of the renin-angiotensin system prevents diabetes by promoting the recruitment and differentiation of adipocytes. Increased formation of adipocytes would counteract the ectopic deposition of lipids in other tissues (muscle, liver, pancreas), thereby improving insulin sensitivity and preventing the development of type 2 diabetes. (*Hypertension.* 2002;40:609-611.)

**Key Words:** angiotensin ■ diabetes ■ adipose tissue ■ insulin resistance ■ obesity

Recent clinical trials suggest that blockade of the renin-angiotensin system (RAS), either by inhibiting the angiotensin-converting enzyme (ACE)[1,2] or by blocking the angiotensin type 1 ($AT_1$)[3] receptor, may substantially lower the risk for type 2 diabetes. Thus, in the Captopril Primary Prevention Project (CAPPP) trial, incidence of diabetes was 14% lower in the captopril group than in the conventional group,[1] whereas, in the Heart Outcomes Prevention Evaluation (HOPE) trial, there was 34% reduction in relative risk for the development of type 2 diabetes.[2] Similarly, in the Intervention For Endpoint Reduction in Hypertension study (LIFE), the incidence of type 2 diabetes was reduced by 25% in the losartan group, albeit versus patients treated with atenolol.[3] The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II (Ang II) inhibits adipogenic differentiation of human adipocytes via the $AT_1$ receptor[4] and that expression of Ang II–forming enzymes in adipose tissue is inversely correlated with insulin sensitivity,[5] we propose the hypothesis that RAS blockade prevents diabetes by promoting the differentiation of adipocytes.

Obesity is by far the strongest risk factor for the development of type 2 diabetes. Paradoxically, however, failure to expand adipose tissue to accommodate excess calories has been recently implicated in the development of type 2 diabetes.[6] According to this idea, failure of adipocyte differentiation promotes the storage of excess calories in the liver, muscles, pancreas, and other tissues, thereby contributing to the development of insulin resistance and β-cell failure ("lipotoxicity" hypothesis).[7] This hypothesis is supported by several observations: surgical implantation of adipose tissue reverses diabetes in lipodystrophic mice,[8] large adipocyte size (suggesting difficulty in differentiating) is the best correlate for diabetes onset in obese Pima Indians,[9] insulin sensitivity during overfeeding correlates with the recruitment of new adipocytes, and the in vitro yield of newly differentiated adipocytes is greater in lean than in obese subjects.[10] Furthermore, hepatic steatosis and excess lipid in muscle and pancreas is characteristic of obese diabetics.[7] It has also recently been suggested that the prime mechanism by which thiazolidinediones reverse insulin resistance is by stimulating the adipogenic differentiation of fat cell precursors.[11]

Our hypothesis is summarized in the Figure. We suggest that increased formation of angiotensin II by large insulin-resistant adipocytes inhibits recruitment of preadipocytes, resulting in increased storage of lipids in muscle and other tissues, thereby increasing insulin sensitivity. In contrast, RAS blockade promotes recruitment of preadipocytes, thereby increasing the number of small insulin-sensitive adipocytes. Redistribution of lipids from muscle and other tissues to adipose tissue would result in improved insulin sensitivity.

## Testing the Hypothesis

Testing the hypothesis that RAS blockade prevents diabetes by promoting the differentiation of new fat cells is not straightforward. As a first step, it would be helpful to further

Received July 15, 2002; first decision August 8, 2002; revision accepted August 21, 2002.

From HELIOS Klinikum Berlin, Franz Volhard Clinic–Charité, Humboldt University of Berlin, and Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Correspondence to Arya M. Sharma, MD, Canada Research Chair for Cardiovascular Obesity Research and Management, McMaster University, Hamilton, Ontario L8L 2X2, Canada. E-mail sharma@ccc.mcmaster.ca

A.M.S. and F.C.L. have served as consultants and have received research support from several companies producing ACE inhibitors or angiotensin receptor blockers. Work leading to the proposition of this hypothesis was supported by a grant-in-aid to A.M.S. from Sanofi-Synthelabo, a manufacturer of an angiotensin receptor blocker.



*Hypertension* is available at http://www.hypertensionaha.org DOI: 10.1161/01.HYP.0000036448.44066.53

PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. *Lancet.* 1999;353:611–616.
2. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. *JAMA.* 2001;286: 1882–1885.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002;359:995–1003.
4. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. *Diabetes.* 2002;51:1699–1707.
5. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. *J Hypertension.* 2002;20:965–973.
6. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? *Nat Genet.* 2000;26:13.
7. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. *Diabetologia.* 1999;42:128–138.
8. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. *J Clin Invest.* 2000;105:271–278.
9. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. *Diabetologia.* 1995;38: 1213–1217.
10. Kashiwagi A, Mott D, Bogardus C, Lillioja S, Reaven GM, Foley JE. The effects of short-term overfeeding on adipocyte metabolism in Pima Indians. *Metabolism.* 1985;34:364–370.
11. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. *J Clin Invest.* 1998;15: 1354–1361.
12. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. *J Clin Invest.* 1997;100: 3149–3153.
13. Kissebah AH, Krakower GR. Regional adiposity and morbidity. *Physiol Rev.* 1994;74:761–811.
14. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. *Endocrinology.* 2001;142:487–492.
15. Weyer C, Wolford JK, Hanson RL, Foley JE, Tataranni PA, Bogardus C, Pratley RE. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21–q23 and is associated with a common polymorphism in LMNA in Pima Indians. *Mol Genet Metab.* 2001;72:231–238.




This figure summarizes our hypothesis. A, Increased formation of angiotensin II by large insulin-resistant adipocytes inhibits recruitment of preadipocytes, resulting in increased storage of lipids in muscle and other tissues, thereby decreasing insulin sensitivity. B, Blockade of the renin-angiotensin system promotes recruitment of preadipocytes, thereby increasing the number of small insulin-sensitive adipocytes. Redistribution of lipids from muscle and other tissues to adipose tissue results in improved insulin sensitivity.

explore the regulation and function of the adipose-tissue RAS, particularly regarding the issue whether large insulin-resistant fat cells do indeed produce more Ang II than smaller adipocytes. These studies will need to go beyond gene-expression analyses and should include functional assays on Ang II formation, always taking into consideration that in vitro conditions such as hypoxia may sometimes lead to results that cannot be extrapolated to the intact organism. It would also be of interest to explore whether there are regional differences in the influence of RAS blockade on adipocyte differentiation. Thus, for example, the prodifferentiating effects of thiazolidinediones have been demonstrated to be stronger on subcutaneous than on omental preadipocytes.[12] This issue is of importance because further expansion of visceral adipose tissue by RAS blockade would be undesired, given its involvement in the metabolic and vascular complications of obesity.[13]

Demonstrating that the profound stimulatory effect of $AT_1$-receptor blockade on adipogenic differentiation observed in our in vitro study is indeed present in vivo is clearly not a trivial task. One approach could perhaps be to perform fat biopsies in human subjects before and at some time point (weeks or months) during $AT_1$-receptor blockade. If our hypothesis is correct, $AT_1$-receptor blockade should perhaps reduce the average adipocyte size as a sign of new adipocyte formation in individuals without weight loss. Similar observations have been made with thiazolidinediones, where troglitazone did not change the total weight of white adipose tissues but increased the number of small adipocytes approximately 4-fold and decreased the number of large adipocytes by approximately 50%.[11] One would also need to demonstrate that any decrease in adipocyte size by RAS blockade should result both in an improvement in ex vivo insulin sensitivity of these adipocytes and improvement of insulin sensitivity of the patient. Furthermore, $AT_1$-receptor blockade should result in the disappearance of lipids from muscle and liver as these are redistributed back to adipose tissue, a process that can be followed by nuclear magnetic resonance spectroscopy.

Ultimately, however, larger prospective studies would be necessary to demonstrate that induction of adipogenic differentiation by $AT_1$-receptor blockade is indeed related to the prevention of type 2 diabetes in high-risk individuals. Such a study would not only require a large number of subjects but also would take several years to perform.

In rodent models, Ang II has been shown to promote adipogenic differentiation of preadipocytes,[14] the exact opposite of our finding in humans. Thus, rodent models would apparently not be suited for testing our hypothesis.

## Implications for Clinical Practice

Currently, several large studies are underway to further explore the relationship between RAS blockade and the development of type 2 diabetes. Thus, the Diabetes REduction Approaches with Medication (DREAM) study will follow 4000 individuals with impaired glucose tolerance at high risk of developing diabetes who are randomized to ramipril, rosiglitazone, or placebo. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), a study in 29 000 cardiovascular high-risk patients, will also include the new development of type 2 diabetes as a secondary endpoint. If these studies confirm the preventive effect of RAS blockade on the development of type 2 diabetes, the demonstration that RAS blockade promotes the differentiation of adipocytes would provide a scientific rationale for the use of ACE inhibitors or $AT_1$-receptor blockers for the prevention of diabetes in high-risk individuals. Furthermore, it would also allow us to target individuals who have larger adipocytes and/or higher activities of angiotensin-forming enzymes in their adipose tissue. Such patients would, therefore, be more likely to develop diabetes than individuals with smaller adipocytes. The same may apply to individuals who have hepatic steatosis or increased myocytic lipid stores, signs of impaired adipose-tissue expansion. Recent genetic studies have identified a locus on chromosome 1 related to adipocyte size.[15] It would clearly be of interest to explore the effect of RAS blockade on adipocyte growth and function and the development of diabetes in individuals with an apparently increased genetic predisposition for large adipocytes. [Author: The last 2 references[14,15] were not cited in this paper. Per journal style, please cite or delete references.]

## References

1. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester

# From the HOPE to the ONTARGET and the TRANSCEND Studies: Challenges in Improving Prognosis

Salim Yusuf, DPhil

**The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of cardiovascular death, myocardial infarction (MI), and death in patients at risk for cardiovascular events but without heart failure. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that ramipril also reduced atherosclerosis. These results suggest that the renin–angiotensin system (RAS) has a more important role in the development and progression of atherosclerosis than previously believed, and they indicate the need for further clinical studies to define the range of benefits available from modifying the RAS. Achieving maximum benefit may require treatment with both an ACE inhibitor and an angiotensin II type-1 receptor blocker (ARB). The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) study indicated that combining an ACE inhibitor with an ARB decreased blood pressure and improved the ejection fraction more than treatment with either drug alone in patients with congestive heart failure. The Valsartan in Heart Failure Trial (Val-HeFT) showed that the combination of an ACE inhibitor and an ARB reduced hospitalization for heart failure in patients with congestive heart failure by 27.5%, although no decrease in all-cause mortality was observed. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is a large, long-term study (23,400 patients, 5.5 years). It will compare the benefits of ACE inhibitor treatment, ARB treatment, and treatment with an ACE inhibitor and ARB together, in a study population with established coronary artery disease, stroke, peripheral vascular disease, or diabetes with end-organ damage. Patients with congestive heart failure will be excluded. In a parallel study, patients unable to tolerate an ACE inhibitor will be randomized to receive telmisartan or placebo (the Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease [TRANSCEND]). The primary endpoint for both trials is a composite of cardiovascular death, MI, stroke, and hospitalization for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. These 2 trials are expected to provide new insights into the optimal treatment of patients at high risk of complications from atherosclerosis.** 

**Am J Cardiol 2002;89(suppl):18A–26A**

The Heart Outcomes Prevention Evaluation (HOPE) trial showed that the angiotensin-converting enzyme (ACE) inhibitor ramipril is effective in preventing major cardiovascular events in high-risk patients without hypertension or those whose hypertension is sufficiently controlled with other treatments.[1] These data suggest that ACE inhibitors may exert direct actions on blood vessels beyond their hemodynamic effects. The results stimulate research in 2 directions: (1) toward understanding how modulating the renin–angiotensin system (RAS) protects blood vessels and (2) toward clinical studies defining the complete spectrum of benefit that can result from inhibiting the RAS system using multiple approaches. This article reviews recent data and research directions culminating in the design of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study and the Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Inhibitor–Intolerant Patients with Cardiovascular Disease (TRANSCEND), which are intended to further both of the above goals.

## A POSSIBLE ROLE FOR ANGIOTENSIN II IN THE DEVELOPMENT AND PROGRESSION OF CARDIOVASCULAR DISEASE

Historically, the RAS has been viewed as a regulatory system limited to blood pressure and fluid electrolyte regulation. Disorders of this system contribute to the pathophysiology of hypertension, renal disease, and congestive heart failure. These conditions can be improved by ACE inhibition and/or blockade of angiotensin II type-1 receptors.[2] However, recent work suggests that angiotensin II also has a direct role in atherothrombosis.[3]

Victor Dzau[3] has proposed that angiotensin II, which is produced by the effects of ACE on angiotensin I, is critical to a number of steps in the development of atherosclerosis and thrombosis (Figure 1).

From the Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Reprints are not available.

Address for correspondence: Salim Yusuf, DPhil, Division of Cardiology, Department of Medicine, McMaster University, Hamilton General Hospital, Room 253, McMaster Clinic, 237 Barton Street East, Hamilton, Ontario L8L2X2, Canada. E-mail: yusufs@mcmaster.ca.

 

0002-9149/02/$ – see front matter
PII S0002-9149(01)02323-2




**FIGURE 1. Proposed model integrating angiotensin II (A II) into the development and progression of vascular disease. ACE = angiotensin-converting enzyme; BP = blood pressure; ICAM = intracellular adhesion molecule; LDL = low-density lipoprotein cholesterol; NO = nitric oxide; PAI-1 = plasminogen activator inhibitor–1; VCAM = vascular cell adhesion molecule. (Reprinted with permission from *Hypertension*.[3])**

Angiotensin II is synthesized by the endothelium and could directly constrict the vessel wall. ACE, angiotensin II, and its receptor are increased within atherosclerotic lesions,[4] perhaps because of increased oxidative stress or endothelial dysfunction caused by known risk factors.[3] Increased tissue ACE and angiotensin II may contribute to vessel pathology through a combination of mechanisms (Figure 1). Angiotensin II stimulates receptors on different cell types within the lesion, resulting in production of secondary mediators, such as endothelin, plasminogen activator inhibitor–1, tissue factor, cytokines, growth factors, and proteolytic enzymes. In turn, these mediators cause vasoconstriction, thrombosis, inflammation, plaque rupture, and vascular lesion formation (Figure 1), which could lead to cardiovascular events.

A hypothesis derived from this model is that reduction of angiotensin II production via inhibition of ACE or prevention of angiotensin II type 1 signaling by an angiotensin II type-1 receptor blocker (ARB) may disrupt the cascade of events causing development and progression of heart disease. From this perspective, patients with any form of existing atherosclerosis would be considered high-risk patients and would therefore be expected to benefit from inhibition of the RAS. Data from the HOPE study are consistent with this possibility.

## THE HEART OUTCOMES PREVENTION EVALUATION STUDY

The HOPE study[1] randomized 9,297 high-risk patients >55 years of age, who had clinical evidence of vascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease), or diabetes and 1 other cardiovascular risk factor (hypertension, elevated levels of total cholesterol, low levels of high-density lipoprotein cholesterol, cigarette smoking, or microalbuminuria). None had heart failure or




**FIGURE 2. Kaplan-Meier estimates of the primary composite outcome of myocardial infarction, stroke, or death from cardiovascular causes from the Hypertension Outcomes Prevention Evaluation (HOPE) study. (Reprinted with permission from *N Engl J Med.*[1] Copyright © 2000 Massachusetts Medical Society. All rights reserved.)**

were known to have a low ejection fraction. The population did not include patients with hypertension unless the blood pressure was already controlled (average blood pressure at entry was 139 ± 20/79 ± 11 mm Hg at baseline). After randomization, patients were treated with placebo or ramipril orally once daily at 2.5 mg for 1 week, 5 mg for the next 3 weeks, and then 10 mg for the rest of the trial (a mean of 4.5 years).[1]

The primary outcome was a composite of myocardial infarction (MI), stroke, or death from cardiovascular causes (Figure 2, Table 1). A significant 21% decrease in the primary endpoint was observed with ramipril treatment (event rate of 17.8% [placebo] to 14% [ramipril]). There were clear and significant reductions in cardiovascular death, stroke, and MI. The shape of the Kaplan-Meier curve shows that the difference between the ramipril- and placebo-treated groups appeared fairly early and increased over time, suggesting even greater benefit with prolonged treatment (Figure 2).[1]

**TABLE 1** Outcomes of the Heart Outcomes Prevention (HOPE) Evaluation Study

| Outcome | Relative Risk (95% CI) | p-Value |
|---|---|---|
| Primary outcomes and incidence of death from any cause | | |
| • Myocardial infarction, stroke, or death due to cardiovascular causes | 0.78 (0.70–0.86) | <0.001 |
| —Death due to cardiovascular causes | 0.74 (0.64–0.87) | <0.001 |
| —Myocardial infarction | 0.80 (0.70–0.90) | <0.001 |
| —Stroke | 0.68 (0.56–0.84) | <0.001 |
| • Death due to noncardiovascular causes | 1.03 (0.85–1.26) | 0.74 |
| • Death due to any cause | 0.84 (0.75–0.95) | 0.005 |
| Secondary outcomes | | |
| • Revascularization | 0.85 (0.77–0.94) | 0.002 |
| • Hospitalization for unstable angina | 0.98 (0.87–1.10) | 0.68 |
| • Complications related to diabetes | 0.84 (0.72–0.98) | 0.03 |
| • Hospitalization for heart failure | 0.88 (0.70–1.10) | 0.25 |
| Other outcomes | | |
| • Heart failure | 0.77 (0.67–0.87) | <0.001 |
| • Cardiac arrest | 0.62 (0.41–0.94) | 0.02 |
| • Worsening angina | 0.89 (0.82–0.96) | 0.004 |
| • New diagnosis of diabetes | 0.66 (0.51–0.85) | 0.001 |
| • Unstable angina with electrocardiographic changes | 0.97 (0.79–1.19) | 0.76 |

Adapted from *N Engl J Med.*[1]




**FIGURE 3. Beneficial effects of treatment with ramipril on the composite outcome (myocardial infarction, stroke, cardiovascular death) in various predefined subgroups with different sources of cardiovascular risk. (Reprinted with permission from *N Engl J Med.*[1] Copyright © 2000 Massachusetts Medical Society. All rights reserved.)**

A significant decrease in death from cardiovascular causes (from 8.1% to 6.1%) and death from any cause (from 12.2% to 10.4%) was observed (Table 1).[1] No difference in death from noncardiovascular causes was found, reinforcing the observation that decreases in mortality are caused by reductions in cardiovascular disease. The incidence of MI was reduced by 19% (from 12.3% to 9.9%), and the incidence of stroke was reduced by 31% (from 4.9% to 3.1%), which is 3 times the decrease that would be predicted based on the modest reduction (3.5/1.5 mm Hg) of blood pressure alone. Significant reductions were also observed in the need for revascularization procedures, complications related to diabetes, the incidence of heart failure, cardiac arrest, worsening angina, and a new diagnosis of diabetes (Table 1).[1] The reductions in the range of endpoints affected support the hypothesis that ACE inhibition modifies the fundamental processes in the vascular wall in multiple territories.

Another important finding from the HOPE study was that the reduction in vascular events was observed in patients with different types of underlying vascular disease. Consistent benefits were observed in patients, regardless of age; presence or absence of diabetes, hypertension, prior MI, cerebrovascular disease, peripheral vascular disease, or microalbuminuria; or gender (Figure 3).[1] All subgroups studied showed benefit.

## THE STUDY TO EVALUATE CAROTID ULTRASOUND CHANGES IN PATIENTS TREATED WITH RAMIPRIL AND VITAMIN E

A substudy of the HOPE trial—the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE)—was directed at measuring the impact of ramipril treatment on progression of atherosclerosis.[5] A total of 732 patients matching the previously described selection criteria underwent duplicate B-mode carotid ultrasound examinations at baseline, at about 2.5 years, and at the end of the study. The results are shown in

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS  4  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS  5  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS  6  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS  7  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available
 NEWS  8  NOV 20   CA/CAplus to MARPAT accession number crossover limit increased
                   to 50,000
 NEWS  9  DEC 01   CAS REGISTRY updated with new ambiguity codes
 NEWS 10  DEC 11   CAS REGISTRY chemical nomenclature enhanced
 NEWS 11  DEC 14   WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 12  DEC 14   GBFULL and FRFULL enhanced with IPC 8 features and
                   functionality
 NEWS 13  DEC 18   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS 14  DEC 18   CA/CAplus patent kind codes updated
 NEWS 15  DEC 18   MARPAT to CA/CAplus accession number crossover limit increased
                   to 50,000
 NEWS 16  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS 17  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS 18  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 19  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 20  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS 21  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 22  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS 23  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS 24  JAN 29   PHAR reloaded with new search and display fields
 NEWS 25  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 26  FEB 13   CASREACT coverage to be extended
 NEWS 27  Feb 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 28  Feb 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 29  Feb 23   KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 30  Feb 26   MEDLINE reloaded with enhancements
 NEWS 31  Feb 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 32  Feb 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 33  Feb 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 34  Feb 26   CAS Registry Number crossover limit increased from 10,000
                   to 300,000 in multiple databases

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
```

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:15:39 ON 02 MAR 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:15:53 ON 02 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 FEB 2007  HIGHEST RN 923894-67-1
DICTIONARY FILE UPDATES:  28 FEB 2007  HIGHEST RN 923894-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s telmisartan
L1            8 TELMISARTAN

=> d 8

L1   ANSWER 8 OF 8  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   144701-48-4  REGISTRY
ED   Entered STN:  02 Dec 1992
CN   [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-
     benzimidazol]-3'-yl)methyl]-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-
     benzimidazol]-1'-yl)methyl]- (9CI)
OTHER NAMES:
CN   4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-
     benzimidazolyl]methyl]-2-biphenylcarboxylic acid
CN   BIBR 277
```

CN BIBR 277SE
CN Micardis
CN Pritor
CN Telmisartan
MF C33 H30 N4 O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

598 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
600 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus uspatful medline

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 7.35 | 7.56 |

FILE 'CAPLUS' ENTERED AT 12:16:26 ON 02 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE 'USPATFULL' ENTERED AT 12:16:26 ON 02 MAR 2007


FILE 'MEDLINE' ENTERED AT 12:16:26 ON 02 MAR 2007

=> s l1 or telmisartan or pritor or micardis or bibr 277 or bibr 277se
L2 1943 L1 OR TELMISARTAN OR PRITOR OR MICARDIS OR BIBR 277 OR BIBR 277SE

```
=> s l2 and (diabetes or diabete or insuline resistance or hyperinsulinemia or
glucose intolerance or insuline sensitivity )
L3          761 L2 AND (DIABETES OR DIABETE OR INSULINE RESISTANCE OR HYPERINSUL
                INEMIA OR GLUCOSE INTOLERANCE OR INSULINE SENSITIVITY )

=> s l3 and pd<+2003
<------User Break------>

=> s l3 and pd<=2003
L4          124 L3 AND PD<=2003

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5          113 DUP REM L4 (11 DUPLICATES REMOVED)

=> focus
PROCESSING COMPLETED FOR L5
L6          113 FOCUS L5 1-

=> d ibib abs hitstr 1-113

L6   ANSWER 1 OF 113  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2003:96709  CAPLUS
DOCUMENT NUMBER:          138:163224
TITLE:                    Effects of telmisartan on arterial stiffness
                          in type 2 diabetes patients with essential
                          hypertension
AUTHOR(S):                Asmar, Roland; Gosse, Phillipe; Topouchian, Jirar;
                          N'tela, Gilbert; Dudley, Amanda; Shepherd, Gillian L.
CORPORATE SOURCE:         The Cardiovascular Institute, Paris, Fr.
SOURCE:                   JRAAS (2002), 3(3), 176-180
                          CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER:                JRAAS Ltd.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Arterial wall stiffness, an important independent risk factor for
     cardiovascular disease in patients with hypertension, is worsened by the
     coexistence of diabetes mellitus.  This randomized, prospective,
     double-blind, crossover trial assessed the effects of telmisartan
     on arterial stiffness in patients with Type 2 diabetes with
     essential hypertension.  After a two-week placebo wash out period, 28
     ambulatory patients received telmisartan (40 mg) or placebo for
     three weeks.  Following a second two-week placebo wash out period,
     patients received the alternate treatment for a further three weeks.
     Augmentation index and central blood pressure (BP) were determined using the
     SphygmoCor device and pulse wave velocity (PWV) was measured using an
     automatic device, the Complior, at the beginning and the end of each
     period.  Telmisartan significantly reduced the carotid-femoral
     PWV compared with placebo (mean adjusted treatment difference -0.95 m/s;
     95% CI: -1.67, -0.23 m/s; p = 0.013).  Peripheral and central diastolic,
     systolic and pulse pressures were also significantly reduced with
     telmisartan compared with placebo.  In conclusion,
     telmisartan reduces arterial stiffness and peripheral and central
     BPs as assessed by PWV and pulse contour anal. in hypertensive patients
     with Type 2 diabetes.  These properties of telmisartan
     suggest that it may improve cardiovascular outcome in this patient
     population.
IT   144701-48-4, Telmisartan
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (telmisartan effect on arterial stiffness in type 2
        diabetes patients with essential hypertension)
RN   144701-48-4  CAPLUS
CN   [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-
```

benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:824351 CAPLUS
DOCUMENT NUMBER: 136:112467
TITLE: Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus
AUTHOR(S): Asmar, Roland
CORPORATE SOURCE: The Cardiovascular Institute, Paris, 75016, Fr.
SOURCE: JRAAS (2001), 2(Suppl. 2), S8-S11
CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER: JRAAS Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Arterial wall stiffness is an important independent risk factor for cardiovascular disease in hypertensive patients, which is further exacerbated by co-existent diabetes mellitus. Increased arterial stiffness is directly associated with an increase in pulse wave velocity (PWV) and indirectly with increased central and peripheral blood pressure. Following a two-week placebo run-in period, 27 patients with mild to moderate essential hypertension and Type 2 diabetes mellitus, were randomized to once daily treatment with either telmisartan 40 mg or placebo for three weeks, and after a two-week washout period, crossed-over to the alternative treatment for a further three weeks. Carotid/femoral and carotid/radial PWV were measured non-invasively using the automatic Complior device, and central parameters (central blood pressure, pulse contour anal., and augmentation index) were measured using the SphygmoCor system, at the start and end of each treatment period. Compared with placebo, treatment with telmisartan significantly reduced carotid/femoral PWV (mean adjusted treatment difference -0.95 m/s, 95% confidence intervals: -1.67, -0.23 m/s, p=0.013), as well as peripheral and central diastolic, systolic and pulse pressure. In conclusion, the results of this study show that telmisartan is effective in reducing arterial stiffness in hypertensive patients with Type 2 diabetes mellitus, and may potentially have beneficial effects on cardiovascular outcomes, beyond blood-pressure lowering effects, in this patient group.

IT 144701-48-4, Telmisartan
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(telmisartan effect on arterial distensibility and central blood pressure in patients with hypertension and type 2 diabetes mellitus)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:795609 CAPLUS

DOCUMENT NUMBER: 139:270158

TITLE: The telmisartan programme of research to show telmisartan end-organ proteCTION (PROTECTION) programme

AUTHOR(S): Weber, Michael

CORPORATE SOURCE: State University of New York Downstate College of Medicine, New York, USA

SOURCE: Journal of Hypertension (2003), 21(Suppl. 6), S37-S46
CODEN: JOHYD3; ISSN: 0263-6352

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Angiotensin-II receptor blockers (ARBs) have been shown to provide stroke, cardiac and renal protection in high-risk hypertensive patients. Telmisartan is a powerful and selective ARB that provides sustained blood pressure reduction for a full 24 h after a single dose and continues to protect against circadian blood pressure surges in the critical early morning hours. The objective of the Program of Research tO show Telmisartan End-organ proteCTION (PROTECTION) is to measure the end-organ protective effects of telmisartan in patients at high risk of renal, cardiac and vascular damage. An extensive series of clin. trials is being conducted to compare telmisartan with valsartan, losartan, amlodipine and ramipril in patients at increased risk of end-organ damage. Nine clin. studies will examine the effects of telmisartan in about 5000 hypertensive patients with isolated systolic hypertension, type 2 diabetes, obesity, left ventricular hypertrophy or renal disease. All of the studies will be conducted using state-of-the-art technol., including such techniques as ambulatory blood pressure monitoring and magnetic resonance imaging. This program will also investigate the effects of an ARB on key surrogate

markers of organ tissue damage. This series of trials will characterize the end-organ protective effects of telmisartan in hypertensive patient populations at high risk of clin. events.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(telmisartan treatment for end-organ protection in hypertensive patients and the telmisartan program PROTECTION)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:306863 CAPLUS
DOCUMENT NUMBER: 135:251642
TITLE: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats
AUTHOR(S): Wienen, Wolfgang; Richard, Serge; Champeroux, Pascal; Audeval-Gerard, Chantal
CORPORATE SOURCE: Department of Pharma Research, Boehringer Ingelheim Pharma KG, Biberach, Germany
SOURCE: JRAAS (2001), 2(1), 31-36
CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER: JRAAS Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study compared the cardiovascular and renal effects of long-term telmisartan (3 and 10 mg/kg/day) and lisinopril (10 mg/kg/day) in an animal model combining hypertension and diabetes mellitus. It was a parallel-group study of diabetic, spontaneously hypertensive rats (SHR), treated with control or active treatment for eight months. A non-diabetic SHR control group was run in parallel. Diabetes was induced by streptozotocin (45 mg/kg i.v.) in SHRs aged 9-10 wk. Animals were treated with telmisartan (3 or 10 mg/kg/day), lisinopril (10 mg/kg/day) or vehicle. Plasma glucose levels, blood pressure (BP), and urinary protein and albumin excretion were measured monthly. Telmisartan treatment significantly reduced BP of diabetic SHRs in a dose-dependent manner ($p<0.05$, low-dose, n=18; $p<0.01$, high-dose, n=15). The BP reduction in the lisinopril group was similar to that in the telmisartan 10 mg/kg/day group. Compared with

non-diabetic SHRs, untreated diabetic SHRs developed severe proteinuria and albuminuria over the exptl. period ($p<0.01$). In diabetic SHRs, proteinuria and albuminuria were dose-dependently and significantly attenuated by treatment with telmisartan ($p<0.01$ with the higher dose) and lisinopril ($p<0.01$). Compared with the untreated diabetic SHRs, cardiac hypertrophy was significantly reduced after treatment with both doses of telmisartan and with lisinopril. Telmisartan , 10 mg/kg/day, but not lisinopril, significantly attenuated the diabetes-induced increase in glomerular volume In conclusion, telmisartan, 10 mg/kg/day, is at least as beneficial as lisinopril, 10 mg/kg/day, in lowering BP, reducing cardiac hypertrophy and attenuating renal excretion of protein and albumin in this model.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparative antihypertensive, renoprotective, and cardioprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:656399 CAPLUS
DOCUMENT NUMBER: 139:191449
TITLE: Renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy
INVENTOR(S): Pedersen-Bjergaard, Ulrik; Agerholm-Larsen, Birgit; Thorsteinsson, Birger; Pramming, Stig
PATENT ASSIGNEE(S): Den.
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003158090 | A1 | 20030821 | US 2002-195330 | 20021004 <-- |

PRIORITY APPLN. INFO.: US 2001-306859P P 20010723

AB The present invention provides novel methods of treatment of diabetes mellitus as well as methods of diagnosing the susceptibility of hypoglycemia in an individual. The method of treatment includes administering to an individual a sufficient amount of at least one inhibitor of the renin-angiotensin II system and at least one antidiabetic, for example insulin. Another objective of the present invention is to provide methods of preventing hypoglycemia in an individual in need thereof comprising administering to said individual a pharmaceutical effective amount of an inhibitor of the renin-angiotensin II system. In particular, such an individual may be an individual suffering from diabetes mellitus. A further objective of the present invention is to provide methods to diagnose the susceptibility to hypoglycemia of an individual comprising detecting within a predetd. tissue sample the genotype of the angiotensin-converting enzyme (ACE) gene; or detecting within a predetd. tissue sample the activity of ACE; and correlating said genotype or activity to the susceptibility of hypoglycemia.

IT 144701-48-4, Telmisartan
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 6 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:376495 CAPLUS

DOCUMENT NUMBER: 135:236137

TITLE: The role of angiotensin II receptor antagonists in the management of diabetes

AUTHOR(S): Barnett, Anthony H.

CORPORATE SOURCE: Birmingham Heartlands Hospital, Birmingham, UK

SOURCE: Blood Pressure, Supplement (2001), (1), 21-26
CODEN: BPSUEY; ISSN: 0803-8023

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Diabetic nephropathy, which develops in about 30% of patients with diabetes, is a progressive condition. It is characterized by increased blood pressure, declining glomerular filtration rate and

albuminuria. Lowering of blood pressure in diabetic patients is associated with reduced cardiovascular risk and renal protection. Inhibitors of angiotensin-converting enzyme (ACE) are the current gold standard treatment for hypertension in patients with type I diabetes because, in addition to their blood pressure lowering ability, they are thought to oppose the increased intraglomerular pressure that is mediated in part by angiotensin II. The angiotensin II receptor antagonists, a more recently developed class of antihypertensive agents, appear to be as effective as ACE inhibitors in delaying the progression of renal injury in animal models of diabetes. They act by selectively blocking the binding of angiotensin II to the AT1 receptor and may, therefore, offer a more complete blockade of the renin-angiotensin system than ACE inhibitors. The renal and antihypertensive effects of this class of drug in patients with diabetes are now being investigated in long-term clin. trials. The multicenter Diabetics Exposed to Telmisartan And EnalaprIL (DETAIL) study is a randomized, double-blind, parallel-group comparison of the renal and antihypertensive effects of the angiotensin II receptor antagonist telmisartan and the ACE inhibitor enalapril in 272 patients with type II diabetes. The primary outcome is change in glomerular filtration rate over the 5 yr of the study.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of angiotensin II receptor antagonists in management of diabetes)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:167787 CAPLUS

DOCUMENT NUMBER: 134:202715

TITLE: Pharmaceutical formulations of ACE and ATII inhibitors for prevention of stroke, diabetes and/or congestive heart failure

INVENTOR(S): Schoelkens, Bernward; Bender, Norbert; Rangoonwala, Badrudin; Dagenais, Gilles; Gerstein, Hertzel; Ljunggren, Anders; Yusuf, Salim

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001015673 | A2 | 20010308 | WO 2000-EP8341 | 20000825 <-- |
| WO 2001015673 | A3 | 20020307 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2382387 | C | 20010308 | CA 2000-2382387 | 20000825 <-- |
| CA 2382387 | A1 | 20010308 | | |
| CA 2500709 | A1 | 20010308 | CA 2000-2500709 | 20000825 <-- |
| BR 2000013540 | A | 20020430 | BR 2000-13540 | 20000825 <-- |
| EP 1212081 | A2 | 20020612 | EP 2000-965898 | 20000825 <-- |
| EP 1212081 | B1 | 20051026 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| TR 200200518 | T2 | 20020621 | TR 2002-518 | 20000825 <-- |
| TR 200202466 | T2 | 20021223 | TR 2002-2466 | 20000825 <-- |
| TR 200202467 | T2 | 20021223 | TR 2002-2467 | 20000825 <-- |
| HU 200202461 | A2 | 20021228 | HU 2002-2461 | 20000825 <-- |
| JP 2003508426 | T | 20030304 | JP 2001-519887 | 20000825 <-- |
| EE 200200085 | A | 20030415 | EE 2002-85 | 20000825 <-- |
| EP 1437131 | A1 | 20040714 | EP 2004-6330 | 20000825 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| AT 307604 | T | 20051115 | AT 2000-965898 | 20000825 |
| RU 2272651 | C2 | 20060327 | RU 2002-107673 | 20000825 |
| ES 2250192 | T3 | 20060416 | ES 2000-965898 | 20000825 |
| BG 106319 | A | 20021229 | BG 2002-106319 | 20020118 <-- |
| NO 2002000850 | A | 20020221 | NO 2002-850 | 20020221 <-- |
| ZA 2002001471 | A | 20030303 | ZA 2002-1471 | 20020221 <-- |
| AU 2005203694 | A1 | 20050908 | AU 2005-203694 | 20050817 |
| US 2006194868 | A1 | 20060831 | US 2006-415137 | 20060502 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| SE 1999-3028 | A | 19990827 |
| AU 2000-76484 | A3 | 20000825 |
| CA 2000-2382387 | A3 | 20000825 |
| EP 2000-965898 | A3 | 20000825 |
| US 2000-645556 | B1 | 20000825 |
| WO 2000-EP8341 | W | 20000825 |

AB The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS), i.e., inhibitors of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor (ATII) antagonists or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, in the manufacture of a medicament for the prevention and/or treatment of stroke, diabetes and/or congestive heart failure (CHF). A large-scale clin. trial was designed to examine the effect of the ACE inhibitor ramipril vs. placebo in reducing cardiovascular events. There was a clear 32% reduction in the ramipril group in the number of patients who developed a stroke, and this is surprising since patients were normotensive when recruited to the study. The number of patients who developed CHF was significantly reduced by 21% in the ramipril group, which is unexpected since patients had no signs or symptoms of CHF at

study start. Equally surprising is the marked 36% reduction in the number of patients who developed diabetes in the ramipril group.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of inhibitors of renin-angiotensin system for prevention and/or treatment of stroke, diabetes and/or congestive heart failure)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 8 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:78061 USPATFULL | | | |
| TITLE: | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | | | |
| INVENTOR(S): | Davis, Harry R., Berkeley Heights, NJ, UNITED STATES<br>Kosoglou, Teddy, Jamison, PA, UNITED STATES | | | |
| PATENT ASSIGNEE(S): | Schering Corporation (U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003053981 | A1 | 20030320 | <-- |
| APPLICATION INFO.: | US 2002-57534 | A1 | 20020125 | (10) |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2001-264600P | | 20010126 | (60) |
| | US 2001-323842P | | 20010921 | (60) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530 | | | |
| NUMBER OF CLAIMS: | 81 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 4194 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted β-lactam sterol

absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2002:323139 USPATFULL |
| TITLE: | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| INVENTOR(S): | Davis, Harry R., Berkeley Heights, NJ, UNITED STATES<br>Kosoglou, Teddy, Jamison, PA, UNITED STATES |
| PATENT ASSIGNEE(S): | Schering Corporation (U.S. corporation) |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002183305 | A1 | 20021205 | <-- |
| APPLICATION INFO.: | US 2002-57646 | A1 | 20020125 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-264275P | 20010126 (60) |
| | US 2001-323842P | 20010921 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | APPLICATION |
| LEGAL REPRESENTATIVE: | SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530 |
| NUMBER OF CLAIMS: | 81 |
| EXEMPLARY CLAIM: | 1 |
| LINE COUNT: | 4256 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2002:336849 USPATFULL |
| TITLE: | Sterol absorption inhibitor compositions |
| INVENTOR(S): | Cho, Wing-Kee Philip, Princeton, NJ, UNITED STATES<br>Davis, Harry R., Berkeley Heights, NJ, UNITED STATES<br>Kosoglou, Teddy, Jamison, PA, UNITED STATES<br>Picard, Gilles J., Braine L'Alleud, BELGIUM |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002192203 | A1 | 20021219 | <-- |
| | US 7030106 | B2 | 20060418 | |
| APPLICATION INFO.: | US 2002-136968 | A1 | 20020501 (10) | |
| RELATED APPLN. INFO.: | Division of Ser. No. US 2002-57323, filed on 25 Jan 2002, PENDING | | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-264396P | 20010126 (60) |
| | US 2001-323839P | 20010921 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | APPLICATION |

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 4987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes , obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:273408 USPATFULL
TITLE: Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
Kosoglou, Teddy, Jamison, PA, UNITED STATES
Picard, Gilles J., Brussels, BELGIUM
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002151536 | A1 | 20021017 | <-- |
| APPLICATION INFO.: | US 2002-57323 | A1 | 20020125 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-264396P | 20010126 (60) |
| | US 2001-323839P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 5004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes , obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:283080 USPATFULL
TITLE: Method of treatment and/or prophylaxis
INVENTOR(S): Smith, Maree Therese, Bardon, AUSTRALIA
Brown, Lindsay Charles, Sinnamon Park, AUSTRALIA

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003199424 | A1 | 20031023 | <-- |
| APPLICATION INFO.: | US 2003-393056 | A1 | 20030320 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2002-365858P | 20020320 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 2302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the use of angiotensin II receptor I (AT.sub.1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The present invention also discloses the use of AT.sub.1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially in individuals having, or at risk of developing, a neuropathic condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(method of treatment and prophylaxis of neuropathic condition)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 13 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:245001 USPATFULL
TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
INVENTOR(S): Boehm, Peter, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
Meinicke, Wolf Thomas, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Riedel, Axel, Maselheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003171415 | A1 | 20030911 | <-- |
| APPLICATION INFO.: | US 2003-354713 | A1 | 20030130 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2001-EP9428, filed on 16 Aug 2001, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 2000-20691 | 20000822 |
| | DE 2001-DE108215 | 20010220 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment of indications which can be positively influenced by inhibition of AT.sub.1 mediated effects with maintenance of AT.sub.2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT.sub.1 receptors in the subepithelial area or increase of AT.sub.2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 14 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:93574 USPATFULL

TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
INVENTOR(S): Gougoutas, Jack Z., Princeton, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003064935 | A1 | 20030403 | <-- |
| | US 6774112 | B2 | 20040810 | |
| APPLICATION INFO.: | US 2002-117914 | A1 | 20020408 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-283097P | 20010411 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1995
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula ##STR1##

wherein

R.sup.1, R.sup.2 and R.sup.2a are independently hydrogen, OH, OR.sup.5, alkyl, --OCHF.sub.2, --OCF.sub.3, --SR.sup.5a or halogen;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5b, alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CONR.sup.6R.sup.6a, --CO.sub.2R.sup.5c, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5d)R.sup.6d, --CN, --NHCOR.sup.5e, --NHSO.sub.2R.sup.5f, --NHSO.sub.2Aryl, --SR.sup.5g, --SOR.sup.5h, --SO.sub.2R.sup.5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:759925 CAPLUS
DOCUMENT NUMBER: 139:316443
TITLE: Renal involvement in hypertensive cardiovascular disease
AUTHOR(S): Sharma, A. M.

CORPORATE SOURCE: McMaster University, Hamilton, ON, Can.
SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F12-F18
CODEN: EHJSFT; ISSN: 1520-765X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Cardiovascular morbidity and mortality are elevated in renally impaired patients, especially if they are hypertensive. Diabetes is also associated with a high prevalence of cardiovascular morbidity and end-stage renal disease. Albuminuria, elevated serum creatinine, decreased creatinine clearance and proteinuria independently predict cardiovascular risk. Even patients with mild renal impairment should be treated to slow kidney disease progression and reduce vascular damage. Blood pressure control is effective in reducing vascular complications of diabetes, but not all classes of antihypertensive agents provide renoprotection. Angiotensin-converting enzyme inhibitors are superior to beta-blockers in preventing or delaying the loss of kidney function associated with hypertension. The renoprotection appears to be in part independent of the antihypertensive effect. Angiotensin II receptor blockers (ARBs) also reduce the risk of renal complications in diabetics. Telmisartan seems well suited to provide renoprotection because, unlike other ARBs, it is almost exclusively excreted by the liver and no initial dose adjustment is required for patients with mild-to-moderate renal impairment. Other advantages of telmisartan include its very high volume of distribution and long terminal elimination half-life. Clin. trials to evaluate telmisartan will address the problems of diabetes, renal impairment and end-organ disease.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(relationship between hypertensive cardiovascular disease and renal disease)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:166532 USPATFULL
TITLE: C-aryl glucoside SGLT2 inhibitors and method
INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES

Ellsworth, Bruce, Princeton, NJ, UNITED STATES
Meng, Wei, Pennington, NJ, UNITED STATES
Wu, Gang, Princeton, NJ, UNITED STATES
Sher, Philip M., Plainsboro, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003114390 | A1 | 20030619 | <-- |
| | US 6936590 | B2 | 20050830 | |
| APPLICATION INFO.: | US 2002-264410 | A1 | 20021004 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 2410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1##

alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:96100 USPATFULL
TITLE: Retinoid-related receptor function regulating agent
INVENTOR(S): Sugiyama, Yasuo, Kawanishi, JAPAN
Momose, Yu, Takarazuka, JAPAN
Kimura, Hiroyuki, Sakai, JAPAN
Sakamoto, Junichi, Toyonaka, JAPAN
Odaka, Hiroyuki, Kobe, JAPAN
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6545009 | B1 | 20030408 | <-- |
| | WO 2000001679 | | 20000113 | <-- |
| APPLICATION INFO.: | US 2000-720644 | | 20001228 (9) | |
| | WO 1999-JP3520 | | 19990630 | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-186698 | 19980701 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Tsang, Cecilia
ASSISTANT EXAMINER: Sackey, Ebenezer
LEGAL REPRESENTATIVE: Cha, Mark, Ramesh, Elaine
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia,

preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:251945 USPATFULL
TITLE: C-aryl glucoside SGLT2 inhibitors and method
INVENTOR(S): Ellsworth, Bruce, Princeton, NJ, UNITED STATES
Washburn, William N., Titusville, NJ, UNITED STATES
Sher, Philip M., Plainsboro, NJ, UNITED STATES
Wu, Gang, Princeton, NJ, UNITED STATES
Meng, Wei, Pennington, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002137903 | A1 | 20020926 | <-- |
| | US 6515117 | B2 | 20030204 | |
| APPLICATION INFO.: | US 2002-151436 | A1 | 20020520 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-679027, filed on 4 Oct 2000, GRANTED, Pat. No. US 6414126

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-194615P | 20000405 (60) |
| | US 1999-158773P | 19991012 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An SGLT2 inhibiting compound is provided having the formula ##STR1##

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:160855 USPATFULL
TITLE: C-aryl glucoside SGLT2 inhibitors and method
INVENTOR(S): Ellsworth, Bruce, Princeton, NJ, United States
Washburn, William N., Titusville, NJ, United States
Sher, Philip M., Plainsboro, NJ, United States
Wu, Gang, Princeton, NJ, United States
Meng, Wei, Pennington, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6414126 | B1 | 20020702 | <-- |
| APPLICATION INFO.: | US 2000-679027 | | 20001004 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-194615P | 20000405 (60) |
| | US 1999-158773P | 19991012 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gitomer, Ralph
ASSISTANT EXAMINER: Khare, Devesh
LEGAL REPRESENTATIVE: Provoost, Jonathan N.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

where

R.sup.1, R.sup.2, and R.sup.2a are independently hydrogen, OH, OR.sup.5, lower alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i or halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5a, OAryl, OCH.sub.2Aryl, lower alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2R.sup.5b, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2R.sup.5d, --NHSO.sub.2Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2R.sup.5g, --SO.sub.2Aryl, or a five, six or seven membered heterocycle, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently lower alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle;

A is O, S, NH, or (CH.sub.2).sub.n where n is 0-3.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:265968 USPATFULL
TITLE: Oxyiminoalkanoic acid derivatives
INVENTOR(S): Momose, Yu, Hyogo, JAPAN
Odaka, Hiroyuki, Hyogo, JAPAN
Imoto, Hiroshi, Shiga, JAPAN
Kimura, Hiroyuki, Osaka, JAPAN
Sakamoto, Junichi, Osaka, JAPAN

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003186985 | A1 | 20031002 | <-- |
| | US 6924300 | B2 | 20050802 | |
| APPLICATION INFO.: | US 2002-331056 | A1 | 20021227 (10) | |

RELATED APPLN. INFO.: Division of Ser. No. US 2000-714699, filed on 16 Nov 2000, GRANTED, Pat. No. US 6495581 Division of Ser. No. US 1999-423854, filed on 15 Nov 1999, GRANTED, Pat. No.

US 6251926 A 371 of International Ser. No. WO 1999-JP2407, filed on 10 May 1999, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-127921 | 19980511 |
| | JP 1998-127922 | 19980511 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 6054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methylpyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:106793 USPATFULL
TITLE: Method of treatment
INVENTOR(S): Shahinfar, Shahnaz, Newton Square, PA, UNITED STATES
Zhang, Zhongxin, Blue Bell, PA, UNITED STATES
Brenner, Barry M., Weston, MA, UNITED STATES

| | NUMBER | KIND | DATE | | |
|---|---|---|---|---|---|
| PATENT INFORMATION: | US 2003073705 | A1 | 20030417 | | <-- |
| APPLICATION INFO.: | US 2002-143415 | A1 | 20020510 | (10) | |

| | NUMBER | DATE |
|---|---|---|

| | | |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-290839P | 20010514 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907 | |
| NUMBER OF CLAIMS: | 32 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 6 Drawing Page(s) | |
| LINE COUNT: | 1200 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine, or pharmaceutically acceptable salts thereof are useful.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 22 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2001:97948 USPATFULL |
| TITLE: | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| INVENTOR(S): | Momose, Yu, Takarazuka, Japan<br>Odaka, Hiroyuki, Kobe, Japan<br>Imoto, Hiroshi, Kusatsu, Japan<br>Kimura, Hiroyuki, Sakai, Japan<br>Sakamoto, Junichi, Toyonaka, Japan |
| PATENT ASSIGNEE(S): | Takeda Chemical Industries, Ltd., Osaka, Japan<br>(non-U.S. corporation) |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6251926 | B1 | 20010626 | <-- |

| | | | |
|---|---|---|---|
| | WO 9958510 | 19991118 | <-- |
| APPLICATION INFO.: | US 1999-423854 | 19991115 | (9) |
| | WO 1999-JP2407 | 19990510 | |
| | | 19991115 | PCT 371 date |
| | | 19991115 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-127921 | 19980511 |
| | JP 1998-127922 | 19980511 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
ASSISTANT EXAMINER: Wright, Sonya
LEGAL REPRESENTATIVE: Riesen, Philippe Y.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 5841
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:332756 USPATFULL
TITLE: Oxyiminoalkanoic acid derivatives
INVENTOR(S): Momose, Yu, Takarazuka, JAPAN
Odaka, Hiroyuki, Kobe, JAPAN
Imoto, Hiroshi, Kusatsu, JAPAN
Kimura, Hiroyuki, Sakai, JAPAN
Sakamoto, Junichi, Toyonaka, JAPAN
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN
(non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6495581 | B1 | 20021217 | <-- |
| APPLICATION INFO.: | US 2000-714699 | | 20001116 | (9) |

RELATED APPLN. INFO.: Division of Ser. No. US 423854, now patented, Pat. No. US 6251926

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-127921 | 19980511 |
| | JP 1998-127922 | 19980511 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Wright, Sonya
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer

of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methyl pyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof which has excellent hypoglycemic and hypolipidemic actions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:283219 USPATFULL | | | |
| TITLE: | Heterocyclic containing biphenyl aP2 inhibitors and method | | | |
| INVENTOR(S): | Robl, Jeffrey A., Newtown, PA, UNITED STATES<br>Magnin, David R., Hamilton, NJ, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003199563 | A1 | 20031023 | <-- |
| | US 6927227 | B2 | 20050809 | |
| APPLICATION INFO.: | US 2002-321137 | A1 | 20021217 (10) | |
| RELATED APPLN. INFO.: | Division of Ser. No. US 2000-519079, filed on 6 Mar 2000, GRANTED, Pat. No. US 6548529 | | | |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 1999-127745P | | 19990405 (60) | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000 | | | |
| NUMBER OF CLAIMS: | 34 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 3547 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:226410 USPATFULL
TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
INVENTOR(S): Anderson, Craig, Devonport/Auckland, NEW ZEALAND
Yusuf, Salim, Carlisle, CANADA
Sleight, Peter, Wheatley, Oxfordshire, UNITED KINGDOM
Hilbrich, Lutz, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003158223 | A1 | 20030821 | <-- |
| APPLICATION INFO.: | US 2002-79703 | A1 | 20020220 | (10) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 26 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:172321 USPATFULL
TITLE: Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES

Robl, Jeffrey A., Newtown, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002091078 | A1 | 20020711 | <-- |
| | US 6649622 | B2 | 20031118 | |
| APPLICATION INFO.: | US 2001-771310 | A1 | 20010126 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-178598P | 20000128 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 3597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein A, B, X, and Y are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:149184 USPATFULL
TITLE: Pyridone inhibitors of fatty acid binding protein and method
INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES
Robl, Jeffrey A., Newtown, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002077340 | A1 | 20020620 | <-- |
| | US 6670380 | B2 | 20031230 | |
| APPLICATION INFO.: | US 2001-989212 | A1 | 20011120 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-252014P | 20001120 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided having the formula ##STR1##

wherein A, Q, and X are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such compounds alone or in combination with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:888552 CAPLUS
DOCUMENT NUMBER: 137:380012
TITLE: Method of treatment for prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function
INVENTOR(S): Shahinfar, Shahnaz; Brenner, Barry M.; Zhang, Zhongxin
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002092081 | A1 | 20021121 | WO 2002-US14919 | 20020510 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003073705 | A1 | 20030417 | US 2002-143415 | 20020510 <-- |
| CA 2445913 | A1 | 20031029 | CA 2002-2445913 | 20020510 <-- |
| EP 1389105 | A1 | 20040218 | EP 2002-731759 | 20020510 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2005501815 | T | 20050120 | JP 2002-588998 | 20020510 |
| PRIORITY APPLN. INFO.: | | | US 2001-290839P P | 20010514 |
| | | | WO 2002-US14919 W | 20020510 |

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[((2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4, -b]pyridine, or pharmaceutically acceptable salts thereof are useful.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:226419 USPATFULL

TITLE: Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES
Hariharan, Narayanan, Richboro, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003158232 | A1 | 20030821 | <-- |
| | US 6967212 | B2 | 20051122 | |
| APPLICATION INFO.: | US 2002-294525 | A1 | 20021114 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-153454, filed on 22 May 2002, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-294380P | 20010530 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 3975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R.sup.2a, R.sup.2b, R.sup.2c, X.sub.1 to X.sub.7, R.sup.1, R.sup.2, R.sup.3, R.sup.3a, R.sup.4, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:134647 USPATFULL
TITLE: Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES
Hariharan, Narayanan, Richboro, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003092736 | A1 | 20030515 | <-- |
| APPLICATION INFO.: | US 2002-153454 | A1 | 20020522 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-294380P | 20010530 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R.sup.2a, R.sup.2b, R.sup.2c, X.sub.1 to X.sub.7, R.sup.1, R.sup.2, R.sup.3, R.sup.3a, R.sup.4, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:102390 USPATFULL
TITLE: Heterocyclic containing biphenyl aP2 inhibitors and method
INVENTOR(S): Robl, Jeffrey A., Newtown, PA, United States
Sulsky, Richard B., West Trenton, NJ, United States
Magnin, David R., Hamilton, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6548529 | B1 | 20030415 | <-- |
| APPLICATION INFO.: | US 2000-519079 | | 20000306 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-127745P | 19990405 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Shameem, Golam M M
LEGAL REPRESENTATIVE: Hermenau, Ronald S., Kilcoyne, John, Rodney, Burton
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:428761 CAPLUS
DOCUMENT NUMBER: 137:11000
TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction
INVENTOR(S): Sahota, Pritam Singh
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| WO 2002043807 | A2 | 20020606 | WO 2001-EP13976 | | 20011129 | <-- |
| WO 2002043807 | A3 | 20030814 | | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW | | | | | | |
| RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | | | |
| CA 2430924 | A1 | 20020606 | CA 2001-2430924 | | 20011129 | <-- |
| AU 2002026365 | A5 | 20020611 | AU 2002-26365 | | 20011129 | <-- |
| EP 1353727 | A2 | 20031022 | EP 2001-995680 | | 20011129 | <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| JP 2004514703 | T | 20040520 | JP 2002-545776 | | 20011129 | |
| US 2002107236 | A1 | 20020808 | US 2001-8445 | | 20011203 | <-- |
| US 2004087484 | A1 | 20040506 | US 2003-433189 | | 20030624 | |
| PRIORITY APPLN. INFO.: | | | US 2000-250540P | P | 20001201 | |
| | | | WO 2001-EP13976 | W | 20011129 | |

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 33 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:790344 CAPLUS
DOCUMENT NUMBER: 133:340269
TITLE: Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy
INVENTOR(S): Nakagawa, Shizue; Nagisa, Yasutaka; Ikeda, Hitoshi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000066161 | A1 | 20001109 | WO 2000-JP2766 | 20000427 <-- |
| W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2371554 | A1 | 20001109 | CA 2000-2371554 | 20000427 <-- |
| BR 2000010084 | A | 20020115 | BR 2000-10084 | 20000427 <-- |
| EP 1197223 | A1 | 20020417 | EP 2000-921056 | 20000427 <-- |
| EP 1197223 | B1 | 20050216 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| NZ 514855 | A | 20040130 | NZ 2000-514855 | 20000427 |
| AU 774799 | B2 | 20040708 | AU 2000-41434 | 20000427 |
| RU 2239454 | C2 | 20041110 | RU 2001-132073 | 20000427 |
| AT 289204 | T | 20050315 | AT 2000-921056 | 20000427 |
| PT 1197223 | T | 20050429 | PT 2000-921056 | 20000427 |
| ES 2233362 | T3 | 20050616 | ES 2000-921056 | 20000427 |
| JP 2001010975 | A | 20010116 | JP 2000-134243 | 20000428 <-- |
| US 7064141 | B1 | 20060620 | US 2001-958740 | 20011016 |
| ZA 2001008527 | A | 20021017 | ZA 2001-8527 | 20011017 <-- |
| NO 2001005257 | A | 20011026 | NO 2001-5257 | 20011026 <-- |

US 2006189669 A1 20060824 US 2006-406345 20060419
PRIORITY APPLN. INFO.: JP 1999-121498 A 19990428
WO 2000-JP2766 W 20000427
US 2001-958740 A3 20011016

OTHER SOURCE(S): MARPAT 133:340269

AB Disclosed are drugs which contain a compound having an angiotensin II antagonism or its salt and are useful in, for example, preventing or treating simplex retinopathy or preproliferating retinopathy by inhibiting the progression thereof. Administration of candesartan cilexetil to diabetes model rats inhibited the production of VEGF and improved retinal elec. potentials. Formulations for capsules, tablets, and ophthalmic suspensions containing the invention compds. are also provided.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin II antagonists for treatment of retinopathy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 34 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:113449 USPATFULL

TITLE: Methods for tissue protection using highly effective inhibition of the renin-angiotensin system

INVENTOR(S): Weinberg, Marc S., Seekonk, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003078190 | A1 | 20030424 | <-- |
| APPLICATION INFO.: | US 2002-155824 | A1 | 20020524 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-293835P | 20010525 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211

NUMBER OF CLAIMS: 133

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 3074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and pharmaceutical compositions are provided for protecting tissue of a subject from the effects of angiotensin II. The methods involve administering to subjects angiotensin receptor blockers (ARB), either by themselves at doses beyond those recommended or effective for the management of hypertension, or in combination with angiotensin-converting enzyme inhibitors (ACEI). The pharmaceutical compositions include both an ARB and an ACEI and are formulated in certain preferred embodiments for once-daily oral administration. The methods and pharmaceutical compositions are useful for the treatment of proteinuria, chronic or congestive heart failure, aneurysms, and vascular tissue hypertrophy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan 144701-48-4D, Telmisartan, prodrug derivs.
(renin-angiotensin system inhibition for protecting tissue from effects of angiotensin II)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 35 OF 113 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2001:36849 USPATFULL |
| TITLE: | Method for reducing mortality with an angiotensin II antagonist |
| INVENTOR(S): | Beere, Polly A., Lahaska, PA, United States<br>Chang, Paul I., Doylestown, PA, United States<br>Pitt, Bertram, Ann Arbor, MI, United States<br>Rucinska, Eva J., Blue Bell, PA, United States<br>Segal, Robert, Gwynedd Valley, PA, United States<br>Sharma, Divakar, Hatfield, PA, United States<br>Snavely, Duane B., Chalfont, PA, United States |
| PATENT ASSIGNEE(S): | Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation) |

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6201002 | B1 | 20010313 | <-- |
| APPLICATION INFO.: | US 1998-3159 | | 19980106 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1997-34927P | 19970110 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | Granted |
| PRIMARY EXAMINER: | Krass, Frederick |
| LEGAL REPRESENTATIVE: | Camara, Valerie J., Daniel, Mark R. |
| NUMBER OF CLAIMS: | 33 |
| EXEMPLARY CLAIM: | 1 |
| NUMBER OF DRAWINGS: | 5 Drawing Figure(s); 5 Drawing Page(s) |
| LINE COUNT: | 2373 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(angiotensin II antagonists to treat symptomatic heart failure)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 36 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2002652897 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12411451
TITLE: Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
AUTHOR: Sharma Arya M; Janke Jurgen; Gorzelniak Kerstin; Engeli Stefan; Luft Friedrich C
CORPORATE SOURCE: HELIOS Klinikum Berlin, Franz Volhard Clinic-Charite, Humboldt University of Berlin, and Max Delbruck Center for Molecular Medicine, Berlin, Germany.. sharma@ccc.mcmaster.ca
SOURCE: Hypertension, (2002 Nov) Vol. 40, No. 5, pp. 609-11.
Journal code: 7906255. E-ISSN: 1524-4563.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200211
ENTRY DATE: Entered STN: 5 Nov 2002
Last Updated on STN: 11 Dec 2002
Entered Medline: 8 Nov 2002

AB Obesity is the prime risk factor for the development of type 2 diabetes. Recent clinical trials have shown that blockade of the renin-angiotensin system, either by inhibiting the angiotensin-converting enzyme or blocking the angiotensin type 1 receptor, may substantially lower the risk for type 2 diabetes. The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II markedly inhibits adipogenic differentiation of human adipocytes via the angiotensin type I receptor and that expression of angiotensin II-forming enzymes in adipose tissue is inversely correlated with insulin sensitivity, we propose the hypothesis that blockade of the renin-angiotensin system prevents diabetes by promoting the recruitment and differentiation of adipocytes. Increased formation of adipocytes would counteract the ectopic deposition of lipids in other tissues (muscle, liver, pancreas), thereby improving insulin sensitivity and preventing the development of type 2 diabetes.

L6 ANSWER 37 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:122803 CAPLUS
DOCUMENT NUMBER: 142:219083
TITLE: Preparation of phosphorus-containing rapamycin derivatives for use in pharmaceutical compositions as immunosuppressive and anticancer agents
INVENTOR(S): Metcalf, Chester A., III; Rozamus, Leonard W.; Wang, Yihan; Berstein, David L.
PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 635,054.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2005032825 | A1 | 20050210 | US 2004-862149 | 20040604 |
| US 7091213 | B2 | 20060815 | | |
| US 2003220297 | A1 | 20031127 | US 2003-357152 | 20030203 <-- |
| US 2004073024 | A1 | 20040415 | US 2003-635054 | 20030806 |
| US 2006264405 | A1 | 20061123 | US 2006-429582 | 20060505 |

| | | | | | |
|---|---|---|---|---|---|
| US 2006264456 | A1 | 20061123 | US 2006-494418 | | 20060727 |
| PRIORITY APPLN. INFO.: | | | US 2002-353252P | P | 20020201 |
| | | | US 2002-426928P | P | 20021115 |
| | | | US 2002-428383P | P | 20021122 |
| | | | US 2002-433930P | P | 20021217 |
| | | | US 2003-357152 | A2 | 20030203 |
| | | | US 2003-635054 | A2 | 20030806 |
| | | | US 2003-486367P | P | 20030711 |
| | | | US 2004-862149 | A2 | 20040604 |
| | | | US 2004-889163 | B2 | 20040712 |
| | | | US 2005-711859P | P | 20050826 |

OTHER SOURCE(S): CASREACT 142:219083; MARPAT 142:219083

GI




I

AB Rapamycin derivs. containing phosphorus moiety, such as I [A = O, S, NR2, absent; Q = V, OV, SV, NR2, absent; V = aliphatic, heteroaliph., aryl, heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR2VA; J = P(:K)(YR5)2, P(YR5)2, P(:K)(YR5)GR6; K = O, S; Y = O, S, NR2, bond; R2, R5 = aliphatic, heteroaliph., aryl, heteroaryl, H; R6 = PK(YR5)YR5, SO2YR5, C(O)YR5; G = O, S, NR2, (M)X; M = (un)substituted methylene, alkyl, alkylene; X = 1-6], and pharmaceutically acceptable derivs. thereof, were prepared for therapeutic use as immunosuppressive and anticancer agents. These rapamycin derivs. are useful for treatment of graft vs. host disease, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation, ocular uveitis; adult T-cell leukemia, lymphoma, fungal infections, hyperproliferative restenosis, graft vascular atherosclerosis, coronary artery disease, cerebrovascular disease, arteriosclerosis, atherosclerosis, nonatheromatous arteriosclerosis, or vascular wall damage from cellular events leading toward immune mediated vascular damage, stroke or multi-infarct dementia. Thus, I [A-QJ = OP(O)(OBu)Me] was prepared by reacting rapamycin with methylphosphonic dichloride and n-butanol using 3,5-lutidine in CH2Cl2 under a nitrogen atmospheric Binding affinity of the rapamycin phosphorus derivs. for human FKBP-12 protein was assayed, dosages for restenosis prevention were discussed.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of phosphorus-containing rapamycin derivs. for use in pharmaceutical compns. as immunosuppressive and anticancer agents)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:157602 CAPLUS
DOCUMENT NUMBER: 136:205430
TITLE: Pharmaceutical compositions containing AT-receptor antagonist or insulin secretion enhancers
INVENTOR(S): Allison, Malcolm; Gatlin, Marjorie Regan
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002015933 | A2 | 20020228 | WO 2001-EP9587 | 20010820 <-- |
| WO 2002015933 | A3 | 20030814 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001087698 | A5 | 20020304 | AU 2001-87698 | 20010820 <-- |
| EP 1351683 | A2 | 20031015 | EP 2001-967289 | 20010820 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004514654 | T | 20040520 | JP 2002-520854 | 20010820 |
| US 2004034065 | A1 | 20040219 | US 2003-362340 | 20030616 |
| US 2006089389 | A1 | 20060427 | US 2005-295928 | 20051207 |
| US 2006281790 | A1 | 20061214 | US 2006-508353 | 20060823 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-643641 | A | 20000822 |
| US 2000-327553P | P | 20000822 |
| WO 2001-EP9587 | W | 20010820 |
| US 2003-362340 | B1 | 20030616 |
| US 2005-295928 | B1 | 20051207 |

AB A pharmaceutical composition comprises as active ingredients an AT1-receptor antagonist or a salt, an insulin secretion enhancer or a its salt or an insulin sensitizer or its salt. Thus, tablets contained Starlix DS 60, lactose monohydrate 141.5, microcryst. cellulose 71, Povidone-K30 12, and Croscarmellose sodium 18.4, colloidal SiO2 6.4, Mg stearate 5.7, and Opadry 9 mg.

IT 144701-48-4, Telmisartan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing AT-receptor antagonist or insulin secretion enhancers)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 39 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:762798 CAPLUS
DOCUMENT NUMBER: 135:308910
TITLE: Pharmaceutical compositions containing an aldosterone synthase inhibitor and an AT1-receptor antagonist
INVENTOR(S): Steele, Ronald Edward
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001076574 | A2 | 20011018 | WO 2001-EP4116 | 20010410 <-- |
| WO 2001076574 | A3 | 20020425 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2405895 | A1 | 20011018 | CA 2001-2405895 | 20010410 | <-- |
| BR 2001010079 | A | 20021231 | BR 2001-10079 | 20010410 | <-- |
| EP 1282410 | A2 | 20030212 | EP 2001-940317 | 20010410 | <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2003530343 | T | 20031014 | JP 2001-574092 | 20010410 | <-- |
| NZ 521855 | A | 20041029 | NZ 2001-521855 | 20010410 | |
| NZ 534086 | A | 20060831 | NZ 2001-534086 | 20010410 | |
| US 2003083342 | A1 | 20030501 | US 2002-149107 | 20020827 | <-- |
| IN 2002CN01650 | A | 20050128 | IN 2002-CN1650 | 20021008 | |
| NO 2002004920 | A | 20021127 | NO 2002-4920 | 20021011 | <-- |
| ZA 2002008204 | A | 20031014 | ZA 2002-8204 | 20021011 | <-- |
| US 2004204444 | A1 | 20041014 | US 2004-826106 | 20040415 | |
| US 2005059697 | A1 | 20050317 | US 2004-940544 | 20040914 | |
| US 2006122217 | A1 | 20060608 | US 2005-291008 | 20051130 | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-196742P | P | 20000412 |
| NZ 2001-521855 | A1 | 20010410 |
| WO 2001-EP4116 | W | 20010410 |
| US 2002-149107 | A3 | 20020827 |
| US 2004-940544 | B1 | 20040914 |

AB The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. A pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof is used for the prevention of, delay of progression of, and treatment of a disease or condition selected from the group consisting of hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, hypothyroidism, myocardial infarction, etc. For example, a hard gelatin capsules were prepared containing valsartan 80.0 mg, microcryst. cellulose 110.0 mg, Polyvidone K30 45.2 mg, sodium lauryl sulfate 1.2 mg, crospovidone 26.0 mg, and magnesium stearate 2.6 mg by a granulation method.

IT 144701-48-4, Telmisartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 40 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:188513 USPATFULL
TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon T., Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003130306 | A1 | 20030710 | <-- |
| | US 6673815 | B2 | 20040106 | |
| APPLICATION INFO.: | US 2002-289053 | A1 | 20021106 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-333022P | 20011106 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 1699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, X.sub.1 is CH or N and, A, E, M, G, X.sub.2, X.sub.3, X.sub.4, R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:134608 USPATFULL
TITLE: Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Wang, Wei, Princeton, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003092697 | A1 | 20030515 | <-- |

| | | | |
|---|---|---|---|
| | US 7105556 | B2 | 20060912 |
| APPLICATION INFO.: | US 2002-153342 | A1 | 20020522 (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-294505P | 20010530 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 2127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, X.sub.1 is C or N, and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, A, m, n, X.sub.2, X.sub.3 and X.sub.4 are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:757520 CAPLUS
DOCUMENT NUMBER: 139:255390
TITLE: Method of treatment and prophylaxis of neuropathic condition
INVENTOR(S): Smith, Maree Therese; Brown, Lindsay
PATENT ASSIGNEE(S): The University of Queensland, Australia
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| WO 2003077912 | A1 | 20030925 | WO 2003-AU336 | | 20030320 | <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | | |
| AU 2003209851 | A1 | 20030929 | AU 2003-209851 | | 20030320 | <-- |
| US 2003199424 | A1 | 20031023 | US 2003-393056 | | 20030320 | <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-365858P | P | 20020320 | |
| | | | WO 2003-AU336 | W | 20030320 | |

AB The invention is involves the use of angiotensin II receptor 1 (AT1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The invention also discloses the use of AT1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially
in individuals having, or at risk of developing, a neuropathic condition.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treatment and prophylaxis of neuropathic condition)
RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:390959 CAPLUS
DOCUMENT NUMBER: 133:12837
TITLE: Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
AUTHOR(S): Israili, Z. H.
CORPORATE SOURCE: Emory University School of Medicine, Atlanta, GA, 30303, USA
SOURCE: Journal of Human Hypertension (2000), 14(Suppl. 1), S73-S86
CODEN: JHHYEN; ISSN: 0950-9240
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 174 refs. Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive agents. Recent clin. trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement in renal function), and cardioprotective effect in patients with heart failure. Several large long-term studies are in progress to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart disease and diabetic nephropathy. The ARBs specifically block the interaction of angiotensin II at the AT, receptor, thereby relaxing smooth muscle, increasing salt and water excretion, reducing plasma volume, and decreasing cellular hypertrophy. These agents exert their blood pressure-lowering effect mainly by reducing peripheral vascular resistance usually without a rise in heart rate. Most of the com. available ARBs control blood pressure for 24 h after once daily dosing. Sustained efficacy of blood pressure control, without any evidence of tachyphylaxis,

has been demonstrated after long-term administration (3 yr) of some of the ARBs. The efficacy of ARBs is similar to that of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or calcium channel blockers in patients with similar degree of hypertension. Higher daily doses, dietary salt restriction, and concomitant diuretic or ACE inhibitor administration amplify the antihypertensive effect of ARBs. The ARBs have a low incidence of adverse effects (headache, upper respiratory infection, back pain, muscle cramps, fatigue and dizziness), even in the elderly patients. After the approval of losartan, five other ARBs (candesartan cilexetil, eprosartan, irbesartan, telmisartan, and valsartan) and three combinations with hydrochlorothiazide (irbesartan, losartan and valsartan) have been approved as antihypertensive agents, and some 28 compds. are in various stages of development. The ARBs are non-peptide compds. with varied structures; some (candesartan, losartan, irbesartan, and valsartan) have a common tetrazolo-biphenyl structure. Except for irbesartan, all active ARBs have a carboxylic acid group. Candesartan cilexetil is a prodrug, while losartan has a metabolite (EXP3174) which is more active than the parent drug. No other metabolites of ARBs contribute significantly to the antihypertensive effect. The variation in the mol. structure of the ARBs results in differences in the binding affinity to the receptor and pharmacokinetic profiles. The differences observed in lipid solubility, absorption/distribution, plasma protein binding, bioavailability, biotransformation, plasma half-life, and systemic elimination influence the time of onset, duration of action, and efficacy of the ARBs. On the basis of the daily mg dose, the anti-hypertensive potency of the ARBs follows the sequence: candesartan cilexetil > telmisartan losartan > irbesartan valsartan > eprosartan. After oral administration, the ARBs are rapidly absorbed (time for peak plasma levels = 0.5-4 h) but they have a wide range of bioavailability (from a low of 13% for eprosartan to a high of 60-80% for irbesartan); food does not influence the bioavailability, except for valsartan (a reduction of 40-50%) and eprosartan (increase). A limited dose-peak plasma levels/areas under the plasma level-time curve proportionality is observed for some of the ARBs. Most of these drugs have high plasma protein binding (95-100%); irbesartan has the lowest binding among the group (90%). The steady-state vols. of distribution vary from a low of 9 L (candesartan) to a high of 500 L ( telmisartan). Plasma elimination half-life is short for candesartan cilexetil and losartan (1-4 h), intermediate for eprosartan and valsartan (5-10 h), and longer for candesartan, irbesartan and telmisartan (11-38 h); the active metabolite of losartan has a longer half-life than for the parent drug. The drugs and their active metabolites do not accumulate to a significant extent after repeated dosing, except for telmisartan (100%). Most of the orally administered dose of ARBs is excreted via bile into the feces; from 2% ( telmisartan) to 33% (candesartan) of the oral dose is excreted in the urine. In most cases, changes in pharmacokinetic parameters due to aging, mild to moderate renal disease and heart failure do not require dosage modification; dosage has to be individualized for eprosartan, losartan, telmisartan and valsartan in patients with hepatic disease. In general, pharmacokinetic drug-drug interactions are rare, with the exception of combination of digoxin and telmisartan. The ARBs are an important treatment option for hypertension, being relatively safe and efficacious. The beneficial effects of the ARB therapy go beyond blood pressure control. They may prove to have beneficial hemodynamic and neurohormonal effects in heart failure and provide renoprotection in diabetic nephropathy.

REFERENCE COUNT: 189 THERE ARE 189 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 44 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:141004 USPATFULL
TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003096846 | A1 | 20030522 | <-- |
| | US 6653314 | B2 | 20031125 | |
| APPLICATION INFO.: | US 2002-80981 | A1 | 20020222 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002
Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 5718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:100110 USPATFULL
TITLE: Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES
Ress, Rudyard J., Flemington, NJ, UNITED STATES
Strony, John T., Lebanon, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
Hauer, William, Warren, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003069221 | A1 | 20030410 | <-- |
| APPLICATION INFO.: | US 2002-57339 | A1 | 20020125 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-323842P | 20010921 (60) |
| | US 2001-264396P | 20010126 (60) |
| | US 2001-264600P | 20010126 (60) |
| | US 2001-264275P | 20010126 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 3423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2003255815 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12781906
TITLE: The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
AUTHOR: Unger Thomas
CORPORATE SOURCE: Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany.. Thomas.unger@charite.de
SOURCE: The American journal of cardiology, (2003 May 22) Vol. 91, No. 10A, pp. 28G-34G. Ref: 52
Journal code: 0207277. ISSN: 0002-9149.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200307
ENTRY DATE: Entered STN: 4 Jun 2003
Last Updated on STN: 10 Jul 2003
Entered Medline: 9 Jul 2003

AB The renin-angiotensin system evolved to maintain volume homeostasis and blood pressure and to prevent ischemia during acute volume loss. But in the present age, these mechanisms are redundant, and the clinical significance of angiotensin II results from its pathologic effects, which are mediated by the angiotensin II type 1 (AT(1)) receptor. Activation of AT(1) receptors has been linked to pathologic processes that contribute to atherosclerosis and ischemic events, including oxidative stress, inflammatory processes, low-density lipoprotein cholesterol trafficking, and prothrombotic states. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) program will compare the efficacy of the angiotensin II receptor blocker (ARB) telmisartan, the angiotensin-converting enzyme (ACE) inhibitor ramipril, and combination therapy with telmisartan plus ramipril for reducing cardiovascular risk. The ARB telmisartan is distinguished by its long duration of action, which compares favorably with some other ARBs and conventional antihypertensives. Ramipril was shown in the Heart Outcomes Prevention Evaluation (HOPE) study to reduce the risk for myocardial infarction (MI) and other cardiovascular events in patients at high risk for cardiovascular events but without heart failure or a low ejection fraction. The ONTARGET program consists of 2 randomized, double-blind, multicenter international trials: a principal trial, ONTARGET, and a parallel trial, Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease (TRANSCEND). The treatment arms for the principal ONTARGET study are telmisartan 80 mg, ramipril 10 mg, and combination therapy with telmisartan 80 mg plus ramipril 10 mg; for the parallel study TRANSCEND, the treatment arms are telmisartan 80 mg and placebo. Both trials will assess cardiovascular outcomes in patients at high risk using the same criteria as that of the HOPE study, with a single exception: the TRANSCEND trial will enroll patients who do not tolerate

ACE inhibitor treatment. The primary end points in both ONTARGET and TRANSCEND are death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. The secondary end points include newly diagnosed heart failure, revascularization, new-onset type 2 diabetes mellitus, nephropathy, cognitive decrease and dementia, and newly diagnosed atrial fibrillation; these will be used for hypothesis generation.

L6 ANSWER 47 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2002274881 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12015188
TITLE: Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
AUTHOR: Rippin J; Bain S C; Barnett A H
CORPORATE SOURCE: Department of Medicine, University of Birmingham, Birmingham B9 5SS, UK. (DETAIL study).
SOURCE: Journal of diabetes and its complications, (2002 May-Jun) Vol. 16, No. 3, pp. 195-200.
Journal code: 9204583. ISSN: 1056-8727.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200210
ENTRY DATE: Entered STN: 17 May 2002
Last Updated on STN: 8 Oct 2002
Entered Medline: 4 Oct 2002

AB The DETAIL (diabetics exposed to telmisartan and enalapril) study will compare the long-term renal outcome of treatment with the angiotensin II receptor antagonist (ARA) telmisartan versus the angiotensin-converting enzyme (ACE) inhibitor enalapril in patients with mild-to-moderate hypertension and diabetic nephropathy. In short-term clinical studies, ACE inhibitors reduce microalbuminuria and, in the longer term, they are superior to conventional therapies in maintaining normal renal function. ARAs also appear to be renoprotective in diabetic animals. In this double-blind, parallel-group study, 252 patients with Type 2 diabetes and concurrent hypertension (mean seated systolic blood pressure < or = 180 mm Hg, on treatment seated diastolic blood pressure < or = 95 mm Hg) have been randomised to once-daily telmisartan 40 mg or enalapril 10 mg; doses are mandatorily titrated to 80 and 20 mg once daily, respectively, after 4 weeks. The primary endpoint will be the change from baseline in glomerular filtration rate (GFR) after 5 years of therapy, using the iohexol method and central laboratory analysis. The secondary endpoints to be evaluated will be: changes in GFR in relation to baseline after 1-4 years of therapy; percentage changes in albumin excretion rate after 1-5 years; and incidences of end-stage renal disease, cardiovascular events, all-cause mortality, and adverse events. The planned date for the completion of the study is 2005.

L6 ANSWER 48 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:203196 CAPLUS
DOCUMENT NUMBER: 138:215317
TITLE: Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
INVENTOR(S): Liang, Matthew H.; Manson, Joann E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003049314 | A1 | 20030313 | US 2001-942084 | 20010828 <-- |
| US 6576256 | B2 | 20030610 | | |

PRIORITY APPLN. INFO.: US 2001-942084 20010828

AB Methods and compns. are provided for reducing the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The methods comprise administering a combination of: a cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B6, vitamin B12, and folic acid. Pharmaceutical formulations combining all the active agents in unit-dose form for once-daily dosing are provided. Tablets containing pravastatin 40 mg, ramipril 10 mg, aspirin (in enteric coated granules) 81 mg, Vitamin B6 50 mg, Vitamin B12 1 mg, folic acid 3 mg, calcium carbonate 50 mg, magnesium oxide 25 mg, magnesium carbonate 25 mg, microcryst. cellulose 25 mg, lactose 25 mg, and magnesium stearate 1 mg are used to treat subjects at elevated cardiac risk.

IT 144701-48-4, Telmisartan
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as renin-angiotensin system inhibitor; treatment of patients at elevated cardiovascular risk with combination of cholesterol-lowering agent, inhibitor of renin-angiotensin system, and aspirin)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 49 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:574955 CAPLUS
DOCUMENT NUMBER: 137:129903
TITLE: Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| WO 2002058731 | A2 | 20020801 | WO 2002-US1196 | | 20020125 | <-- |
| WO 2002058731 | A3 | 20031120 | | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM | | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | | |
| CA 2434436 | A1 | 20020801 | CA 2002-2434436 | | 20020125 | <-- |
| CA 2562982 | A1 | 20020801 | CA 2002-2562982 | | 20020125 | <-- |
| CA 2563051 | A1 | 20020801 | CA 2002-2563051 | | 20020125 | <-- |
| US 2003069221 | A1 | 20030410 | US 2002-57339 | | 20020125 | <-- |
| EP 1385548 | A2 | 20040204 | EP 2002-707500 | | 20020125 | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| BR 2002006644 | A | 20040225 | BR 2002-6644 | | 20020125 | |
| HU 200303923 | A2 | 20040301 | HU 2003-3923 | | 20020125 | |
| EP 1413331 | A2 | 20040428 | EP 2004-161 | | 20020125 | |
| EP 1413331 | A3 | 20040630 | | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| JP 2004517919 | T | 20040617 | JP 2002-559065 | | 20020125 | |
| CN 1582168 | A | 20050216 | CN 2002-804219 | | 20020125 | |
| EP 1541175 | A2 | 20050615 | EP 2005-3029 | | 20020125 | |
| EP 1541175 | A3 | 20060412 | | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| EP 1671650 | A1 | 20060621 | EP 2006-5831 | | 20020125 | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| CN 1915429 | A | 20070221 | CN 2006-10126233 | | 20020125 | |
| ZA 2003005692 | A | 20041025 | ZA 2003-5692 | | 20030723 | |
| ZA 2003005694 | A | 20041025 | ZA 2003-5694 | | 20030723 | |
| ZA 2003005693 | A | 20050209 | ZA 2003-5693 | | 20030723 | |
| IN 2003CN01150 | A | 20050422 | IN 2003-CN1150 | | 20030724 | |
| NO 2003003358 | A | 20030912 | NO 2003-3358 | | 20030725 | <-- |
| US 2004097482 | A1 | 20040520 | US 2003-639900 | | 20030813 | |
| US 2005153952 | A1 | 20050714 | US 2004-998400 | | 20041129 | |
| US 2006199793 | A1 | 20060907 | US 2005-158429 | | 20050622 | |
| PRIORITY APPLN. INFO.: | | | US 2001-264275P | P | 20010126 | |
| | | | US 2001-264396P | P | 20010126 | |
| | | | US 2001-264600P | P | 20010126 | |
| | | | US 2001-323842P | P | 20010921 | |
| | | | US 2001-323839P | P | 20010921 | |
| | | | CA 2002-2434682 | A3 | 20020125 | |
| | | | CN 2002-807208 | A3 | 20020125 | |
| | | | EP 2002-705933 | A3 | 20020125 | |
| | | | EP 2002-707500 | A3 | 20020125 | |
| | | | EP 2002-714773 | A3 | 20020125 | |
| | | | US 2002-57323 | A3 | 20020125 | |
| | | | US 2002-57646 | A1 | 20020125 | |
| | | | WO 2002-US1196 | W | 20020125 | |
| | | | US 2002-136968 | A3 | 20020501 | |
| OTHER SOURCE(S): | MARPAT 137:129903 | | | | | |

GI



I

AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.

IT 144701-48-4, Telmisartan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 50 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:127720 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003087935 | A1 | 20030508 | <-- |
| | US 6727271 | B2 | 20040427 | |
| APPLICATION INFO.: | US 2002-81075 | A1 | 20020222 (10) | |

RELATED APPLN. INFO.: Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 5712
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:100164 USPATFULL
TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003069275 | A1 | 20030410 | <-- |
| | US 6919358 | B2 | 20050719 | |
| APPLICATION INFO.: | US 2002-80965 | A1 | 20020222 (10) | |

RELATED APPLN. INFO.: Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 5710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic,

hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:708455 CAPLUS
DOCUMENT NUMBER: 138:378867
TITLE: Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms
AUTHOR(S): Miyata, Toshio; van Ypersele de Strihou, Charles; Ueda, Yasuhiko; Ichimori, Kohji; Inagi, Reiko; Onogi, Hiroshi; Ishikawa, Naoyoshi; Nangaku, Masaomi; Kurokawa, Kiyoshi
CORPORATE SOURCE: Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan
SOURCE: Journal of the American Society of Nephrology ( 2002), 13(10), 2478-2487
CODEN: JASNEU; ISSN: 1046-6673
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The implication of advanced glycation end products (AGE) in the pathogenesis of atherosclerosis and of diabetic and uremic complications has stimulated a search for AGE inhibitors. This study evaluates the AGE inhibitory potential of several well-tolerated hypotensive drugs. Olmesartan, an angiotensin II type 1 receptor (AIIR) antagonist, as well as temocaprilat, an angiotensin-converting enzyme (ACE) inhibitor, unlike nifedipine, a calcium blocker, inhibit in vitro the formation of two AGE, pentosidine and Nε-carboxymethyllysine (CML), during incubation of nonuremic diabetic, nondiabetic uremic, or diabetic uremic plasma or of BSA fortified with arabinose. This effect is shared by all tested AIIR antagonists and ACE inhibitors. On an equimolar basis, they are more efficient than aminoguanidine or pyridoxamine. Unlike the latter two compds., they do not trap reactive carbonyl precursors for AGE, but impact on the production of reactive carbonyl precursors for AGE by chelating transition metals and inhibiting various oxidative steps, including carbon-centered and hydroxyl radicals, at both the pre- and post-Amadori steps. Their effect is paralleled by a lowered production of reactive carbonyl precursors. Finally, they do not bind pyridoxal, unlike aminoguanidine. Altogether, this study demonstrates for the first time that widely used hypotensive agents, AIIR antagonists and ACE inhibitors, significantly attenuate AGE production This study provides a new framework for the assessment of families of AGE-lowering compds. according to their mechanisms of action.

IT 144701-48-4, Telmisartan
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower formation of advanced glycation end products and mechanisms therein)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 53 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:160755 USPATFULL
TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
INVENTOR(S): Cheng, Peter T., Princeton, NJ, United States
Devasthale, Pratik, Plainsboro, NJ, United States
Jeon, Yoon, Belle Mead, NJ, United States
Chen, Sean, Princeton, NJ, United States
Zhang, Hao, Belle Mead, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6414002 | B1 | 20020702 | <-- |
| APPLICATION INFO.: | US 2001-812960 | | 20010320 (9) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-155400P | 19990922 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
ASSISTANT EXAMINER: Sackey, Ebenezer
LEGAL REPRESENTATIVE: Burton Rodney
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5133
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:759924 CAPLUS
DOCUMENT NUMBER: 139:316442
TITLE: New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?
AUTHOR(S): Jennings, G.
CORPORATE SOURCE: Baker Heart Research Institute, Melbourne, Australia
SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F3-F11
CODEN: EHJSFT; ISSN: 1520-765X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The risk for coronary heart disease (CHD) increases with the number of risk factors. Thus, the clin. focus in prevention of CHD should be on patients with multiple risk factors. Both hypertension and a history of myocardial infarction are acknowledged risk factors for heart failure - the most severe form of CHD - but hypertension is more common. Anal. of data from the Framingham Heart Study shows that hypertension is associated with a greater population-attributable risk for heart failure. Angiotensin II, acting via the angiotensin II type 1 receptor, has been implicated in pathol. associated with ischemic heart disease and heart failure. Data on the efficacy of angiotensin-converting enzyme inhibitors in reducing cardiovascular events are comprehensive, with benefits demonstrated for patients with multiple risk factors, target organ damage, acute myocardial infarction and heart failure. Several recent trials have shown that angiotensin II receptor blockers reduce the progression of nephropathy in patients with type 2 diabetes mellitus. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program will provide a large body of data on the efficacy of the angiotensin II receptor Mocker telmisartan in lowering cardiovascular morbidity and mortality in patients with multiple risk factors.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of angiotensin II receptor blockers in cardiovascular risk management)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 55 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:166611 USPATFULL
TITLE: Combinations
INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003114469 | A1 | 20030619 | <-- |
| APPLICATION INFO.: | US 2002-231427 | A1 | 20020828 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-325485P | 20010927 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 2636
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition, comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and

(b) at least one of the active ingredients selected from the group consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:266021 USPATFULL
TITLE: Fibrinogen-lowering agents
INVENTOR(S): Imura, Yoshimi, Toyono-gun, JAPAN
Hirakata, Masao, Kobe-shi, JAPAN

| | NUMBER | KIND | DATE |
|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003187038 | A1 | 20031002 | <-- |
| APPLICATION INFO.: | US 2003-344719 | A1 | 20030214 | (10) |
| | WO 2001-JP7239 | | 20010824 | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 2000-260881 | 20000825 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 1512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We offer a fibrinogen-lowering agent comprising a compound having an angiotensin II antagonistic activity, a prodrug thereof, or a salt thereof. Because of having an excellent effect of lowering fibrinogen, the above fibrinogen-lowering agent is useful as a prophylactic or therapeutic agent for various diseases caused by hyperfibrionogenemia, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(fibrinogen lowering agents containing angiotensin II antagonists)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 57 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:201442 USPATFULL
TITLE: Combinations
INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003139429 | A1 | 20030724 | <-- |
| | US 7019010 | B2 | 20060328 | |
| APPLICATION INFO.: | US 2002-236651 | A1 | 20020906 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-325485P | 20010927 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition, comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and

(b) at least one of the active ingredients selected from the group consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:120858 USPATFULL
TITLE: Combination of organic compounds
INVENTOR(S): Steele, Ronald Edward, Long Valley, NJ, UNITED STATES

| | NUMBER | KIND | DATE | | |
|---|---|---|---|---|---|
| PATENT INFORMATION: | US 2003083342 | A1 | 20030501 | | <-- |
| APPLICATION INFO.: | US 2002-149107 | A1 | 20020827 | (10) | |
| | WO 2001-EP4116 | | 20010410 | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereofeither alone or in combination with (ii) an AT.sub.1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically

acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 59 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2001:173610 USPATFULL | | | |
| TITLE: | Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist | | | |
| INVENTOR(S): | Segal, Robert, Gwynedd Valley, PA, United States<br>Robinson, Paul J., Hertfordshire, United Kingdom<br>Deckelbaum, Lawrence I., Gladwyne, PA, United States | | | |
| PATENT ASSIGNEE(S): | Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 6300356 | B1 | 20011009 | <-- |
| | WO 9943210 | | 19990902 | <-- |
| APPLICATION INFO.: | US 2000-601938 | | 20000810 | (9) |
| | WO 1999-US3828 | | 19990222 | |
| | | | 20000810 | PCT 371 date |
| | | | 20000810 | PCT 102(e) date |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | GB 1998-8937 | | 19980427 | |
| | US 1998-75915P | | 19980225 | (60) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | GRANTED | | | |
| PRIMARY EXAMINER: | Krass, Frederick | | | |
| LEGAL REPRESENTATIVE: | Camara, Valerie J., Daniel, Mark R. | | | |
| NUMBER OF CLAIMS: | 17 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 7 Drawing Figure(s); 6 Drawing Page(s) | | | |
| LINE COUNT: | 1520 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in die risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II receptor antagonists for decreasing QT dispersion or inhibiting progression of QT prolongation in humans)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 60 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2002104848 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11835907
TITLE: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
AUTHOR: Yusuf Salim
CORPORATE SOURCE: Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.. yusufs@mcmaster.ca
SOURCE: The American journal of cardiology, (2002 Jan 24) Vol. 89, No. 2A, pp. 18A-25A; discussion 25A-26A. Journal code: 0207277. ISSN: 0002-9149.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (META-ANALYSIS)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200202
ENTRY DATE: Entered STN: 12 Feb 2002
Last Updated on STN: 23 Feb 2002
Entered Medline: 22 Feb 2002

AB The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of cardiovascular death, myocardial infarction (MI), and death in patients at risk for cardiovascular events but without heart failure. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that ramipril also reduced atherosclerosis. These results

suggest that the renin-angiotensin system (RAS) has a more important role in the development and progression of atherosclerosis than previously believed, and they indicate the need for further clinical studies to define the range of benefits available from modifying the RAS. Achieving maximum benefit may require treatment with both an ACE inhibitor and an angiotensin II type-1 receptor blocker (ARB). The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) study indicated that combining an ACE inhibitor with an ARB decreased blood pressure and improved the ejection fraction more than treatment with either drug alone in patients with congestive heart failure. The Valsartan in Heart Failure Trial (Val-HeFT) showed that the combination of an ACE inhibitor and an ARB reduced hospitalization for heart failure in patients with congestive heart failure by 27.5%, although no decrease in all-cause mortality was observed. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is a large, long-term study (23,400 patients, 5.5 years). It will compare the benefits of ACE inhibitor treatment, ARB treatment, and treatment with an ACE inhibitor and ARB together, in a study population with established coronary artery disease, stroke, peripheral vascular disease, or diabetes with end-organ damage. Patients with congestive heart failure will be excluded. In a parallel study, patients unable to tolerate an ACE inhibitor will be randomized to receive telmisartan or placebo (the Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease [TRANSCEND]). The primary endpoint for both trials is a composite of cardiovascular death, MI, stroke, and hospitalization for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. These 2 trials are expected to provide new insights into the optimal treatment of patients at high risk of complications from atherosclerosis.

L6 ANSWER 61 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:709669 CAPLUS
DOCUMENT NUMBER: 140:1129
TITLE: Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation
AUTHOR(S): Yamagishi, S.; Amano, S.; Inagaki, Y.; Okamoto, T.; Inoue, H.; Takeuchi, M.; Choei, H.; Sasaki, N.; Kikuchi, S.
CORPORATE SOURCE: Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan
SOURCE: Drugs under Experimental and Clinical Research ( 2003), 29(2), 75-80
CODEN: DECRDP; ISSN: 0378-6501
PUBLISHER: Bioscience Ediprint Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The renin-angiotensin system has been implicated in the development and progression of atherosclerosis, thereby contributing to adverse cardiovascular events. However, its role in diabetic retinopathy remains to be elucidated. Since pericyte loss and dysfunction have been considered as one of the characteristic changes of the early phase of diabetic retinopathy, we investigated the effects of angiotensin II (Ang II) on the growth and function of bovine cultured retinal pericytes. Ang II stimulated intracellular reactive oxygen species (ROS) generation in pericytes in a dose-dependent manner. Telmisartan, a newly developed Ang II type 1 receptor antagonist, completely inhibited ROS generation in pericytes induced by Ang II. Ang II decreased DNA synthesis in pericytes, which was significantly prevented by an antioxidant N-acetylcysteine. Furthermore, telmisartan or N-acetylcysteine were found to completely inhibit the Ang II-induced upregulation of

vascular endothelial growth factor mRNA levels in pericytes. The present results suggest that Ang II-type 1 receptor interaction could induce pericyte loss and dysfunction through intracellular ROS generation, thus being involved in the development and progression of diabetic retinopathy.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 62 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2005:33212 USPATFULL

TITLE: Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof

INVENTOR(S): Ojima, Mami, Amagasaki, JAPAN
Kitayoshi, Takahito, Suita, JAPAN
Miyamoto, Masaomi, Takarazuka, JAPAN

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN (non-U.S. corporation)

| | NUMBER | KIND | DATE | | |
|---|---|---|---|---|---|
| PATENT INFORMATION: | US 6852743 | B1 | 20050208 | | |
| | WO 2001005428 | | 20010125 | | <-- |
| APPLICATION INFO.: | US 2002-31398 | | 20020118 | (10) | |
| | WO 2000-JP4830 | | 20000719 | | |
| | | | 20020118 | PCT 371 date | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1999-205877 | 19990721 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(preventives for recurrence of cerebrovascular failure containing benzimidazoles as angiotensin II antagonists)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 63 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:289188 USPATFULL
TITLE: Activator of PPAR delta
INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, UNITED STATES
Haffner, Curt Dale, Durham, NC, UNITED STATES
Lambert, Millard Hurst, III, Durham, NC, UNITED STATES
Maloney, Patrick Reed, Durham, NC, UNITED STATES
Sierra, Michael Lawrence, Les Ulis, FRANCE
Sternbach, Daniel David, Durham, NC, UNITED STATES
Sznaidman, Marcos Luis, Durham, NC, UNITED STATES
Willson, Timothy Mark, Durham, NC, UNITED STATES
Xu, Huaqiang Eric, Durham, NC, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003203947 | A1 | 20031030 | <-- |
| | US 6723740 | B2 | 20040420 | |
| APPLICATION INFO.: | US 2003-383011 | A1 | 20030306 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-18935, filed on 19 Dec 2001, PENDING A 371 of International Ser. No. WO 2000-EP5720, filed on 22 Jun 2000, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 1999-14977 | 19990625 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:127094 USPATFULL
TITLE: Methods for identifying novel multimeric agents that modulate receptors
INVENTOR(S): Christensen, Burton G., Alamo, CA, UNITED STATES

Griffin, John H., Atherton, CA, UNITED STATES
Jenkins, Thomas E., La Honda, CA, UNITED STATES
Judice, J. Kevin, El Granada, CA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003087306 | A1 | 20030508 | <-- |
| APPLICATION INFO.: | US 2001-15534 | A1 | 20011213 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-493462, filed on 28 Jan 2000, ABANDONED Continuation of Ser. No. US 1999-327904, filed on 8 Jun 1999, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1998-92938P | 19980715 (60) |
| | US 1998-88466P | 19980608 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Page(s)
LINE COUNT: 8387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same of different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2004:72635 USPATFULL
TITLE: Activators of PPAR delta
INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, United States
Haffner, Curt Dale, Durham, NC, United States
Lambert, III, Millard Hurst, Durham, NC, United States
Maloney, Patrick Reed, Durham, NC, United States
Sierra, Michael Lawrence, Les Ulis, FRANCE
Sternbach, Daniel David, Durham, NC, United States
Sznaidman, Marcos Luis, Durham, NC, United States
Willson, Timothy Mark, Durham, NC, United States
Xu, Huaqiang Eric, Durham, NC, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6710063 | B1 | 20040323 | |
| | WO 2001000603 | | 20010104 | <-- |
| APPLICATION INFO.: | US 2001-18935 | | 20011219 (10) | |
| | WO 2000-EP5720 | | 20000622 | |

| | NUMBER | DATE |
|---|---|---|

PRIORITY INFORMATION: GB 1999-14977 19990625
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Shameem, Golam M. M.
LEGAL REPRESENTATIVE: Brink, Robert H.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:306948 USPATFULL
TITLE: Composition and method for treating hypertension
INVENTOR(S): Stokes, Gordon, St Leonards, AUSTRALIA
PATENT ASSIGNEE(S): Northern Sydney Area Health Service (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003216384 | A1 | 20031120 | <-- |
| APPLICATION INFO.: | US 2002-255447 | A1 | 20020925 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | AU 2002-2369 | 20020516 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for the treatment and/or prevention of hypertension, said composition comprising an synergistic anti-hypertensive combination of a therapeutically effective amount of at least one angiotensin II inhibitor, and a therapeutically effective amount of at least one nitric oxide donor; said composition optionally further comprising a pharmaceutically acceptable carrier, diluent and/or adjuvant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II inhibitor-nitric oxide donor synergistic combination for treating hypertension)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 67 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2003:312692 USPATFULL | | | |
| TITLE: | Phosphorus-containing compounds and uses thereof | | | |
| INVENTOR(S): | Berstein, David L., Waban, MA, UNITED STATES<br>Metcalf, Chester A., III, Needham, MA, UNITED STATES<br>Rozamus, Leonard W., Bedford, MA, UNITED STATES<br>Wang, Yihan, Newton, MA, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2003220297 | A1 | 20031127 | <-- |
| APPLICATION INFO.: | US 2003-357152 | A1 | 20030203 | (10) |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | US 2002-353252P | | 20020201 | (60) |
| | US 2002-426928P | | 20021115 | (60) |
| | US 2002-428383P | | 20021122 | (60) |
| | US 2002-433930P | | 20021217 | (60) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | David L. Berstein, ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234 | | | |
| NUMBER OF CLAIMS: | 39 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 3696 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns a new family of phosphorus-containing compounds containing a moiety JQA--in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a chemical bond linking a R.sup.5 moiety to P;

and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:199127 USPATFULL
TITLE: Methods of treating sexual dysfunction associated with hypertension
INVENTOR(S): Sahota, Pritam Singh, New Providence, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002107236 | A1 | 20020808 | <-- |
| APPLICATION INFO.: | US 2001-8445 | A1 | 20011203 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-250540P | 20001201 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of treating SD associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 69 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:759933 CAPLUS
DOCUMENT NUMBER: 139:301175
TITLE: PROGRESS beyond HOPE and LIFE: the ONTARGET trial

programme
AUTHOR(S): Sleight, P.
CORPORATE SOURCE: John Radcliffe Hospital, Oxford, UK
SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F40-F47
CODEN: EHJSFT; ISSN: 1520-765X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Large-scale cardiovascular trials traditionally have targeted clin. hypertension, diabetes or survivors of myocardial infarction, but the recent trend in such trials has been to consider the treatment of high-risk individuals rather than specific diseases. This allows the use of a much broader screening process to enroll patients. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) act directly on the renin-angiotensin system to effect blood pressure control. The Heart Outcomes Prevention Evaluation (HOPE) and the Perindopril pROtection against REcurrent Stroke Study (PROGRESS) showed that angiotensin-converting enzyme inhibitors (ramipril and perindopril plus the diuretic indapamide), significantly decreased the risk for stroke and other adverse cardiovascular outcomes. Both studies showed benefits in patients with conventionally normal blood pressure. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial showed that losartan, an ARB, could also significantly decrease the risk of stroke to an extent greater than that predicted by the decrease in blood pressure. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program is currently underway to study the effect of ramipril and the ARB telmisartan, and a combination of the two agents in patients at high risk of cardiovascular disease.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 70 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:99270 USPATFULL
TITLE: Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
INVENTOR(S): Kamei, Shigeru, Takarazuka-shi, JAPAN
Ojima, Mami, Amagasaki-shi, JAPAN
Kitayoshi, Takahito, Suita-shi, JAPAN
Igari, Yasutaka, Kobe-shi, JAPAN

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003068374 | A1 | 20030410 | <-- |
| APPLICATION INFO.: | US 2002-204185 | A1 | 20020819 | (10) |
| | WO 2001-JP1191 | | 20010220 | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 2000-48980 | 20000221 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 2121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release preparation containing a physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer which are improved in the release-control and

stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(sustained-release compns. containing physiol. active compds. hardly-soluble in water, polyvalent metal compds., and biodegradable polymers)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 71 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:266305 USPATFULL
TITLE: Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES
Ress, Rudyard J., Flemington, NJ, UNITED STATES
Strony, John T., Lebanon, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002147184 | A1 | 20021010 | <-- |
| APPLICATION INFO.: | US 2002-56680 | A1 | 20020125 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-324123P | 20010921 (60) |
| | US 2001-264396P | 20010126 (60) |
| | US 2001-264600P | 20010126 (60) |
| | US 2001-264275P | 20010126 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 3296
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and

(b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2006:154381 USPATFULL | | | |
| TITLE: | Method for preventing, treating or inhibiting development of simple retinopathy and preproliferative retinopathy | | | |
| INVENTOR(S): | Nakagawa, Shizue, Osaka, JAPAN<br>Nagisa, Yasutaka, Higashiosaka, JAPAN<br>Ikeda, Hitoshi, Higashiosaka, JAPAN | | | |
| PATENT ASSIGNEE(S): | Takeda Pharmaceutical Company Limited, Osaka, JAPAN (non-U.S. corporation) | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 7064141 | B1 | 20060620 | |
| | WO 2000066161 | | 20001109 | <-- |
| APPLICATION INFO.: | US 2000-958740 | | 20000427 | (9) |
| | WO 2000-JP2766 | | 20000427 | |
| | | | 20011016 | PCT 371 date |
| | NUMBER | | DATE | |
| PRIORITY INFORMATION: | JP 1999-121498 | | 19990428 | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | GRANTED | | | |
| PRIMARY EXAMINER: | Fay, Zohreh | | | |
| LEGAL REPRESENTATIVE: | Wenderoth, Lind & Ponack, L.L.P. | | | |
| NUMBER OF CLAIMS: | 2 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 1057 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(angiotensin II antagonists for treatment of retinopathy)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 73 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173948 USPATFULL
TITLE: Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
INVENTOR(S): Strony, John T., Lebanon, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119796 | A1 | 20030626 | <-- |
| | US 7056906 | B2 | 20060606 | |
| APPLICATION INFO.: | US 2002-247085 | A1 | 20020919 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-324118P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 2932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one hormone replacement therapy composition; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5α-stanols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:99262 USPATFULL
TITLE: Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
INVENTOR(S): Chungi, Shubha, Sharon, MA, UNITED STATES
Iorio, Theodore L., Millis, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003068366 | A1 | 20030410 | <-- |
| | US 6669955 | B2 | 20031230 | |
| APPLICATION INFO.: | US 2001-941948 | A1 | 20010828 (9) | |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 1701
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B.sub.6, B.sub.12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulation is provided as a simple and convenient therapy to reduce the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The formulation is also therapeutic for individuals during or immediately following an occurrence of acute myocardial infarction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:330256 USPATFULL
TITLE: Use of inhibitors of the renin-angiotensin system
INVENTOR(S): Montgomery, Hugh Edward, London, UNITED KINGDOM
Martin, John Francis, London, UNITED KINGDOM
Erusalimsky, Jorge Daniel, London, UNITED KINGDOM

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002187939 | A1 | 20021212 | <-- |
| | US 7071183 | B2 | 20060704 | |
| APPLICATION INFO.: | US 2002-206659 | A1 | 20020726 (10) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-529628, filed on 15 Jun 2000, PENDING A 371 of International Ser. No. WO 1998-GB3122, filed on 19 Oct 1998, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 1997-22026 | 19971017 |
| | GB 1998-10855 | 19980520 |
| | US 1997-67819P | 19971205 (60) |
| | US 1998-94902P | 19980731 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with

hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(renin-angiotensin system inhibitors for treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency or for enhancing metabolic function)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 76 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:120855 USPATFULL
TITLE: Compositions and methods for treating colorectal polyps and cancer
INVENTOR(S): Tamura, Masaaki, Nashville, TN, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003083339 | A1 | 20030501 | <-- |
| APPLICATION INFO.: | US 2002-133056 | A1 | 20020426 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-286621P | 20010426 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 4380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of decreasing a biological function of an AT.sub.2 receptor in a subject in need thereof is disclosed. The method includes administering an effective amount of a therapeutic agent to the subject to decrease a biological function of an AT.sub.2 receptor. Cancer

therapy, particularly colorectal cancer therapy, by the method is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(compns. and methods for treating colorectal polyps and cancer)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 77 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:113776 USPATFULL
TITLE: In vivo delivery methods and compositions
INVENTOR(S): Kensey, Kenneth, Malvern, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003078517 | A1 | 20030424 | <-- |
| APPLICATION INFO.: | US 2001-839785 | A1 | 20010420 (9) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood

viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(in vivo delivery methods and compns.)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 78 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:79112 USPATFULL
TITLE: Tnf-alpha inhibitors
INVENTOR(S): Ikeya, Kazuaki, Ikoma-gun, JAPAN
Kitayoshi, Takahito, Suita-shi, JAPAN

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003055039 | A1 | 20030320 | <-- |
| | US 6833381 | B2 | 20041221 | |
| APPLICATION INFO.: | US 2002-203805 | A1 | 20020814 | (10) |
| | WO 2001-JP1069 | | 20010215 | |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB TNF-α inhibitors containing a heterocyclic compound having angiotensin II antagonistic activity which are useful as preventives/remedies for inflammatory diseases, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan
(TNF-α inhibitors containing heterocyclic compds. having angiotensin II antagonisms)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 79 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2002:119847 USPATFULL | | | |
| TITLE: | In vivo delivery methods and compositions | | | |
| INVENTOR(S): | Kensey, Kenneth R., Malvern, PA, UNITED STATES | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2002061835 | A1 | 20020523 | <-- |
| APPLICATION INFO.: | US 2001-828761 | A1 | 20010409 (9) | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PATENTED Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PATENTED Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, PATENTED | | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212 | | | |
| NUMBER OF CLAIMS: | 36 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 19 Drawing Page(s) | | | |
| LINE COUNT: | 2173 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in

combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(methods for in vivo drug delivery based on monitoring blood flow parameters)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 80 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:54986 USPATFULL
TITLE: In vivo delivery methods and compositions
INVENTOR(S): Kensey, Kenneth, Malvern, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002032149 | A1 | 20020314 | <-- |
| APPLICATION INFO.: | US 2001-841389 | A1 | 20010424 (9) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 81 OF 113 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2001:212586 USPATFULL | | | |
| TITLE: | In vivo delivery methods and compositions | | | |
| INVENTOR(S): | Kensey, Kenneth R., Malvern, PA, United States | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2001044584 | A1 | 20011122 | <-- |
| APPLICATION INFO.: | US 2001-819924 | A1 | 20010328 (9) | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735 | | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, | | | |

PHILADELPHIA, PA, 19103-2212
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 82 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:328709 CAPLUS
DOCUMENT NUMBER: 137:345373
TITLE: Angiotensin II receptor antagonists role in arterial hypertension
AUTHOR(S): Hernandez-Hernandez, R.; Sosa-Canache, B.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.; Cammarata, R.
CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.
SOURCE: Journal of Human Hypertension (2002), 16(Suppl. 1), S93-S99
CODEN: JHHYEN; ISSN: 0950-9240

PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT1 receptor blockers antagonize all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the AT1 receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT1 receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being with low incidence of side effects even at long term use. Monotherapy in mild-to-moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of thiazide diuretic is added, 60-70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium antagonists and beta-blocking agents. AT1 receptor blockers are specially indicated in patients with hypertension who are being treated with ACE inhibitors and developed side effects such as, cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted and seem promising.
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 83 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:390956 CAPLUS
DOCUMENT NUMBER: 133:187
TITLE: Angiotensin II receptor antagonists in arterial hypertension
AUTHOR(S): Hernandez-Hernandez, R.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.
CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.
SOURCE: Journal of Human Hypertension (2000), 14(Suppl. 1), S69-S72
CODEN: JHHYEN; ISSN: 0950-9240
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 34 refs. Angiotensin II receptor antagonists (AT-1) represent a new group of orally active antihypertensive agents. Activation on AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone with production of thirst, and promote growth of vascular and cardiac muscle; these effects are blocked by AT-1 antagonist agents. The first chemical useful, orally active AT-1 receptor antagonist was losartan, followed by other agents currently in clin. use, such as: valsartan, eprosartan, irbesartan, telmisartan, candesartan, and many others under investigation. AT-1 receptor antagonists are effective in reducing high blood pressure in hypertensive patients. Monotherapy in mild to moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of a thiazide diuretic is added, 60 to 70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme inhibitors,

diuretics, calcium antagonists and beta-blocking agents. Tolerability has been reported to be very good. AT-1 receptor antagonists would be a drug of choice in otherwise well-controlled hypertensive patients treated with angiotensin-converting enzyme inhibitors who developed cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 84 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:232558 USPATFULL
TITLE: Aldosterone blocker therapy to prevent or treat inflammation-related disorders
INVENTOR(S): Rocha, Ricardo, Gurnee, IL, UNITED STATES
Zack, Marc, Evanston, IL, UNITED STATES
McMahon, Ellen, Sunset Hills, MO, UNITED STATES
Blasi, Eileen R., St. Louis, MO, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003162759 | A1 | 20030828 | <-- |
| APPLICATION INFO.: | US 2001-916136 | A1 | 20010726 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-221358P | 20000727 (60) |
| | US 2001-261352P | 20010112 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 55 Drawing Page(s)
LINE COUNT: 5061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aldosterone blockers used for the treatment and prevention of inflammation are disclosed

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 85 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173961 USPATFULL
TITLE: Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119809 | A1 | 20030626 | <-- |
| | US 7132415 | B2 | 20061107 | |
| APPLICATION INFO.: | US 2002-247095 | A1 | 20020919 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-323942P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,

07033-0530
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides therapeutic combinations and methods including at least one sterol or 5α-stanol absorption inhibitor that can be useful for treating xanthomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:322441 USPATFULL
TITLE: Haplotypes of the AGTR1 gene
INVENTOR(S): Anastasio, Alison E., New Haven, CT, UNITED STATES
Finkel, Kevin, Cheshire, CT, UNITED STATES
Koshy, Beena, North Haven, CT, UNITED STATES
Lee, Helen, Shelton, CT, UNITED STATES
PATENT ASSIGNEE(S): Genaissance Pharmaceuticals, Inc. (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002182605 | A1 | 20021205 | <-- |
| | US 6521747 | B2 | 20030218 | |
| APPLICATION INFO.: | US 2001-867915 | A1 | 20010530 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-228542P | 20000828 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENAISSANCE PHARMACEUTICALS, 5 SCIENCE PARK, NEW HAVEN, CT, 06511
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel genetic variants of the Angiotensin Receptor 1 (AGTR1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the AGTR1 gene. Compositions and methods for haplotyping and/or genotyping the AGTR1 gene in an individual are also disclosed. Polynucleotides defined by the sequence of the haplotypes disclosed herein are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 87 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119917 USPATFULL
TITLE: Ethers of 7-desmethylrapamycin
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES
Enever, Robin, New City, NY, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061905 | A1 | 20020523 | <-- |
| | US 6440991 | B2 | 20020827 | |
| APPLICATION INFO.: | US 2001-956322 | A1 | 20010919 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-237469P | 20001002 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides ethers of 7-desmethylrapamycin which are useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 88 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119916 USPATFULL
TITLE: Hydroxyesters of 7-desmethylrapamycin
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES
Enever, Robin, New City, NY, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061904 | A1 | 20020523 | <-- |
| | US 6399626 | B2 | 20020604 | |
| APPLICATION INFO.: | US 2001-955685 | A1 | 20010919 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-237470P | 20001002 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 640
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides hydroxyesters of 7-desmethylrapamycin which are useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 89 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:119915 USPATFULL
TITLE: 1-oxorapamycins
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002061903 | A1 | 20020523 | <-- |
| | US 6399625 | B2 | 20020604 | |
| APPLICATION INFO.: | US 2001-954880 | A1 | 20010918 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-235750P | 20000927 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 854
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides 1-oxorapamycins, which are useful in inducing immunosuppression, as a neurotrophic agent, and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 90 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:78778 USPATFULL
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND
Oddou, Pascale, Basel, SWITZERLAND
Neuhart, Eric Michel, Mulhouse, FRANCE

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002042436 | A1 | 20020411 | <-- |
| | US 6544968 | B2 | 20030408 | |
| APPLICATION INFO.: | US 2001-915048 | A1 | 20010725 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | EP 1999-810061 | 19990126 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II receptor antagonists for treating acute myocardial infarction)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 91 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:17328 USPATFULL
TITLE: Dha-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES
Swindell, Charles, Merion, PA, UNITED STATES
Webb, Nigel, Bryn Mawr, PA, UNITED STATES
Bradley, Matthews, Layton, PA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002010208 | A1 | 20020124 | <-- |
| | US 6602902 | B2 | 20030805 | |
| APPLICATION INFO.: | US 2001-846838 | A1 | 20010501 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 92 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:123317 USPATFULL
TITLE: Rapidly disintegrable solid preparation
INVENTOR(S): Shimizu, Toshihiro, Hyogo, Japan
Sugaya, Masae, Osaka, Japan
Nakano, Yoshinori, Hyogo, Japan

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2001010825 | A1 | 20010802 | <-- |
| | US 7070805 | B2 | 20060704 | |

APPLICATION INFO.: US 2001-800839 A1 20010307 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-403429, filed on 20 Oct 1999, PENDING A 371 of International Ser. No. WO 1999-JP4015, filed on 27 Jul 1999, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1998-213049 | 19980728 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 93 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2001002404 | A1 | 20010531 | <-- |
| | US 6576636 | B2 | 20030610 | |
| APPLICATION INFO.: | US 2000-730450 | A1 | 20001205 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 94 OF 113 MEDLINE on STN
ACCESSION NUMBER: 2004085581 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14974331
TITLE: [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?]. Gefasspatient mit hohem Infarktrisiko. Schutzt der AT1-Blocker so gut wie ein ACE-Hemmer?.

AUTHOR: Anonymous
SOURCE: MMW Fortschritte der Medizin, (2003 Dec 18) Vol. 145, No. 51-52, pp. 39.
Journal code: 100893959. ISSN: 1438-3276.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200404
ENTRY DATE: Entered STN: 21 Feb 2004
Last Updated on STN: 28 Apr 2004
Entered Medline: 27 Apr 2004

L6 ANSWER 95 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:334719 USPATFULL
TITLE: Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003235595 | A1 | 20031225 | <-- |
| APPLICATION INFO.: | US 2003-397969 | A1 | 20030325 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, GRANTED, Pat. No. US 6458383 Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 110
EXEMPLARY CLAIM: 1
LINE COUNT: 3903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to oral pharmaceutical compositions and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. Compositions of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the composition forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the compositions provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 96 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:307001 USPATFULL
TITLE: Thrombin receptor antagonists
INVENTOR(S): Chackalamannil, Samuel, Califon, NJ, UNITED STATES
Clasby, Martin C., Plainsboro, NJ, UNITED STATES
Greenlee, William J., Teaneck, NJ, UNITED STATES
Wang, Yuguang, North Brunswick, NJ, UNITED STATES
Xia, Yan, Edison, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
Chelliah, Mariappan V., Edison, NJ, UNITED STATES

PATENT ASSIGNEE(S): SCHERING CORPORATION (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003216437 | A1 | 20031120 | <-- |
| APPLICATION INFO.: | US 2003-412982 | A1 | 20030414 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2002-373072P | 20020416 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heterocyclic-substituted tricyclics of the formula ##STR1##

or a pharmaceutically acceptable salt thereof, wherein:

the dotted line represents an optional single bond;

represents an optional double bond;

n is 0-2;

Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14;

R.sup.13 and R.sup.14 are independently selected from (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, --OH, (C.sub.1-C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or

R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms;

Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and

B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 97 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:277178 USPATFULL
TITLE: PDE9 inhibitors for treating cardiovascular disorders
INVENTOR(S): DeNinno, Michael Paul, Gales Ferry, CT, UNITED STATES
Hughes, Bernadette, Sandwich, UNITED KINGDOM
Kemp, Mark Ian, Sandwich, UNITED KINGDOM
Palmer, Michael John, Sandwich, UNITED KINGDOM
Wood, Anthony, Sandwich, UNITED KINGDOM
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|

PATENT INFORMATION: US 2003195205 A1 20031016 <--
APPLICATION INFO.: US 2002-283514 A1 20021030 (10)

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GB 2001-26395 | 20011102 |
| | GB 2001-30695 | 20011221 |
| | GB 2002-16761 | 20020718 |
| | US 2002-350777P | 20020122 (60) |
| | US 2002-399905P | 20020730 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 1888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R.sup.1 is H or C.sub.1-6 alkyl, wherein R.sup.1 is attached to either N.sup.1 or N.sup.2; R.sup.2 is C.sub.1-6 alkyl optionally substituted by hydroxy or alkoxy; C.sub.3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar.sup.1; R.sup.3 is C.sub.1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar.sup.2; C.sub.3-7cycloalkyl optionally substituted by C.sub.1-6alkyl; OAr.sup.2; SAr.sup.2; NHC(O)C.sub.1-6 alkyl; het.sup.2; xanthene; and naphthalene. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 98 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:238541 USPATFULL
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND
Oddou, Pascale, Basel, SWITZERLAND
Neuhart, Eric Michel, Mulhouse, FRANCE

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 2003166699 | A1 | 20030904 <-- |
| | US 6767905 | B2 | 20040727 |
| APPLICATION INFO.: | US 2003-376049 | A1 | 20030227 (10) |

RELATED APPLN. INFO.: Division of Ser. No. US 2001-915048, filed on 25 Jul 2001, GRANTED, Pat. No. US 6544968 Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | EP 1999-810061 | 19990126 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the

secondary prevention of acute MI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144701-48-4, Telmisartan
(angiotensin II receptor antagonists for treating acute myocardial infarction)
RN 144701-48-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)




L6 ANSWER 99 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:214427 USPATFULL
TITLE: Method of treating cardiovascular disease
INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES
Sehgal, Surendra N., Snohomish, WA, UNITED STATES
Adelman, Steven J., Doylestown, PA, UNITED STATES
PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003149070 | A1 | 20030807 | <-- |
| | US 6670355 | B2 | 20031230 | |
| APPLICATION INFO.: | US 2002-313217 | A1 | 20021206 (10) | |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-880295, filed on 13 Jun 2001, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-212117P | 20000616 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 100 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173960 USPATFULL
TITLE: Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
INVENTOR(S): LeBeaut, Alexandre P., Morristown, NJ, UNITED STATES
Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119808 | A1 | 20030626 | <-- |
| APPLICATION INFO.: | US 2002-246996 | A1 | 20020919 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-324121P | 20010921 (60) |
| | US 2002-351957P | 20020125 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 3092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects associated with certain HMG-CoA reductase inhibitors by coadministration of at least one sterol or 5α-stanol absorption inhibitor, pharmaceutically acceptable salts or solvates thereof, and at least one HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 101 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:173582 USPATFULL
TITLE: Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
Ress, Rudyard J., Flemington, NJ, UNITED STATES
Strony, John T., Lebanon, NJ, UNITED STATES
Veltri, Enrico P., Princeton, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003119428 | A1 | 20030626 | <-- |
| | US 7053080 | B2 | 20060530 | |
| APPLICATION INFO.: | US 2002-247397 | A1 | 20020919 | (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING | | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-323840P | 20010921 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 3027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for the treatment of obesity using sterol or 5α-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5α-stanol absorption inhibitors and at least one obesity control medication.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 102 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:110457 USPATFULL
TITLE: Method and apparatus for dispensing inhalator medicament
INVENTOR(S): Johnson, Keith A., Durham, NC, UNITED STATES
Casper, Robert A., Sanford, NC, UNITED STATES
Gardner, David L., Chapel Hill, NC, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003075172 | A1 | 20030424 | <-- |
| APPLICATION INFO.: | US 2002-267013 | A1 | 20021008 | (10) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-344544P | 20011019 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISS, BATEMAN, O'BRYANT & COMPAGNI, 136 SOUTH MAIN STREET, SUITE 700, SALT LAKE CITY, UT, 84101
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 846
AB An apparatus and method for delivering a plurality of medication includes providing first and second medicament on a medicament pack in separate containers for preventing either medicament from interfering with the stability of the other. In accordance with the method, the medicaments are preferably delivered in a single inhalation.

L6 ANSWER 103 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:37867 USPATFULL
TITLE: Methods for effecting neuroprotection
INVENTOR(S): Ferguson, Alastair V., Kingston, CANADA
Bains, Jaideep S., Calgary, CANADA

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002022587 | A1 | 20020221 | <-- |
| APPLICATION INFO.: | US 2001-817229 | A1 | 20010327 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-192585P | 20000328 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for preventing damage to excitable cells following ischemic by administering to a patient who is undergoing or who has undergone an ischemic event an effective amount of a compound which increases a transient potassium (K.sup.+) conductance in the excitable cells of the patient. The present invention also provides a method for screening for compounds which increase a transient K.sup.+ current in the excitable cells of a patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 104 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:173168 USPATFULL
TITLE: Solid pharmaceutical preparation
INVENTOR(S): Shimizu, Toshihiro, Itami, Japan
Sugaya, Masae, Ikeda, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6299904 | B1 | 20011009 | <-- |
| | WO 9853798 | | 19981203 | <-- |
| APPLICATION INFO.: | US 1999-424434 | | 19991123 | (9) |
| | WO 1998-JP2298 | | 19980526 | |
| | | | 19991123 | PCT 371 date |
| | | | 19991123 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-136724 | 19970527 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Fubara, Blessing
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohols selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 105 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:119057 USPATFULL
TITLE: Solid preparation
INVENTOR(S): Toshihiro, Shimizu, Osaka, Japan
Masae, Sugaya, Osaka, Japan

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2001009678 | A1 | 20010726 | <-- |
| | US 6586004 | B2 | 20030701 | |
| APPLICATION INFO.: | US 2001-800748 | A1 | 20010307 | (9) |

RELATED APPLN. INFO.: Division of Ser. No. US 1999-424434, filed on 23 Nov 1999, PENDING A 371 of International Ser. No. WO 1998-JP2298, filed on 26 May 1998, UNKNOWN

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-136724 | 19970527 |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohol selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 106 OF 113 USPATFULL on STN
ACCESSION NUMBER: 1998:98932 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 5795909 | | 19980818 | <-- |
| APPLICATION INFO.: | US 1996-651312 | | 19960522 | (8) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 107 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:214415 USPATFULL
TITLE: Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
INVENTOR(S): Eisert, Wolfgang, Hannover, GERMANY, FEDERAL REPUBLIC OF

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003149058 | A1 | 20030807 | <-- |
| APPLICATION INFO.: | US 2003-376072 | A1 | 20030227 | (10) |

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-694610, filed on 23 Oct 2000, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | DE 1999-991211210 | 19991022 |
| | US 1999-167797P | 19991129 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment of the human or non-human animal body for treating fibrin-dependent microcirculation disorders is disclosed, for example, microcirculation disorders caused by metabolic diseases, inflammatory reactions or autoimmune diseases; peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation comprising administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a pyrimido-pyrimidine selected from dipyridamole, mopidamol and the pharmaceutically acceptable salts thereof, and the use of said pyrimido-pyrimidine for the manufacture of a corresponding pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 108 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2003:85867 USPATFULL
TITLE: Oral delivery formulation
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES
Solari, Nancy E., West Newton, MA, UNITED STATES
Flangan, Margaret A., Stow, MA, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2003059471 | A1 | 20030327 | <-- |
| APPLICATION INFO.: | US 2001-997277 | A1 | 20011129 (9) | |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1997-69501P | 19971215 (60) |
| | US 1998-73867P | 19980204 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 2950
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Flakes containing drugs and methods for forming and using such flakes are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 109 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:323094 USPATFULL
TITLE: Dipeptide derivatives
INVENTOR(S): Fink, Cynthia Anne, Lebanon, NJ, UNITED STATES

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002183260 | A1 | 20021205 | <-- |
| | US 6777443 | B2 | 20040817 | |
| APPLICATION INFO.: | US 2002-142693 | A1 | 20020509 (10) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-291088P | 20010515 (60) |
| | US 2001-339575P | 20011211 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula ##STR1##

wherein R, R.sub.1, COOR.sub.2, R.sub.3-R.sub.7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 110 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:32538 USPATFULL
TITLE: Treatment for cardiovascular disease
INVENTOR(S): Kivlighn, Saluh, Doylestown, PA, UNITED STATES
Johnson, Richard, Bellaire, TX, UNITED STATES
Mazzali, Marilda, Houston, TX, UNITED STATES
PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002019360 | A1 | 20020214 | <-- |
| APPLICATION INFO.: | US 2001-892505 | A1 | 20010628 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-214825P | 20000628 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: McDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005-3096
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 111 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2002:22499 USPATFULL
TITLE: Method of treating cardiovascular disease
INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES
Sehgal, Surendra N., Snohomish, WA, UNITED STATES
Adelman, Steven J., Doylestown, PA, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ, 07054-0874 (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 2002013335 | A1 | 20020131 | <-- |
| APPLICATION INFO.: | US 2001-880295 | A1 | 20010613 (9) | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2000-212117P | 20000616 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 112 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:48090 USPATFULL
TITLE: Method for reducing pericardial fibrosis and adhesion formation
INVENTOR(S): Spinale, Francis G., Charleston, SC, United States
de Gasparo, Marc, Rossemaison, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6211217 | B1 | 20010403 | <-- |
| APPLICATION INFO.: | US 1999-270412 | | 19990316 (9) | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Ferraro, Gregory D.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT.sub.1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine (valsartan) of formula ##STR1##

or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 113 OF 113 USPATFULL on STN
ACCESSION NUMBER: 2001:21788 USPATFULL
TITLE: Stabilized pharmaceutical preparation
INVENTOR(S): Fukuta, Makoto, Nara, Japan
Itoh, Hiroki, Suita, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6187340 | B1 | 20010213 | <-- |
| APPLICATION INFO.: | US 1998-149122 | | 19980909 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-245778 | 19970910 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Williamson, Michael A.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stabilized pharmaceutical preparation which is coated with a coating agent comprising an agent for the protection from light, said agent being capable of producing free radicals when exposed to ultraviolet rays, and a free radical scavenger; which is stable to light, especially ultraviolet rays, or heat, and which has excellent storage-stability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.